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The topic of the research presented in this doctoral thesis is glaucomatous visual field 
progression. This introduction aims to provide a concise context for the subsequent 
chapters by outlining the background of the research questions that led to this thesis. 
Definition of glaucoma 
The term glaucoma refers to a group of diseases that have in common a characteristic 
optic neuropathy and irreversible loss of visual function.1 Glaucomatous optic neuropa-
thy is recognized by progressive optic nerve cupping caused by axonal loss. Patients 
with glaucoma typically gradually lose their visual field (i.e. peripheral vision) and may 
lose all vision. Glaucoma is the second leading cause of blindness worldwide.2  
 
A major factor in the presumed pathogenesis of glaucoma is intraocular pressure (IOP). 
Higher IOP has consistently shown to be strongly related with glaucomatous damage 
and is by far the most important factor and up till now the only proven factor that can 
be treated. Medical, laser or surgical treatment all aim at lowering IOP.3 Although some 
medications claim to be neuroprotective or have a beneficial effect on perfusion of the 
optic nerve, there is still not much evidence to support the clinical value of these 
claims.4, 5 However, some patients develop glaucomatous damage despite a normal IOP. 
In this subgroup of normal tension glaucoma (NTG) patients, the disease mechanism is 
assumed to be mainly caused by additional IOP independent factors. However, lowering 
intraocular pressure has also shown to slow down disease progression in NTG.6 An 
intraocular pressure above 21 mmHg is generally considered to be outside the range of 
normal IOP, although this cutoff point is currently seen as highly arbitrary.7 Current 
literature argues that high tension glaucoma and NTG are a continuum of open-angle 
glaucomas with considerable overlap.8  
 
Glaucoma is traditionally classified as open angle or closed angle glaucoma based on the 
underlying disease mechanism.1 A high intraocular pressure can be caused by increased 
production of aqueous humor in the ciliary body of the eye, but more often it is caused 
by reduced outflow of aqueous humor through the drainage channels of the eye in the 
angle of the iris and the cornea, the trabecular meshwork. In closed angle glaucoma 
(ACG), the angle is closed or too narrow leading to a gross obstruction in the outflow of 
aqueous humor. In contrast, open-angle glaucoma (OAG) is believed to be caused by 
increased resistance to aqueous outflow in the trabecular meshwork. This thesis is 
mainly about OAG. The mean worldwide prevalence of OAG is estimated at 2% in 
people over 40 years in 2010.9 OAG is the most prevalent type of glaucoma in Europe 
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with an estimated prevalence of 1.97% in 2010. In contrast, the estimated European 
prevalence for ACG in 2010 is 0.25%.9 
 
Glaucoma can also be classified as primary or secondary depending on the presence or 
absence of ocular or systemic disorders contributing to the pressure rise.1 Within OAG, 
primary OAG (POAG) and NTG are the most common manifestations of the disease. 
Pseudoexfoliation glaucoma (PXG) and pigmentary glaucoma (PG) are examples of 
secondary OAG that are commonly studied together with POAG, as in this thesis. The 
secondary condition of PXG is exfoliation syndrome, in which an abnormal fibrillo-
granular protein (exfoliation material) is produced in the eye. The trabecular outflow of 
the eye is reduced owing to the accumulation of the exfoliation material in the trabecu-
lar meshwork.10 In PG, the trabecular meshwork is impeded by melanin granules origi-
nated from the iris.11 There are several other forms of secondary OAG such as uveitic 
glaucoma, glaucoma due to corticosteroid treatment, and glaucoma caused by in-
creased episcleral venous pressure.12 These subgroups are generally studied separately 
and are not covered in this thesis. 
Treatment of glaucoma 
There is currently no medical intervention that can repair damaged retinal nerve fibers 
in a glaucomatous eye, so there is no cure for glaucoma. Treatment of glaucoma is 
directed at lowering IOP to slow down disease progression. The first-line treatment to 
lower IOP is medication that reduces production of aqueous humor in the ciliary body 
and/or increases outflow of aqueous humor through the trabecular meshwork or 
uveoscleral outflow. The second treatment modality is a laser procedure to open up the 
trabecular meshwork. This could also be the first-line treatment for patients when 
medications are not available or when the patient’s adherence to prescribed medica-
tion is low. Glaucoma surgery is the third and most invasive treatment to lower IOP. 
Surgery aims to improve outflow of aqueous humor through an alternative drainage 
route like the creation of a filtering bleb or implantation of a drainage device.  
Visual function in glaucoma 
Testing in glaucoma can be divided into diagnosis of disease and monitoring of already 
diagnosed glaucoma patients. This thesis is about monitoring of glaucoma patients to 
determine whether glaucomatous damage is worsening. Worsening of glaucomatous 
damage is termed “disease progression”.  
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Monitoring of patients with glaucoma is based on identification of structural and func-
tional changes in the eye. Measurement of structural changes mainly consists of evalua-
tion of the optic disc with use of a slit lamp or scanning laser ophthalmoscopy, and 
evaluation of the retinal nerve fiber layer with use of scanning laser polarimetry or 
optical coherence tomography. Visual field testing (i.e. perimetry) is the most common 
functional measurement in glaucoma. It should be performed in all patients with glau-
coma according to current guidelines.12, 13 More than 99% of eye departments in the UK 
use some form of perimetry.14 Because visual field loss and relevant patient outcomes, 
like visual disability and quality of life, have shown to be related, the research in this 
thesis is focused on visual field testing.15-19 
 
The normal visual field extends approximately 50° superiorly, 60° nasally, 70° inferiorly 
and 90° temporally. Visual field function is generally assessed by standardized automat-
ed perimetry (SAP), which refers to static computerized threshold perimetry of the 
central 30° or 24° visual field performed with ordinary white stimuli on a white back-
ground.12 During the test, a stationary test object is increased in intensity from below 
threshold until perceived by the patient.1 This is repeated at different visual field loca-
tions. Another type of visual field examinations is manual Goldmann kinetic perimetry. 
This older method is still useful, e.g. for patients that are unable to perform SAP and for 
neuro-ophthalmologic patients. In kinetic perimetry, a test object of fixed intensity is 
moved along several meridians toward fixation. Points where the object is first per-
ceived are plotted in a circle.1 
 
Different perimeters are available for the performance of SAP. In this thesis, we focus 
on the Humphrey Field Analyzer (HFA) because a majority of studies in the literature 
used this perimeter. The frequency of its use has even more increased to 77% of the 
studies published since 2000 (see Chapter 3). An example of a single visual field printout 
of a glaucoma patient’s right eye from the HFA is shown in Figure 1. 
 
One of the concerns in modern perimetry is the significant intertest variability in glaucoma 
patients, which makes it difficult to determine with statistical confidence whether glau-
comatous damage is worsening or not.20 Furthermore, it is essential that each SAP test is a 
high quality measurement of the patient’s visual function at that point in time.13 An 
important factor to obtain a high quality measurement is the suitability of the patient for 
visual field testing. For example, the patient should be physically able to sit at the perime-
ter and should be sufficiently intellectually competent to undertake the test. The patient 
should also have any central visual function to enable adequate fixation during the test. 
Other important factors are appropriate near refractive correction and adequate supervi-
sion by a technician during the test.13 
Introduct ion 
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Figure 1: A single visual field printout of a glaucoma patient’s right eye from the Humphrey Field Analyzer. 
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The visual function as determined by SAP is commonly expressed as a mean value of 
different points in the visual field, a visual field index. Two frequently used visual field 
indices from the HFA are the Mean Deviation (MD) value and the Visual field index (VFI). 
Compared with the MD value, the VFI is more concentrated on central areas of the 
visual field.21 The MD is expressed on a decibel scale, where 0 decibel represents a 
normal visual field and -30 decibels an almost extinguished visual field. The VFI is ex-
pressed as a percentage, where 100% represents a normal visual field and 0% repre-
sents a perimetrically blind eye. 
Progression of glaucoma 
The goal of glaucoma treatment is to maintain the patient’s visual function and related 
quality of life, at a sustainable cost.12 Because glaucoma patients have irreversible visual 
field loss by definition, the goal is thus to prevent progression to a more advanced 
disease stage which would cause a further loss of quality of life. It is therefore important 
to regularly and reliably monitor glaucoma patients to detect early deterioration of the 
visual field. The ability to differentiate progressing patients from patients with stable 
disease would direct more intensive treatment to those who are at the highest risk for 
visual disability.22 Beside the presence of glaucomatous progression, the individual 
probability that glaucomatous damage will affect a patient’s quality of life is also de-
pendent on the patient’s age and the current stage of disease.23 On the other hand, a 
correct method to assess progression will reduce side effects of glaucoma treatment for 
patients with stable disease. However, the criteria by which progression should be 
determined are subject of ongoing debate.21, 24-29 
 
The frequency of visual field testing has also been a subject of debate in the last years. 
Recently, experts have reached consensus about some important basic principles of 
performing visual field examinations.13 First, a learning effect may occur during the 
patient’s initial field examination.30 When an obvious learning effect is present, the first 
visual field examination should be replaced by a new visual field. There is consensus to 
perform two baseline visual fields in the first six months of follow-up.13 Performing six 
visual fields in the first two years enables the clinician to rule out rapid visual field 
progression.31 Because time and money constraints, timing of follow-up visual fields 
could be made dependent on the results of previous visual field examinations. As soon 
as progression is suspected to occur, the frequency of visual field examinations is 
increased to confirm or refute the progression.32 Following this principle of adaptive 
testing, the perimetric frequency can be reduced to typically one test per year in pa-
tients at low or medium risk to visual field progression. 
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Risk factors for glaucoma 
Risk factors can be classified into etiologic factors, prognostic factors, and diagnostic 
factors.33 Etiologic factors need to have a causal relation with a disease. Prognostic 
factors and diagnostic factors are merely used to predict current disease (i.e. diagnostic 
factors) or to predict disease in the future (i.e. prognostic factors). Prognostic and 
diagnostic factors do not need to have a causal relation with the disease, but they 
should be practical so that they can be used by clinicians to predict disease. Prognostic 
factors for OAG can be subdivided into prognostic factors for the incidence of OAG, for 
progression of OAG, and risk factors for treatment response in OAG patients.34 
 
Although glaucoma is a leading cause of blindness, most patients with OAG will retain 
some vision for their entire lives. The ability to differentiate rapidly progressing patients 
from slowly progressing patients would greatly help clinicians in daily clinical practice to 
administer the best required treatment. Ultimately, clinical prediction models could be 
developed to further facilitate the aggregation of knowledge on several prognostic 
factors for clinicians.35, 36 We are aware of just a few predictive models for visual field 
progression in glaucoma that have been published.37,38 
Research in this thesis 
Following the importance of measuring glaucomatous visual field progression to reach 
the ultimate goal of glaucoma treatment (i.e. the maintenance of a patient’s quality of 
life), the aim of the research presented in this doctoral thesis was to further investigate 
the phenomenon of glaucomatous visual field progression. We investigated how accu-
rately it can be predicted and gave an overview of the most important prognostic 
factors for glaucomatous visual field progression. We investigated the way progression 
can be determined and how choosing a different method to assess progression will 
influence study results. Furthermore, the literature was summarized and empirical 
research was undertaken to give an advice on the best method to assess progression. 
Finally, we clarified the incidence of end-of-life visual disability and its possible causes.  
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Research questions 
From the previous knowledge about glaucoma and the measurement of glaucomatous 
progression we formulated the following research questions:  
1. What are the prognostic factors for glaucomatous visual field progression?  
(Chapter 2) 
2. Can visual field progression be accurately predicted with the use of available prog-
nostic factors? (Chapter 3) 
3. To what extent does the method to assess progression influence the incidence of 
progression? (Chapter 4) 
4. To what extent have currently available assessment methods been validated? 
(Chapter 5) 
5. What is the best method to assess glaucomatous visual field progression taking into 
account the relation with prognostic factors? (Chapter 6) 
6. What is the prevalence of end-of-life visual disability in treated glaucoma patients? 
(Chapter 7) 
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ABSTRACT 
Topic: An examination of which prognostic factors are associated with glaucomatous 
visual field progression. 
 
Clinical Relevance: Knowledge of prognostic factors helps clinicians to select patients at 
risk of glaucomatous visual field progression and intensify their treatment. 
 
Methods/Literature Reviewed: Consulting relevant databases, we identified 2733 
articles published up to September 2010, of which 85 articles investigating prognostic 
factors for visual field progression in patients with open-angle glaucoma were eligible. 
We summarized results for each factor in tables, noting the direction of the association 
between the prognostic factor and progression, and the accompanying P value. Four 
authors, working blind to the factors, independently judged the extent to which a 
prognostic factor was associated with glaucomatous visual field progression. If there 
were different associations for normal-tension glaucoma (NTG) studies, they were 
judged separately. Consensus was reached at group meetings. 
 
Results: One hundred and three different prognostic factors were investigated in 85 
articles. The following factors were clearly associated with glaucomatous visual field 
progression: age, disc hemorrhages (for NTG), baseline visual field loss, baseline intra-
ocular pressure, and exfoliation syndrome. An association was unlikely for family history 
of glaucoma, atherosclerosis, systemic hypertension, visual acuity, gender (for NTG), 
systolic blood pressure, myopic refractive error (for NTG), and Raynaud’s phenomenon. 
 
Conclusion: The factors we found clearly associated with progression could be used in 
clinical practice and for developing clinical prediction models. For many other factors, 
further research is necessary. 
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Open-angle glaucoma (OAG) is a chronic, progressive optic neuropathy with a charac-
teristic appearance of the optic nerve and associated visual field defects.1 Even in 
treated OAG patients, glaucoma may lead to blindness.2, 3 Hence, knowledge of prog-
nostic factors is important to identify patients at risk of rapid progression, who need 
more intensive treatment to prevent blindness. 
 
Prognostic factors can be used to create prognostic profiles for individual patients. For 
example, OAG patients with exfoliation syndrome frequently show higher rates of 
progression compared to OAG patients without exfoliation syndrome.4 A likely progno-
sis for a patient could guide subsequent medical actions, such as intensity of treatment 
and frequency of follow-up as well as the decision to refrain from certain interventions 
(e.g., glaucoma surgery). Therefore, a patient’s prognosis is of key clinical importance.5 
 
Earlier reviews have addressed the issue of prognostic factors for glaucomatous visual 
field progression.6-8 However, the evidence of the association between distinct prognos-
tic factors and visual field progression has not been evaluated systematically. The 
outcomes of many studies on prognostic factors have been variable, sometimes contra-
dictory, and although current literature argues that both OAG with higher and lower 
intraocular pressures (IOPs) represent one disease continuum, many studies on prog-
nostic factors judged glaucoma patients with IOP in a normal range separately, making 
results difficult to interpret.  
 
The purpose of the present review is to systematically study to what extent various 
prognostic factors have been investigated and which factors are most consistently 
associated with glaucomatous visual field progression. 
Sources and methods of literature search 
Search strategy 
In September 2010, we conducted a systematic search in PubMed, EMBASE, and all 
databases and registers of The Cochrane Library, using these keywords: (glaucoma*) 
AND (prognos* OR predict* OR progress* OR longitudinal OR cohort OR follow-up) AND 
(perimetr* OR visual field* OR HFA (Humphrey Field Analyzer) OR Octopus OR Humph-
rey (not in author)). The search was limited to articles in English, Dutch, French, or 
German. Articles in press were also selected. In total, we identified 2733 articles.  
Chapter  2  
20 
Selection process 
We applied the same broad exclusion criteria as in two previous systematic reviews on 
visual field progression in glaucoma (Figure 1).9, 10 Four additional exclusion criteria 
were applied to find eligible studies on prognostic factors for glaucomatous visual field 
progression (Figure 1). We were only interested in baseline prognostic factors because 
they can be used to predict progression. “Baseline” is defined as “present in a treated 
or untreated glaucoma patient before the follow-up period in which visual field progres-
sion could occur.” Prognostic factors in studies were included only if an association was 
statistically tested. Studies that investigated only interaction terms or clinical interven-
tions were excluded. Furthermore, we included only studies that assessed visual field 
progression quantitatively (i.e., with numeric units for defining progression) and exclud-
ed studies that used qualitative methods (i.e., subjective descriptions of progression; 
e.g., “appearance of a nasal step”) and those that did not define the method used to 
assess progression. All selected studies had to differentiate between eyes with or 
without baseline visual field loss, because risk factors for glaucoma conversion might 
differ from prognostic factors for glaucoma progression. Finally, at least 85% of patients 
analyzed in a study had to be diagnosed with OAG. Of the 2733 identified articles, 85 
fulfilled the predefined selection criteria (Figure 1). We compared the search and 
selection process of our review with the article selection of a review on methodological 
quality of studies on prognostic factors.11 
Study design and overlap 
Studies were included in the review irrespective of their design because all designs were 
essentially suited to investigating prognostic factors. We included 62 case series, 21 
cohort studies, and two case-control studies as defined according to Ophthalmology’s 
study design scheme (Table 1).12 We classified all studies in independent study clusters. 
Studies with populations likely to overlap with populations from another selected study 
were classified in the same cluster. We determined the possibility of overlap between 
studies using information on the patient-recruiting hospitals, author names, trial names, 
references to other studies, and period of recruitment. The 85 articles contained 45 
independent study clusters (Table 1).  
Study quality 
To determine study quality we used a checklist developed for quality assessment of 
prognosis studies recommended by the National Institute for Health and Clinical Excel-
lence (NICE).13 This checklist contains six items on the representativeness of the popula-
tion, loss to follow-up, measurement of prognostic factors, outcome measurement, 
correction for potential confounders, and suitability of the statistical analysis. Table 2 
summarizes the quality of included studies. In total, we found two studies (2%) with 
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“yes” for all six items, 42 studies (49%) for five items, 27 studies (32%) for four items, six 
studies (7%) for three items, five studies (6%) for two items, and three studies (4%) with 
“yes” for one item. 
Data analysis and interpretation 
Even studies of similar design were difficult to compare, mainly due to the many differ-
ent methods used to assess progression, the use of many different prognostic factors, 
differences in study methodology, the high number of studies with correlated results, 
and adjustment for different prognostic factors in the multivariable analysis. For exam-
ple, different methods of assessing progression may give varying incidences of visual 
field progression, ranging from 2% to 62% in six years due solely to the method.9 More-
over, the choice of the method to assess progression and the statistical approach used 
to test the association may influence the strength of the association between a prog-
nostic factor and progression.14 Given that the group of studies was insufficiently 
homogeneous to provide a meaningful summary, we did not conduct a formal meta-
analysis.15 
 
Instead, we used a semi-quantitative approach to summarize the results from multiple 
studies, as we had done in a previous review.16 First, we summarized the evidence of 
each prognostic factor in an evidence table for the univariate results and when present 
the multivariable results corrected for the effects of other variables. The tables classi-
fied each study of a prognostic factor according to the direction of the association 
between the factor and glaucomatous visual field progression (i.e., More progression, 
No relation, or Less progression in the presence of a prognostic factor), and the report-
ed statistical significance of the association (i.e., statistically significant or non-
significant, using a P value ≤0.05). We extracted one conclusion per study for each 
prognostic factor. A study was classified between statistically significant and non-
significant when one analysis resulted in a significant association and the other analysis 
of the same study resulted in a non-significant association. Table 3, shows a sample 
evidence table. We indicated separately those studies comprising a majority (>50%) of 
NTG patients (e.g., studies 5 and 9 in Table 3). We used study-specific definitions to 
define patients with NTG and found 20 studies (24%) with mainly NTG patients (Table 
1). Furthermore, we indicated all clusters of studies with correlated results (e.g., studies 
1a and 1b in Table 3).  
 
Tables with univariate and multivariable results were used to determine the extent to 
which a presumed prognostic factor was associated with glaucomatous visual field 
progression. Four investigators (JSS, HJB, CAW, and PJE) independently judged whether 
the factor was not associated, possibly associated, probably associated, or definitely 
Chapter  2  
22 
associated with visual field progression. All investigators were blinded for the factor 
under investigation and the study that assessed it. When assessing associations, they 
took into account the total number of studies that tested an association, any clustering 
in the results, and the total number of patients investigated in the studies. Higher 
numbers of studies, clusters, and patients were weighted more heavily than lower 
numbers. Whenever available, multivariable results were weighted more heavily than 
univariate results, because these are corrected for the confounding effects of other 
factors. Results from the 20 NTG studies were initially judged separately. In group 
meetings, the four investigators reached consensus on all differences in individual 
judgments. When the investigators noticed a considerable amount of heterogeneity in 
the study results, this was also recorded. The entire assessment process was repeated 
one month later to judge the consistency of the assessments. We used the weighted 
kappa statistic (κ) with quadratic weights to indicate the strength of agreement be-
tween the categories assigned in both consensus rounds.17, 18  
 
Finally, we rated the clinical importance of a prognostic factor according to Ophthal-
mology’s guidelines.12 If a prognostic factor was prevalent, easy to assess, and judged 
clearly (i.e., definitely or probably) associated with glaucomatous visual field progres-
sion, we rated it as very important, level A. If a factor was judged clearly associated with 
progression but not prevalent or easy to assess, we rated it as moderately important, 
level B. Factors with a weaker (i.e., possible) association and in need of more research 
to clarify clinical relevance were rated as possibly relevant, level C. The body of evi-
dence of a prognostic factor was rated as strong (level I), substantial (level II), or weak 
(level III), analogous to our judgments as “definitely,” “probably,” or “possibly” associat-
ed with visual field progression. Prognostic factors that we judged as “not associated” 
with visual field progression were rated as unlikely prognostic factors if they had been 
investigated in ten or more studies. 
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2733 Potentially relevant articles identified and screened for retrieval
  
Exclusion criteria 
No measurement of VF progression (n = 529)
Unconventional or single perimetric measurement (n = 464)
Study population without baseline VF damage (n = 423)
Patients without glaucomatous disease (n = 256)
Review article, editorial, or use of simulated data (n = 217) 
Follow-up less than three years (n = 181) 
Fewer than 25 patients investigated (n = 112) 
Articles not available in the Netherlands or abstracts (n = 61) 
Patients younger than 18 years (n = 36) 
Other languages than English, French, Dutch, or German (n = 29) 
Animal study (n = 18) 
 
407 Articles fulfilled the broad selection criteria
  
Additional exclusion criteria for this review
No baseline prognostic factors for VF progression (n = 234)
Unknown or qualitative method to assess VF progression (n = 66)
Eyes without baseline VF damage were analyzed (n = 17)
Fewer than 85% of the patients in the analysis had OAG (n = 5)
 
85 Articles were included in this review
 
Figure 1: Flow chart of article selection process 
VF = visual field, OAG = open-angle glaucoma 
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Table 1: Characteristics of the 85 included studies 
Cluster 
number 
Publication 
year 
Source of study population Study references 
Case 
series 
Cohort  
studies 
CC 
studies 
1 1977 University of British Columbia and Vancouver General 
Hospital, Vancouver, BC, Canada; University of Utah, 
Salt Lake City, UT, USA 
1  
2 1982-1990 King's College Hospital Glaucoma Centre, London, UK 2, 3  
3 1984 University of Cologne, Cologne, Germany 4  
4 1986-1992 St Paul's Hospital and University of British Columbia 
Eye Clinic, Vancouver, BC, Canada 
5, 6  
5 1988-1993 University Eye Clinic Wurzburg, Wurzburg, Germany 7, 8  
6 1989 l'Hospital Saint-Joseph, Paris, France 9  
7 1989 Wills Eye Hospital, Philadelphia, PA, USA 10*  
8 1990 Addenbrooke's Hospital, Cambridge, UK 11  
9 1991-2004 New England Medical Center Hospitals, and Tutts 
University School of Medicine, Boston, MA, USA 
12, 13  
10 1993 Eye Division of Olympia Medical Clinic, Tokyo, Japan 14*  
11 1996 Massachusetts Eye and Ear Infirmary, Harvard Medical 
School, Boston, MA, USA 
15  
12 1994 Tokyo University School of Medicine, Tokyo, Japan 16*  
13 1994 Moorfields Eye Hospital, London, UK 17  
14 1996 Centre Hospitalier Universitaire d'Angers, Angers, 
France 
18  
15 1996-1997 Wilmer Institute, Baltimore, MD, USA 19, 20  
16 1996-2000 Gifu University Hospital, Gifu-shi, Japan 21*, 22*, 
23*, 24*
25*  
17 1997-1999 University of British Columbia, Vancouver, BC, Canada 26*, 27  
18 1997-2000 St Lucas Hospital, Amsterdam, the Netherlands 28, 29  
19 2001 Collaborative Normal-Tension Glaucoma Study, USA, 
Canada, the Netherlands, Finland 
30*  
20 2000-2005 Moorfields Eye Hospital, London, UK 31*, 32*, 
33* 
 
21 2000-2006 Glaucoma Clinic, Nihon University Hospital, Tokyo, 
Japan 
34*, 35*  
22 2005-2008 University Eye Clinic, Basel, Switzerland 36, 37  
23 2002-2008 Advanced Glaucoma Intervention Study, USA 38 39, 40, 
41 
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Cluster 
number 
Publication 
year 
Source of study population Study references 
Case 
series 
Cohort  
studies 
CC 
studies 
24 2000-2009 Queen Elisabeth Health Sciences Center, Halifax, NS, 
Canada 
42, 43 44, 45, 
46 
 
25 2000-2010 University of Washington, Seattle, WA, USA 47, 48, 
49 
50 
26 2001 University of Iowa, Iowa City, IA, USA 51  
27 2001 Yamanashi Medical University, Yamanashi, Japan 52* 
28 2001-2010 Collaborative Initial Glaucoma Treatment Study, USA 53 54, 55  
29 2002 From population study in Saint Lucia, West Indies 56  
30 2003-2007 Wills Eye Hospital, Philadelphia, PA, USA 57, 58  
31 2003-2009 Early Manifest Glaucoma Treatment Study, Sweden 59 60, 61, 
62, 63 
 
32 2005 Gallego Institute of Ophthalmology, La Coruna, Spain 64  
33 2005 Bristol Eye Hospital, Bristol, UK 65  
34 2005-2008 Helsinki University Eye Hospital, Helsinki, Finland 66, 67  
35 2007 Sant' Andrea Hospital, La Sapienza II University, Roma, 
Italy; University of Genova, Genova, Italy 
68  
36 2008 National Taiwan University Hospital, Taipei, Taiwan 69  
37 2008-2010 Canadian Glaucoma Study, Canada 70, 71  
38 2008-2010 Gallego Institute of Ophthalmology, La Coruna, Spain 72, 73  
39 2009 Asan Medical Center, Seoul, Korea 74*  
40 2009 Moorfields Eye Hospital and UCL Institute of Ophthal-
mology, London, UK 
75  
41 2009-2010 Hong Kong Eye Hospital, Hong Kong, China 76*, 77*  
42 2009-2010 New York Glaucoma Progression Study, New York, NY, 
USA 
78, 79, 
80, 81, 
82 
 
43 2010 Samsung Medical Center, Seoul, Korea 83*  
44 2010 Glaucoma Unit of the Aberdeen Royal Infirmary, 
Aberdeen, UK 
84  
45 2010 Diagnostic Innovations in Glaucoma Study, Hamilton 
Glaucoma Center, University of California, San Diego, 
CA, USA 
85  
Study clusters (n=45) ranked by publication year. Studies are classified according to Ophthalmology's study 
design scheme and are indicated by their number in the reference list.  
*Studies that included >50% normal-tension glaucoma patients in their analyses (n=20). 
CC studies = case-control studies 
Table 1: continued 
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Table 2: Quality scores of the 85 included studies 
Quality items from NICE checklist13 
No.  
Yes 
No.  
No 
No.  
Unclear 
Explanation for scoring studies 
1. The study sample represents the 
population of interest with regard 
to key characteristics, sufficient to 
limit bias to the results. 
73 
(86%) 
0 
(0%) 
12 
(14%) 
We rated studies that investigated only 
glaucoma patients with established 
baseline visual field loss. Baseline 
characteristics (i.e., age, gender, and 
visual field loss) should be adequately 
described. 
2. Loss to follow-up is unrelated to 
key characteristics (i.e., the study 
data adequately represent the 
sample), sufficient to limit 
potential bias. 
3 
(4%) 
70 
(82%) 
12 
(14%) 
We rated cohort studies that either 
reported similar baseline characteristics in 
the group lost to follow-up and the 
analyzed group, or had no loss to follow-
up. By definition, case series and case-
control studies were rated as "No". 
3. The prognostic factor of interest 
is adequately measured in study 
participants, sufficient to limit bias. 
85 
(100%) 
0 
(0%) 
0 
(0%) 
We rated studies that measured prognos-
tic factors in a treated or untreated 
glaucoma patient before the follow-up 
period in which visual field progression 
could occur. 
4. The outcome of interest is 
adequately measured in study 
participants, sufficient to limit bias. 
73  
(86%) 
11  
(13%) 
1 
(1%) 
We rated the outcome as adequately 
measured if the same type of perimeter 
was used in all participants and if the 
perimeter used was an automated 
perimeter. 
5. Important potential confound-
ers are appropriately accounted 
for, limiting potential bias with 
respect to the prognostic factor of 
interest. 
53 
(62%) 
32 
(38%) 
0 
(0%) 
We rated studies that performed a 
multivariable analysis. 
6. The statistical analysis is 
appropriate for the design of the 
study, limiting potential for the 
presentation of invalid results. 
74 
(87%) 
11 
(13%) 
0 
(0%) 
We rated studies that adequately 
described the statistical analysis in a way 
that it is reproducible for others. All 
candidate variables considered for the 
analysis should be listed. 
NICE = National Institute for Health and Clinical Excellence 
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Table 3: Sample evidence table summarizing the study results of a prognostic factor 
Prognostic  
factor “X” 
More progression
No relation
Less progression 
Significant  Non-
significant 
Non-
significant 
 Significant 
Univariate analysis 
(n=10) 1a, 1b
† 2‡ 3, 4, 5*, 6 7, 8 9*   
   No. of clusters 1 1 4 2 1 0 0 
   No. of studies 2 1 4 2 1 0 0 
   No. of patients 130 140 1032 325 48 0 0 
Multivariable analysis 
(n=8) 1a, 1b
†, 4  3, 5* 2, 6, 9*    
   No. of clusters 2 0 2 3 0 0 0 
   No. of studies 3 0 2 3 0 0 0 
   No. of patients 757 0 350 243 0 0 0 
The evidence table summarizes the univariate and multivariable study results of prognostic factor "X". These
tables were used to determine the extent to which prognostic factors were associated with glaucomatous
visual field progression. Each number in the table represents a study. Studies are classified by the direction 
and the statistical significance (P ≤0.05) of the association between the prognostic factor and visual field
progression. The number of study clusters, studies, and patients is summarized below. Prognostic factor "X" 
was judged to be probably associated with more visual field progression in studies with all types of open-angle 
glaucoma and not associated with progression in normal-tension glaucoma studies.  
*Studies 5 and 9 comprised a majority of normal-tension glaucoma patients.  
†Studies 1a and 1b are underlined because they belong to the same study cluster. Their results are likely to be
correlated.  
‡Study 2 was classified as falling between a significant and non-significant association because it used two 
methods to assess progression: one resulted in a statistically significant association and the other resulted in a
non-significant association. 
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Summary of evidence 
Judgment procedure 
The 85 included studies were published between 1977 and 2010 and consisted mainly 
of case series (73%) (see Table 1). From these studies, we classified the results of 103 
different prognostic factors in evidence tables (e.g., Table 3). Fifty-three studies (62%) 
performed a multivariable analysis. From a total of 795 conclusions in the articles, 471 
(59%) were univariate results and 324 (41%) were multivariable results.  
 
We consistently applied the following guidelines in classifying the prognostic factors. 
We assigned “no association” to factors with a consistent pattern of “No relation.” 
Factors with very inconsistent results from different studies were also assigned “no 
association.” “Possible association” was assigned to factors with a weak tendency 
towards more or Less progression with a single significant result. “Probable association” 
was assigned to factors with an obvious tendency towards more or Less progression in a 
moderate number of studies with several studies having significant results. However, if 
only a few significant results appeared in a very consistent pattern, this factor was also 
assigned a “probable association.” “Definite association” was assigned to factors with a 
very consistent pattern of numerous studies with multiple statistically significant results. 
 
Our judgments were generally consistent (κ = 0.89). In all cases of differences, we 
maintained the second judgment, which suggests a learning effect during the first 
consensus round.  
 
The judgment procedure of the association of prognostic factors with visual field pro-
gression resulted in one definite association (1%), seven probable associations (6.8%), 
24 possible associations (23.3%), and 71 times no association (68.9%) (see Tables 4 and 
5). 
 
Eighteen factors were judged to have a different association with progression in NTG 
studies compared with studies investigating all types of OAG. These results are present-
ed separately and implied one definite association, two probable associations, six 
possible associations, and nine times no association (see Tables 4 and 5). We lumped 
the results for all other factors and reported them as factors studied in OAG. 
Definite and probable prognostic factors 
We identified one definite and seven probable prognostic factors for glaucomatous 
visual field progression in OAG. Additionally, in NTG specific studies we identified one 
definite and two probable prognostic factors (see Table 4). The evidence tables of these 
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factors are shown in Table 6 (see appendix Chapter 2). Higher age was definitely associ-
ated with More progression in OAG patients and the presence of disc hemorrhages was 
definitely associated with More progression in NTG patients. Furthermore, more base-
line visual field loss, higher baseline IOP and presence of exfoliation syndrome were 
probably associated with more visual field progression in OAG. Finally, six other factors 
were probably associated with visual field progression, but the judgment was based on 
a low number of studies. Central corneal thickness (CCT), ocular blood flow resistivity 
index, blood anticardiolipin antibody, peripapillary atrophy (for NTG), proven previous 
visual field progression, and stroke (for NTG) were probably associated with progres-
sion. Thirty factors were possibly associated with visual field progression and are shown 
in Table 4. The evidence tables of these factors are shown in Table 6 (see appendix 
Chapter 2). 
Unlikely prognostic factors 
Most prognostic factors were judged to have no association with glaucomatous visual 
field progression, but this was based on a limited number of studies (Table 5). The 
evidence tables of these factors are shown in Table 6 (see appendix Chapter 2), except 
for factors that were studied only once or twice. We identified eight prognostic factors 
that were addressed by ten or more studies, but still showed no evidence of an associa-
tion with visual field progression: family history of glaucoma, atherosclerosis, systemic 
hypertension, visual acuity, gender (for NTG), systolic blood pressure, myopic refractive 
error (for NTG), and Raynaud’s phenomenon. These factors were rated as unlikely 
prognostic factors. 
Heterogeneity 
We noticed a considerable amount of heterogeneity in three probable prognostic 
factors for OAG: baseline visual field loss, baseline IOP and CCT. Although more baseline 
visual field loss was associated with More progression in most studies, six out of 36 
studies showed that a better baseline visual field was associated with More progression 
in the multivariable analysis.19-24 However, only one study, part of the Advanced Glau-
coma Intervention Study (AGIS), found a statistically significant result.24 We observed no 
difference between the mean degree of baseline field loss per study and the direction 
of association. For baseline IOP, two out of 17 studies found that a lower baseline IOP 
was associated with more visual field progression during follow-up in the multivariable 
analysis.22, 25 However, these results were not statistically significant. Correlated, both 
studies investigated baseline IOP as a prognostic factor in the AGIS population. A higher 
mean IOP and IOP fluctuation during follow-up resulted in More progression in these 
studies.22, 25 The heterogeneity we observed for CCT was mainly ascribed to two out of 
five studies pointing at the opposite direction of the association in the univariate analy-
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sis.26, 27 Because both studies applied a univariate pre-selection of predictors and uni-
variate results were not statistically significant, CCT was not tested in the multivariable 
model. The other three studies showed that a thinner CCT was predictive of more visual 
field progression in univariate and multivariable analyses.28-30 Important to note here is 
that these three studies were clustered in the New York Glaucoma Progression Study 
(i.e., cluster 42 in Table 1).  
 
We noticed heterogeneity for the following two unlikely prognostic factors: visual acuity 
and systolic blood pressure. For visual acuity, only one out of 14 studies found a signifi-
cant association between visual acuity and visual field progression.24 Significantly less 
progression was found in patients with a better baseline visual acuity. However, the 
results of this study differed between the two treatment groups, with the other group 
showing a non-significant result.24 All other studies found only non-significant or no 
associations for this factor. In the multivariable results for systolic blood pressure, we 
found two out of ten studies showing significantly more progression with a higher 
systolic blood pressure.31, 32 These studies were derived from the same study cluster 
from Gifu University Hospital (i.e., cluster 16 in Table 1). One other study found signifi-
cantly less progression with higher blood pressures and was derived from the same 
study cluster.33  
 
In 14 other presumed prognostic factors, we noticed considerable heterogeneity: 
gender (for OAG), diabetes, untreated IOP, diastolic blood pressure, IOP fluctuation, 
migraine, NTG, mean diurnal IOP, duration of disease, diurnal IOP fluctuation, mean 
arterial blood pressure, ocular blood flow peak systolic velocity, degree of optic nerve 
cupping, and thyroid disease.  
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Table 4: Prognostic factors associated with glaucomatous visual field progression 
Prognostic factors Diagnostic 
group 
Association Direction Number of studies 
1=no, 2=possible, 
3=probable, 
4=definite 
Increased 
progression 
with: 
Univariate 
analysis 
Multivariable 
analysis 
Total 
Age OAG 4 Older age 39 26 47 
Disc hemorrhages NTG 4 Presence 5 6 7 
Baseline visual field loss OAG 3 More loss 47 36 61 
Baseline IOP OAG 3 Higher IOP 22 17 28 
Exfoliation syndrome OAG 3 Presence 11 6 13 
Central corneal 
thickness 
OAG 3 Thinner 5 3 5 
OBF resistivity index OAG 3 Higher index 3 3 3 
Anticardiolipin antibody 
in blood 
OAG 3 Higher level 2 1 2 
Peripapillary atrophy NTG 3 Presence 0 2 2 
Previous visual field 
progression 
OAG 3 More progres-
sion 
2 1 2 
Stroke NTG 3 Presence 2 2 2 
Gender OAG 2 Female sex 23 17 31 
Cup disc ratio OAG 2 Higher ratio 14 7 17 
Age NTG 2 Older age 10 11 16 
Myopic refractive error 
(spherical equivalent) 
OAG 2 Higher error 12 10 16 
Diabetes OAG 2 Presence 9 5 12 
African descent OAG 2 Presence 7 5 9 
Baseline untreated IOP OAG 2 Higher IOP 6 6 9 
Disc hemorrhages OAG 2 Presence 7 3 8 
Diastolic blood pressure OAG 2 Lower pressure 5 4 6 
Systemic hypertension NTG 2 Presence 4 4 6 
Recovery rate from cold 
exposure test 
NTG 2 Lower rate 0 5 5 
Baseline IOP fluctuation OAG 2 Higher fluctua-
tion 
3 2 4 
Migraine NTG 2 Presence 4 1 4 
Ocular perfusion 
pressure (overall) 
OAG 2 Lower pressure 3 3 4 
Pulse rate OAG 2 Higher rate 1 2 3 
Central corneal 
thickness 
 
NTG 2 Thinner 3 2 3 
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Prognostic factors Diagnostic 
group 
Association Direction Number of studies 
1=no, 2=possible, 
3=probable, 
4=definite 
Increased 
progression 
with: 
Univariate 
analysis 
Multivariable 
analysis 
Total 
Infracentral scotoma 
localization 
OAG 2 Presence 3 0 3 
Peripapillary atrophy OAG 2 Presence 2 2 3 
Normal tension 
glaucoma 
OAG 2 Absence 3 0 3 
OBF end diastolic 
velocity 
OAG 2 Lower velocity 2 2 2 
Systolic ocular perfusion 
pressure 
OAG 2 Lower pressure 1 2 2 
Family history of 
diabetes 
OAG 2 Absence 1 0 1 
Variant of myocilin 
(mt.1(+)) 
OAG 2 Presence 0 1 1 
Asian descent OAG 2 Absence 1 0 1 
Red blood cell distribu-
tion width  
OAG 2 Lower width 1 0 1 
Threat to fixation NTG 2 Presence 1 1 1 
Outflow facility/ ΔIOP 
water drinking test/ 
diurnal ΔIOP 
OAG 2 ↓ / ↑ / ↑ 1 0 1 
IOP increase after 
pupillary dilatation 
OAG 2 Higher increase 1 0 1 
Highest IOP ever 
recorded before 
baseline 
OAG 2 Higher IOP 1 0 1 
Ocular perfusion 
pressure fluctuation 
OAG 2 Higher fluctua-
tion 
1 1 1 
All prognostic factors investigated in the literature are ranked by the strength of their association with visual field progres-
sion (third column) and the number of studies investigating each factor (seventh column). The fourth column indicates the 
direction of association between the prognostic factor and visual field progression.  
OAG = open-angle glaucoma, NTG = normal-tension glaucoma, IOP = intraocular pressure, OBF = ocular blood flow. 
Table 4: continued  
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Table 5: Prognostic factors without evidence of an association with glaucomatous visual field progression 
Prognostic 
factors 
Diagnostic group Association Direction Number of studies 
1=no, 2=possible, 
3=probable, 
4=definite 
Increased 
progression 
with: 
Univariate 
analysis 
Multivariable 
analysis 
Total 
Family history of glaucoma OAG 1 - 12 7 16 
Atherosclerosis OAG 1 - 12 4 14 
Systemic hypertension OAG 1 - 11 6 14 
Visual acuity OAG 1 - 8 7 14 
Gender NTG 1 - 9 6 13 
Systolic blood pressure OAG 1 - 8 10 12 
Myopic refractive error 
(spherical equivalent) 
NTG 1 - 6 8 11 
Raynaud's phenomenon OAG 1 - 9 2 10 
Baseline IOP NTG 1 - 4 7 8 
Diabetes NTG 1 - 4 4 8 
Migraine OAG 1 - 7 2 8 
Smoking OAG 1 - 4 3 6 
Diastolic blood pressure NTG 1 - 2 4 6 
Baseline untreated IOP NTG 1 - 3 6 6 
Mean diurnal IOP OAG 1 - 2 6 6 
Low blood pressure 
tendency 
OAG 1 - 6 1 6 
Duration of disease OAG 1 - 5 3 5 
Diurnal IOP fluctuation OAG 1 - 2 3 5 
Mean ocular perfusion 
pressure 
OAG 1 - 4 3 5 
Right-hand eye OAG 1 - 5 0 5 
Educational level OAG 1 - 1 4 4 
Minimum IOP of diurnal 
variation 
OAG 1 - 2 2 4 
Maximum IOP of diurnal 
variation 
OAG 1 - 2 2 4 
Major hypotension OAG 1 - 3 1 4 
Age at diagnosis OAG 1 - 3 2 3 
MAP OAG 1 - 2 2 3 
Disc size OAG 1 - 3 1 3 
Threat to fixation OAG 1 - 3 0 3 
Cardiac arrhythmia OAG 1 - 3 1 3 
High cholesterol levels OAG 1 - 3 1 3 
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Prognostic 
factors 
Diagnostic group Association Direction Number of studies 
1=no, 2=possible, 
3=probable, 
4=definite 
Increased 
progression 
with: 
Univariate 
analysis 
Multivariable 
analysis 
Total 
Focal ischemic disc 
pathology 
OAG 1 - 1 2 3 
Family history of stroke or vascular hyper-
tension, Marital status, OBF peak systolic 
velocity, Previous cataract surgery, Degree 
of optic nerve cupping, Fellow eye disease, 
Baseline target IOP, Obstructive sleep apnea, 
Thyroid disease, Diastolic ocular perfusion 
pressure, Pupil size, Visual field reliability 
indices, RNFL thickness, Pigment glaucoma 
1 - - - 2 
Alcohol intake, Family history of diabetes 
(NTG), OPTN E50K mutation, African descent 
(NTG), Non-European Descent, Multiple 
blood values, Diurnal MAP fluctuation, 
Nocturnal MAP fluctuation, 24-hour MAP 
fluctuation, Recovery rate from cold 
exposure test, Finger blood flow, 24-hour 
peak MAP, 24-hour trough MAP, Lens 
opacities, Iris color, Previous optic disc 
change, Postoperative IOP spike ≥ 5 mmHg, 
Anemia, Asthma, Blood transfusion, Fatigue 
or weakness, Major surgery, Malignancy, 
Muscle tremor or weakness, Nonmigraine 
headache, Psychological symptoms, Renal 
stones, Stroke, Sensorineural hearing loss, 
Any systemic disease, Vomiting or diarrhea, 
Ocular perfusion pressure (NTG), Pupil 
response, Refractive error in cylinders, 
Retinal artery narrowing 
1 - - - 1 
All prognostic factors investigated in the literature are ranked by the strength of their association with visual field progres-
sion (third column) and the number of studies investigating each factor (seventh column). The fourth column indicates the 
direction of association between the prognostic factor and visual field progression.  
OAG = open-angle glaucoma, NTG = normal-tension glaucoma, IOP = intraocular pressure, OBF = ocular blood flow, MAP = 
mean arterial blood pressure. 
Table 5: continued 
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Discussion 
This review article provides a systematic overview of evidence of all studied prognostic 
factors for glaucomatous visual field progression. Using semi-quantitative analysis, we 
classified two factors as definitely associated, nine as probably, and 30 as possibly 
associated with glaucomatous visual field progression (Table 4).  
 
To create our review, we searched for a method that would go beyond the existing non-
systematic, narrative reviews. We did not do a formal meta-analysis because of the 
large variety in methods and approaches used by the studies. Instead, we summarized 
the knowledge on prognostic factors systematically and objectively, using a semi-
quantitative approach. We conducted a systematic literature search, consistently 
applied established selection criteria to include relevant articles, and summarized all 
study results in evidence tables. Following established assessment guidelines, four 
investigators individually assessed the evidence on each factor, had a consensus round, 
and repeated the entire process a month later. Because our investigators did not know 
which factor was under investigation or the study source, all prognostic factors were 
assessed under similar blind conditions to prevent subjective bias from tacit knowledge 
or convictions. Furthermore, for each factor, the investigators looked at multivariable 
results, which were corrected for the effects of other prognostic factors and were 
weighted more heavily than univariate results. Our approach also enabled us to include 
more studies than a formal meta-analysis could. Many studies included in our semi-
quantitative analysis did not report the effect size of a prognostic factor if it did not test 
statistically significant. Formal meta-analysis would have excluded these studies, be-
cause this analysis form requires an effect size. Our semi-quantitative approach did not 
aim to classify factors as true or not true but to rank them according to their likelihood 
of being prognostic. The results show the validity of our method, since the factors we 
found most likely to be associated with progression (age, disc hemorrhages, baseline 
visual field loss, intraocular pressure and exfoliation syndrome) will be recognized as 
such by many glaucoma specialists.  
 
A previous review by Julvez and colleagues has shown that the methodological quality 
of studies on prognostic factors is generally moderate.11 In the current review, we used 
study inclusion criteria that contained several quality aspects. All of the included studies 
analyzed at least 25 glaucoma patients during a minimal follow-up period of three years 
and used quantitative methods to assess progression. We further rated study quality 
with the NICE-recommended checklist developed for quality assessment of prognosis 
studies.13 Most included studies had good scores for five of the six items (Table 2). 
However, for item 2 (loss to follow-up) we found only three cohort studies that indicat-
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ed No relation between key characteristics and loss to follow-up.33-35 Most included 
studies were case series or case-control studies, which we considered valid to identify 
prognostic factors since they compared patients with progression to patients without 
progression. We also compared our article search and selection process with the review 
by Julvez and colleagues, which included 47 articles.11 Twenty-eight studies that they 
included were not included in our review. After studying those articles, we decided to 
still exclude them mainly because 13 did not study baseline prognostic factors for visual 
field progression, four did not distinguish eyes with and without baseline visual field loss 
in the analyses, and four used an unknown or qualitative method to assess visual field 
progression. On the other hand, we included 66 more studies than Julvez and col-
leagues did, including 28 studies published in the same period covered by Julvez and 
colleagues in their search.11  
 
Studies that investigated NTG patients were initially judged separately, because we 
presumed to find different prognostic factors for NTG. However, current literature 
argues that both OAG with higher and lower IOPs represent one disease continuum.36 
The distinction between normal and high IOP is largely arbitrary and has a historical 
rather than a scientific origin.37 In the 20 studies with a majority of NTG patients, we 
were dependent on the study-specific definitions of NTG. To identify different prognos-
tic factors for OAG with higher and lower IOPs, it would have been ideal if subgroup 
analyses had been available. These analyses have been scarcely performed in the 
literature. Of the 18 factors judged to have a different association with progression for 
NTG, the largest discrepancy (i.e., a difference of two classes) was found for age, optic 
disc hemorrhages, baseline IOP, and stroke. Age was definitely associated with progres-
sion in 47 OAG studies and was possibly associated in 16 NTG studies. This could indi-
cate an increasing vulnerability to glaucomatous damage during life, particularly in OAG 
with higher IOPs. However, this does not mean that older patients should always be 
treated more aggressively. At the same time older patients have a shorter life expectan-
cy that decreases their risk of end-of-life visual disability. Optic disc hemorrhages were 
found to be more associated with progression in NTG. This may indicate different 
mechanisms of optic nerve damage between OAG with higher and lower IOPs. Disc 
hemorrhages may be a sign of the local vascular abnormalities that tend to be associat-
ed with NTG.36 For baseline IOP, we found a stronger association in OAG studies. This is 
likely caused by the higher IOP variation in the OAG population compared with a sub-
group of NTG patients. Stroke was probably associated with progression in NTG based 
on two correlated studies.38, 39 For OAG, only one study investigated this factor and 
found No relation between stroke and progression.34 These results suggest that stroke 
and NTG may share common pathogenetic pathways. However, more research is 
necessary to fully elucidate the importance of stroke for glaucomatous progression.  
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It is important to note that individual studies defined and measured prognostic factors 
differently. A salient example is family history of glaucoma, a long-established risk factor 
for glaucoma conversion.40 Family history of glaucoma is an unlikely prognostic factor 
for visual field progression in our review. In all 16 studies, it was simply defined as 
“family history of glaucoma.” No information was available on how family history was 
determined. This is likely to be of importance, for example, with regard to the degree of 
familial relationship taken into account, the clinical course (i.e., disease progression) of 
affected family members, or severity of disease in terms of intervention types. 
 
Our review treats the heterogeneity of study results qualitatively. For 19 presumed 
prognostic factors assessed under blind conditions we noted a considerable degree of 
heterogeneity across the study results and described inconsistencies in results for the 
five most important factors. A limitation of our review is that the analysis treated 
studies of different design and study quality equally. This is because a semi-quantitative 
approach gives fewer possibilities to differentiate between subtle study differences. 
Additionally, the studies used various covariates for adjustment in the multivariable 
analysis, which our evidence tables did not take into account. However, since univariate 
results generally resulted in the same associations as multivariable results, we feel that 
this effect had only a minor impact on our results. 
 
Our aim is to present an overview of all studied prognostic factors, ranked according to 
their likelihood of being prognostic. We tried to include as many studies as possible so 
that this review might serve as a basis for further studies on prediction of glaucomatous 
visual field progression, for example, for the development of clinical prediction models 
or as an aid to select prognostic factors for further study. Application of clinical predic-
tion models in practice would help clinicians to calculate the glaucoma patient’s individ-
ual risk for clinically significant visual field progression.41 Using a risk calculator to 
estimate the risk of conversion in ocular hypertensive subjects has already been shown 
to change the treatment recommendations of glaucoma specialists.42 As long as there is 
no validated clinical prediction model for glaucoma progression, clinicians could use the 
most important prognostic factors elucidated in this review to make their own risk 
estimations. Information on these factors can be implicitly considered in decisions on 
treatment and monitoring strategies in individual patients. Other information, such as a 
patient’s functional reserve and life expectancy, also plays a vital role in these decisions.  
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Clinical recommendations 
This review provides a database of all studied prognostic factors for glaucomatous visual 
field progression. We have summarized our results to translate them into usable, 
clinically relevant recommendations. 
 
We consider two prognostic factors, found to be associated with glaucomatous visual 
field progression, very important for clinical practice: age for all OAG and disc hemor-
rhages for NTG.A, I  
 
The following six factors, ranked according to their strength of evidence, were found to 
be probably associated with glaucomatous visual field progression: baseline visual field 
loss, baseline IOP, exfoliation syndrome, CCT, peripapillary atrophy (for NTG), and 
proven previous visual field progression.A, II We consider them important for clinical 
practice, given that we feel there is a reasonable basis to evaluate these factors when 
deciding on subsequent treatment and monitoring strategies. 
 
The following prognostic factors were found to be probably associated with visual field 
progression but are not prevalent or easy to assess in clinical practice: ocular blood flow 
resistivity index and blood anticardiolipin antibody for all OAG, and stroke for NTG.B, II 
 
Thirty factors were possibly associated with glaucomatous visual field progression. 
These factors have seldom been studied or showed inconsistent results between 
studies. Further research is needed to establish the relevance of these factors.  
 
Most factors showed no evidence of an association with visual field progression, alt-
hough the conclusion was based on a limited number of studies. Eight factors investi-
gated in a high number of studies showed no evidence of an association. These unlikely 
prognostic factors are ranked according to the number of studies that investigated 
them: family history of glaucoma, atherosclerosis, systemic hypertension, visual acuity, 
gender (for NTG), systolic blood pressure, myopic refractive error (for NTG), and Ray-
naud’s phenomenon. 
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Appendix 
Table 6: Evidence tables of prognostic factors for glaucomatous visual field progression 
 
Evidence tables of definite prognostic factors for glaucomatous visual field progression 
Older age (OAG) More progression No relation Less progression 
Significant Non-significant Non-
significant 
Significant 
Univariate analysis
(n = 39) 
20, 40, 41,  
60, 61, 63, 69, 
70, 71, 80, 81 
2, 56, 
59 
6, 12, 18, 36, 37, 
38, 42, 64, 65, 
66, 67, 72, 73, 
75, 79 
5, 13, 51, 
58, 82, 84 
7, 44, 49 9 
No. of clusters 6 3 12 6 3 0 1 
No. of studies 11 3 15 6 3 0 1 
No. of patients 2351 360 1710 454 377 0 282 
Multivariable analysis
(n = 26) 
3, 17, 38, 40, 
41, 54, 55, 56, 
57, 60, 61, 65, 
69, 70, 81 
62 64, 67, 80 13, 28, 36, 
39, 66, 79 
2  
No. of clusters 11 1 3 6 1 0 0 
No. of studies 15 1 3 6 1 0 0 
No. of patients 2430 255 400 997 57 0 0 
 
Disc hemorrhages 
(NTG) 
More progression No relation Less progression 
Significant Non-significant Non-
significant 
Significant 
Univariate analysis
(n = 5) 
24, 30, 76, 77 52  
No. of clusters 3 0 1 0 0 0 0 
No. of studies 4 0 1 0 0 0 0 
No. of patients 772 0 27 0 0 0 0 
Multivariable analysis 
(n = 6) 
21, 23, 24,  
30, 76, 77 
 
No. of clusters 3 0 0 0 0 0 0 
No. of studies 6 0 0 0 0 0 0 
No. of patients 851 0 0 0 0 0 0 
These evidence tables summarize the univariate and multivariable results of prognostic factors. The tables
were used to determine the extent to which prognostic factors were associated with glaucomatous visual field
progression. The tables are ranked by the strength of the association between prognostic factor and visual
field progression and the number of studies that investigated each factor (i.e., in the same order as in Tables 4
and 5). Each number in the tables represents a study and corresponds with the number in the reference list,
which is the same as the reference list of Table 1. Studies are classified in the tables by the direction and
statistical significance (P ≤0.05) of the association.  
Numbers of study clusters, studies, and patients are summarized in each table.  
Numbers between parentheses represent the total number of studies in the analysis. 
Underlined studies belong to the same study cluster and their results are likely to be correlated.  
OAG = open-angle glaucoma, NTG = normal-tension glaucoma, IOP = intraocular pressure. 
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Evidence tables of probable prognostic factors for glaucomatous visual field progression 
Baseline visual 
field loss (OAG) 
More progression
No relation 
Less progression 
Significant  Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis  
(n = 47) 
5, 7, 9, 40, 60, 
66, 74*, 81 
2, 37, 
79 
10*, 20, 35*, 
36, 38, 42, 
44, 47, 48, 
49, 50, 61, 
69, 73, 75, 
76*, 77*, 80, 
82 
11, 19, 26*, 
30*, 32*, 64, 
65, 51, 59, 72, 
84 
12, 13, 41 34*, 56 70 
   No. of clusters 8 3 13 11 2 2 1 
   No. of studies 8 3 19 11 3 2 1 
   No. of patients 1188 513 3021 1072 471 191 258 
Multivariable 
analysis  
(n = 36) 
2, 3, 35*, 48, 
57, 60, 66,  
79, 81, 85 
22*, 
24*, 54, 
72, 74*
38, 40, 47, 
61, 64, 82 
16*, 17, 21*, 
28, 30*, 34*, 
43, 49, 62 
23*, 50 13, 41, 56 39 
   No. of clusters 8 4 5 9 2 3 1 
   No. of studies 10 5 6 9 2 3 1 
   No. of patients 1874 928 1059 930 135 586 558 
 
Baseline IOP 
(OAG) 
More progression
No relation 
Less progression 
Significant  Non-significant 
Non-
significant  Significant 
Univariate 
analysis   
(n = 22) 
60, 61, 79, 82  7, 36, 38, 40, 58, 59, 73 9, 11, 70 
2, 41, 49, 64, 
66, 75, 81 72  
   No. of clusters 2 0 6 3 7 1 0 
   No. of studies 4 0 7 3 7 1 0 
   No. of patients 960 0 1039 717 971 40 0 
Multivariable 
analysis  
(n = 17) 
2, 51, 61, 79, 
85 60 40, 64 
17, 28, 39, 62, 
66, 72, 82 38, 41 
  
   No. of clusters 5 1 2 7 1 0 0 
   No. of studies 5 1 2 7 2 0 0 
   No. of patients 905 255 210 1439 702 0 0 
*Studies comprising a majority of normal-tension glaucoma patients. 
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Exfoliation 
syndrome (OAG) 
More progression
No relation 
Less progression 
Significant  Non-significant 
Non-
significant  Significant 
Univariate 
analysis  
(n = 11) 
47, 60, 61, 63 80 12, 48, 66, 
70, 79, 81 
    
   No. of clusters 2 1 5 0 0 0 0 
   No. of studies 4 1 6 0 0 0 0 
   No. of patients 676 293 802 0 0 0 0 
Multivariable 
analysis (n = 6) 60, 61, 62  80 47, 66    
   No. of clusters 1 0 1 2 0 0 0 
   No. of studies 3 0 1 2 0 0 0 
   No. of patients 765 0 293 119 0 0 0 
 
Thinner central 
corneal thickness 
(OAG) 
More progression
No relation 
Less progression 
Significant  Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis 
(n = 5) 
79, 82  80  72, 81   
   No. of clusters 1 0 1 0 2 0 0 
   No. of studies 2 0 1 0 2 0 0 
   No. of patients 450 0 293 0 116 0 0 
Multivariable 
analysis  
(n = 3) 
79, 80, 82       
   No. of clusters 1 0 0 0 0 0 0 
   No. of studies 3 0 0 0 0 0 0 
   No. of patients 743 0 0 0 0 0 0 
 
Ocular blood flow 
resistivity index 
(OAG) 
More progression
No relation 
Less progression 
Significant 
  Non-
significant 
Non-
significant  Significant 
Univariate 
analysis (n = 3) 
64‡, 64§,  
72‡, 73‡, 73§ 
  73†   72†, 72§  
   No. of clusters 2 0 1 0 0 1 0 
   No. of studies 3 0 1 0 0 1 0 
   No. of patients 235 0 146 0 0 40 0 
Multivariable 
analysis (n = 3) 
64‡, 64§,  
72‡, 73‡, 73§ 
   72†, 72§    
   No. of clusters 2 0 0 1 0 0 0 
   No. of studies 3 0 0 1 0 0 0 
   No. of patients 235 0 0 40 0 0 0 
†In central reƟnal artery; ‡In ophthalmic artery; §In short posterior ciliary arteries. 
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Anticardiolipin 
antibody in blood 
(OAG) 
More progression
No relation 
Less progression 
Significant  Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 2) 70, 71       
   No. of clusters 1 0 0 0 0 0 0 
   No. of studies 2 0 0 0 0 0 0 
   No. of patients 474 0 0 0 0 0 0 
Multivariable 
analysis (n = 1) 70       
   No. of clusters 1 0 0 0 0 0 0 
   No. of studies 1 0 0 0 0 0 0 
   No. of patients 258 0 0 0 0 0 0 
 
Peripapillary 
atrophy (NTG) 
More progression
No relation 
Less progression 
Significant  Non-significant 
Non-
significant  Significant 
Univariate 
analysis (n = 0)        
   No. of clusters 0 0 0 0 0 0 0 
   No. of studies 0 0 0 0 0 0 0 
   No. of patients 0 0 0 0 0 0 0 
Multivariable 
analysis (n = 2) 16, 23       
   No. of clusters 2 0 0 0 0 0 0 
   No. of studies 2 0 0 0 0 0 0 
   No. of patients 103 0 0 0 0 0 0 
 
Previous visual 
field progression 
(OAG) 
More progression
No relation 
Less progression 
Significant  Non-significant 
Non-
significant  Significant 
Univariate 
analysis (n = 2) 40 46      
   No. of clusters 1 1 0 0 0 0 0 
   No. of studies 1 1 0 0 0 0 0 
   No. of patients 161 81 0 0 0 0 0 
Multivariable 
analysis (n = 1) 40       
   No. of clusters 1 0 0 0 0 0 0 
   No. of studies 1 0 0 0 0 0 0 
   No. of patients 161 0 0 0 0 0 0 
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Stroke (NTG) 
More progression
No relation 
Less progression 
Significant  Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 2) 76  77     
   No. of clusters 1 0 1 0 0 0 0 
   No. of studies 1 0 1 0 0 0 0 
   No. of patients 286 0 256 0 0 0 0 
Multivariable 
analysis (n = 2) 76, 77       
   No. of clusters 1 0 0 0 0 0 0 
   No. of studies 2 0 0 0 0 0 0 
   No. of patients 542 0 0 0 0 0 0 
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Evidence tables of possible prognostic factors for glaucomatous visual field progression 
Female sex (OAG)
More progression
No relation 
Less progression 
Significant  Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 23) 70 2 
6, 12, 20, 36, 
40, 60, 72, 73
9, 51, 61, 71 
18, 38, 41, 
42, 44, 66, 
81, 82 
 65 
   No. of clusters 1 1 7 4 5 0 1 
   No. of studies 1 1 8 4 8 0 1 
   No. of patients 258 57 762 793 1334 0 108 
Multivariable 
analysis (n = 17) 2, 70  57 
3, 13, 36, 
54, 55, 56,  
60, 62, 66, 72 
38, 41, 65 39  
   No. of clusters 2 0 1 8 2 1 0 
   No. of studies 2 0 1 10 3 1 0 
   No. of patients 315 0 135 2534 810 558 0 
 
Cup disc ratio 
(OAG) 
More progression
No relation 
Less progression 
Significant  Non-significant 
Non-
significant  Significant 
Univariate 
analysis (n = 14) 7, 47, 69  
41, 49, 50, 
76*, 77* 
9, 20, 30*, 48, 
51, 65 
   
   No. of clusters 3 0 3 6 0 0 0 
   No. of studies 3 0 5 6 0 0 0 
   No. of patients 507 0 1098 798 0 0 0 
Multivariable 
analysis (n = 7) 16*, 69  38, 50 17, 41, 47    
   No. of clusters 2 0 2 3 0 0 0 
   No. of studies 2 0 2 3 0 0 0 
   No. of patients 318 0 389 617 0 0 0 
*Studies comprising a majority of normal-tension glaucoma patients. 
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Older age (NTG) 
More progression
No relation 
Less progression 
Significant  Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 10) 76, 77  
26, 32, 
34, 35, 74 10, 30 52   
   No. of clusters 1 0 4 2 1 0 0 
   No. of studies 2 0 5 2 1 0 0 
   No. of patients 542 0 349 196 27 0 0 
Multivariable 
analysis (n = 11) 77 24 21, 23, 83 
16, 22, 30, 
34, 35, 76    
   No. of clusters 1 1 2 5 0 0 0 
   No. of studies 1 1 3 6 0 0 0 
   No. of patients 256 70 222 740 0 0 0 
 
Myopic refractive 
error (OAG) 
More progression
No relation 
Less progression 
Significant  Non-significant 
Non-
significant  Significant 
Univariate 
analysis (n = 12) 68, 69  50, 60, 82 9, 13, 51, 61, 65 12, 41   
   No. of clusters 2 0 3 5 2 0 0 
   No. of studies 2 0 3 5 2 0 0 
   No. of patients 372 0 588 715 441 0 0 
Multivariable 
analysis  
(n = 10) 
69 13 38, 50, 57 39, 41, 60, 62 82   
   No. of clusters 1 1 3 2 1 0 0 
   No. of studies 1 1 3 4 1 0 0 
   No. of patients 262 30 524 1469 245 0 0 
 
Diabetes (OAG) 
More progression
No relation 
Less progression 
Significant  Non-significant 
Non-
significant  Significant 
Univariate 
analysis (n = 9)   38, 70 4, 9, 27, 65 12, 41, 42   
   No. of clusters 0 0 2 4 3 0 0 
   No. of studies 0 0 2 4 3 0 0 
   No. of patients 0 0 559 486 485 0 0 
Multivariable 
analysis (n = 5) 54 39  57 38, 41   
   No. of clusters 1 1 0 1 1 0 0 
   No. of studies 1 1 0 1 2 0 0 
   No. of patients 607 558 0 135 702 0 0 
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African descent 
(OAG) 
More progression
No relation 
Less progression 
Significant  Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 7)   12, 20, 38, 40 13, 41, 48    
   No. of clusters 0 0 3 3 0 0 0 
   No. of studies 0 0 4 3 0 0 0 
   No. of patients 0 0 558 583 0 0 0 
Multivariable 
analysis (n = 5) 13 54 38 39, 41    
   No. of clusters 1 1 1 1 0 0 0 
   No. of studies 1 1 1 2 0 0 0 
   No. of patients 30 607 301 959 0 0 0 
 
Baseline untreat-
ed IOP (OAG) 
More progression
No relation 
Less progression 
Significant  Non-significant 
Non-
significant  Significant 
Univariate 
analysis (n = 6) 60, 61  7, 59 70 64   
   No. of clusters 1 0 2 1 1 0 0 
   No. of studies 2 0 2 1 1 0 0 
   No. of patients 510 0 345 258 49 0 0 
Multivariable 
analysis (n = 6) 61 60 64 17, 28, 62    
   No. of clusters 1 1 1 3 0 0 0 
   No. of studies 1 1 1 3 0 0 0 
   No. of patients 255 255 49 525 0 0 0 
 
Disc hemorrhages 
(OAG) 
More progression
No relation 
Less progression 
Significant  Non-significant 
Non-
significant  Significant 
Univariate 
analysis (n = 7) 1, 15, 27, 78  12, 50, 60     
   No. of clusters 4 0 3 0 0 0 0 
   No. of studies 4 0 3 0 0 0 0 
   No. of patients 352 0 383 0 0 0 0 
Multivariable 
analysis (n = 3)   50 55, 60    
   No. of clusters 0 0 1 2 0 0 0 
   No. of studies 0 0 1 2 0 0 0 
   No. of patients 0 0 88 862 0 0 0 
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Diastolic blood 
pressure (OAG) 
More progression
No relation 
Less progression 
Significant  Non-significant 
Non-
significant  Significant 
Univariate 
analysis (n = 5)   70 61 60, 64  73 
   No. of clusters 0 0 1 1 2 0 1 
   No. of studies 0 0 1 1 2 0 1 
   No. of patients 0 0 258 255 304 0 146 
Multivariable 
analysis (n = 4)   64 60, 62   73 
   No. of clusters 0 0 1 1 0 0 1 
   No. of studies 0 0 1 2 0 0 1 
   No. of patients 0 0 49 510 0 0 146 
 
Systemic hyper-
tension (NTG) 
More progression
No relation 
Less progression 
  Non-significant   Significant 
Univariate 
analysis (n = 4) 76  77 30 26   
   No. of clusters 1 0 1 1 1 0 0 
   No. of studies 1 0 1 1 1 0 0 
   No. of patients 286 0 256 160 59 0 0 
Multivariable 
analysis (n = 4) 76   22, 24, 30    
   No. of clusters 1 0 0 2 0 0 0 
   No. of studies 1 0 0 3 0 0 0 
   No. of patients 286 0 0 340 0 0 0 
 
Recovery rate 
from cold 
exposure test 
(NTG) 
More progression
No relation 
Less progression 
Significant  Non-significant 
Non-
significant  Significant 
Univariate 
analysis (n = 0)        
   No. of clusters 0 0 0 0 0 0 0 
   No. of studies 0 0 0 0 0 0 0 
   No. of patients 0 0 0 0 0 0 0 
Multivariable 
analysis (n = 5)    21, 24 23 22 25 
   No. of clusters 0 0 0 1 1 1 1 
   No. of studies 0 0 0 2 1 1 1 
   No. of patients 0 0 0 102 47 110 28 
 
  
Chapter  2  
54 
Baseline IOP 
fluctuation (OAG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 3)   40, 72, 73     
   No. of clusters 0 0 2 0 0 0 0 
   No. of studies 0 0 3 0 0 0 0 
   No. of patients 0 0 347 0 0 0 0 
Multivariable 
analysis (n = 2) 55    40   
   No. of clusters 1 0 0 0 1 0 0 
   No. of studies 1 0 0 0 1 0 0 
   No. of patients 607 0 0 0 161 0 0 
 
Migraine (NTG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 4) 30   26 76, 77   
   No. of clusters 1 0 0 1 1 0 0 
   No. of studies 1 0 0 1 2 0 0 
   No. of patients 160 0 0 59 542 0 0 
Multivariable 
analysis (n = 1) 30       
   No. of clusters 1 0 0 0 0 0 0 
   No. of studies 1 0 0 0 0 0 0 
   No. of patients 160 0 0 0 0 0 0 
 
Ocular perfusion 
pressure (OAG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 3)     72, 73 61  
   No. of clusters 0 0 0 0 1 1 0 
   No. of studies 0 0 0 0 2 1 0 
   No. of patients 0 0 0 0 186 255 0 
Multivariable 
analysis (n = 3)    62 73  61 
   No. of clusters 0 0 0 1 1 0 1 
   No. of studies 0 0 0 1 1 0 1 
   No. of patients 0 0 0 255 146 0 255 
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Pulse rate (OAG) 
More progression 
No relation 
Less progression 
Significant  Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 1)    30    
   No. of clusters 0 0 0 1 0 0 0 
   No. of studies 0 0 0 1 0 0 0 
   No. of patients 0 0 0 160 0 0 0 
Multivariable 
analysis (n = 2) 24   22    
   No. of clusters 1 0 0 1 0 0 0 
   No. of studies 1 0 0 1 0 0 0 
   No. of patients 70 0 0 110 0 0 0 
 
Thinner central 
corneal thickness 
(NTG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 3) 76, 77    74   
   No. of clusters 1 0 0 0 1 0 0 
   No. of studies 2 0 0 0 1 0 0 
   No. of patients 542 0 0 0 101 0 0 
Multivariable 
analysis (n = 2) 76   77    
   No. of clusters 1 0 0 1 0 0 0 
   No. of studies 1 0 0 1 0 0 0 
   No. of patients 286 0 0 256 0 0 0 
 
Infracentral 
scotoma localiza-
tion (OAG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 3) 8 7  4    
   No. of clusters 1 1 0 1 0 0 0 
   No. of studies 1 1 0 1 0 0 0 
   No. of patients 153 197 0 26 0 0 0 
Multivariable 
analysis (n = 0)        
   No. of clusters 0 0 0 0 0 0 0 
   No. of studies 0 0 0 0 0 0 0 
   No. of patients 0 0 0 0 0 0 0 
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Peripapillary 
atrophy (OAG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 2) 82   65    
   No. of clusters 1 0 0 1 0 0 0 
   No. of studies 1 0 0 1 0 0 0 
   No. of patients 245 0 0 108 0 0 0 
Multivariable 
analysis (n = 2)  82  21    
   No. of clusters 0 1 0 1 0 0 0 
   No. of studies 0 1 0 1 0 0 0 
   No. of patients 0 245 0 32 0 0 0 
 
Normal-tension 
glaucoma (OAG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 3)   18, 29    63 
   No. of clusters 0 0 2 0 0 0 1 
   No. of studies 0 0 2 0 0 0 1 
   No. of patients 0 0 185 0 0 0 118 
Multivariable 
analysis (n = 0)        
   No. of clusters 0 0 0 0 0 0 0 
   No. of studies 0 0 0 0 0 0 0 
   No. of patients 0 0 0 0 0 0 0 
 
Ocular blood flow 
end diastolic 
velocity (OAG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 2)  72
†  72§ 73†  72‡, 73‡, 73§ 
   No. of clusters 0 1 0 1 1 0 1 
   No. of studies 0 1 0 1 1 0 2 
   No. of patients 0 40 0 40 146 0 186 
Multivariable 
analysis (n = 2)    72
†, 72§   72‡, 73‡, 73§ 
   No. of clusters 0 0 0 1 0 0 1 
   No. of studies 0 0 0 1 0 0 2 
   No. of patients 0 0 0 40 0 0 186 
†In central reƟnal artery; ‡In ophthalmic artery; §In short posterior ciliary arteries. 
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Systolic ocular 
perfusion pressure 
(OAG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 1)       61 
   No. of clusters 0 0 0 0 0 0 1 
   No. of studies 0 0 0 0 0 0 1 
   No. of patients 0 0 0 0 0 0 255 
Multivariable 
analysis (n = 2)    62   61 
   No. of clusters 0 0 0 1 0 0 1 
   No. of studies 0 0 0 1 0 0 1 
   No. of patients 0 0 0 255 0 0 255 
 
Family history of 
diabetes (OAG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 1)       13 
   No. of clusters 0 0 0 0 0 0 1 
   No. of studies 0 0 0 0 0 0 1 
   No. of patients 0 0 0 0 0 0 30 
Multivariable 
analysis (n = 0)        
   No. of clusters 0 0 0 0 0 0 0 
   No. of studies 0 0 0 0 0 0 0 
   No. of patients 0 0 0 0 0 0 0 
 
Variant of the 
myocilin  
(mt. 1(+)) (OAG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 0)        
   No. of clusters 0 0 0 0 0 0 0 
   No. of studies 0 0 0 0 0 0 0 
   No. of patients 0 0 0 0 0 0 0 
Multivariable 
analysis (n = 1) 57       
   No. of clusters 1 0 0 0 0 0 0 
   No. of studies 1 0 0 0 0 0 0 
   No. of patients 135 0 0 0 0 0 0 
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Asian descent 
(OAG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 1)       30 
   No. of clusters 0 0 0 0 0 0 1 
   No. of studies 0 0 0 0 0 0 1 
   No. of patients 0 0 0 0 0 0 160 
Multivariable 
analysis (n = 0)        
   No. of clusters 0 0 0 0 0 0 0 
   No. of studies 0 0 0 0 0 0 0 
   No. of patients 0 0 0 0 0 0 0 
 
Red blood cell 
distribution width 
(OAG) 
More progression 
No relation 
Less progression 
Significant  Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 1)       70 
   No. of clusters 0 0 0 0 0 0 1 
   No. of studies 0 0 0 0 0 0 1 
   No. of patients 0 0 0 0 0 0 258 
Multivariable 
analysis (n = 0)        
   No. of clusters 0 0 0 0 0 0 0 
   No. of studies 0 0 0 0 0 0 0 
   No. of patients 0 0 0 0 0 0 0 
 
Threat to fixation 
(NTG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 1)  31      
   No. of clusters 0 1 0 0 0 0 0 
   No. of studies 0 1 0 0 0 0 0 
   No. of patients 0 152 0 0 0 0 0 
Multivariable 
analysis (n = 1)  31      
   No. of clusters 0 1 0 0 0 0 0 
   No. of studies 0 1 0 0 0 0 0 
   No. of patients 0 152 0 0 0 0 0 
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Outflow facility/ 
water drinking test/ 
diurnal IOP 
variation (OAG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate  
analysis (n = 1) 14       
   No. of clusters 1 0 0 0 0 0 0 
   No. of studies 1 0 0 0 0 0 0 
   No. of patients 54 0 0 0 0 0 0 
Multivariable 
analysis (n = 0)        
   No. of clusters 0 0 0 0 0 0 0 
   No. of studies 0 0 0 0 0 0 0 
   No. of patients 0 0 0 0 0 0 0 
 
IOP increase after 
pupillary dilatation 
(OAG) 
More progression 
No relation 
Less progression 
Significant  Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 1) 58       
   No. of clusters 1 0 0 0 0 0 0 
   No. of studies 1 0 0 0 0 0 0 
   No. of patients 55 0 0 0 0 0 0 
Multivariable 
analysis (n = 0)        
   No. of clusters 0 0 0 0 0 0 0 
   No. of studies 0 0 0 0 0 0 0 
   No. of patients 0 0 0 0 0 0 0 
 
Highest IOP ever 
recorded before 
baseline (OAG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 1) 27       
   No. of clusters 1 0 0 0 0 0 0 
   No. of studies 1 0 0 0 0 0 0 
   No. of patients 70 0 0 0 0 0 0 
Multivariable 
analysis (n = 0)        
   No. of clusters 0 0 0 0 0 0 0 
   No. of studies 0 0 0 0 0 0 0 
   No. of patients 0 0 0 0 0 0 0 
 
Chapter  2  
60 
Ocular perfusion 
pressure fluctua-
tion (OAG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 1)  74      
   No. of clusters 0 1 0 0 0 0 0 
   No. of studies 0 1 0 0 0 0 0 
   No. of patients 0 101 0 0 0 0 0 
Multivariable 
analysis (n = 1)  74      
   No. of clusters 0 1 0 0 0 0 0 
   No. of studies 0 1 0 0 0 0 0 
   No. of patients 0 101 0 0 0 0 0 
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Evidence tables of prognostic factors without evidence of an association with glaucomatous visual field 
progression 
Family history of 
glaucoma (OAG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 12)  2 
12, 50,  
70 
9, 13, 30*, 48, 
51, 61, 65 
60   
   No. of clusters 0 1 3 7 1 0 0 
   No. of studies 0 1 3 7 1 0 0 
   No. of patients 0 57 386 1027 255 0 0 
Multivariable 
analysis (n = 7) 13  50, 57 16*, 55, 60, 62    
   No. of clusters 1 0 2 3 0 0 0 
   No. of studies 1 0 2 4 0 0 0 
   No. of patients 57 0 223 1173 0 0 0 
 
Atherosclero- 
sis (OAG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 12)   
67, 70,  
76*, 77*, 80
4, 26*, 27,  
30*, 60 
41, 61   
   No. of clusters 0 0 4 4 2 0 0 
   No. of studies 0 0 5 5 2 0 0 
   No. of patients 0 0 1151 570 656 0 0 
Multivariable 
analysis (n = 4)    39, 60, 62 67   
   No. of clusters 0 0 0 2 1 0 0 
   No. of studies 0 0 0 3 1 0 0 
   No. of patients 0 0 0 1068 58 0 0 
 
Systemic hyper-
tension (OAG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 11) 41  38, 70 9, 27, 61, 65 12, 18, 42, 60   
   No. of clusters 1 0 2 4 4 0 0 
   No. of studies 1 0 2 4 4 0 0 
   No. of patients 401 0 559 715 422 0 0 
Multivariable 
analysis (n = 6)   38, 41 39, 55, 60, 62    
   No. of clusters 0 0 1 3 0 0 0 
   No. of studies 0 0 2 4 0 0 0 
   No. of patients 0 0 702 1675 0 0 0 
*Studies comprising a majority of normal-tension glaucoma patients. 
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Visual acuity 
(OAG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 8)   41 30*, 51, 71 
12, 44,  
76*, 77* 
  
   No. of clusters 0 0 1 3 3 0 0 
   No. of studies 0 0 1 3 4 0 0 
   No. of patients 0 0 401 596 695 0 0 
Multivariable 
analysis (n = 7)   38, 41 
17,  
22*, 24*, 25* 
 39  
   No. of clusters 0 0 1 2 0 1 0 
   No. of studies 0 0 2 4 0 1 0 
   No. of patients 0 0 702 376 0 558 0 
 
Female sex (NTG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 9) 30  
32, 35, 34, 
52, 74, 76, 77
10    
   No. of clusters 1 0 5 1 0 0 0 
   No. of studies 1 0 7 1 0 0 0 
   No. of patients 160 0 859 36 0 0 0 
Multivariable 
analysis (n = 6)   30 
16, 22, 24, 25, 
34 
   
   No. of clusters 0 0 1 3 0 0 0 
   No. of studies 0 0 1 5 0 0 0 
   No. of patients 0 0 160 300 0 0 0 
 
Systolic blood 
pressure (OAG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 8)  2 73, 74* 30*, 70 60, 64  61 
   No. of clusters 0 1 2 2 2 0 1 
   No. of studies 0 1 2 2 2 0 1 
   No. of patients 0 57 247 418 304 0 255 
Multivariable 
analysis (n = 10)  
22*, 
24* 
 60, 62, 74* 2, 23*, 61, 64  25* 
   No. of clusters 0 1 0 2 4 0 1 
   No. of studies 0 2 0 3 4 0 1 
   No. of patients 0 180 0 611 408 0 28 
*Studies comprising a majority of normal-tension glaucoma patients. 
 
Prognost ic  factors  for  progress ion 
63 
Myopic refractive 
error (NTG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 6)   34, 35 26, 30, 83 74   
   No. of clusters 0 0 1 3 1 0 0 
   No. of studies 0 0 2 3 1 0 0 
   No. of patients 0 0 128 362 101 0 0 
Multivariable 
analysis (n = 8)   21, 83 
16, 22, 24, 25, 
34, 35 
   
   No. of clusters 0 0 2 3 0 0 0 
   No. of studies 0 0 2 6 0 0 0 
   No. of patients 0 0 175 392 0 0 0 
 
Raynaud's 
phenomenon 
(OAG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 9)   18, 30*, 60 61, 65 
76*, 77*,  
80, 81 
  
   No. of clusters 0 0 3 2 2 0 0 
   No. of studies 0 0 3 2 4 0 0 
   No. of patients 0 0 498 363 911 0 0 
Multivariable 
analysis (n = 2)    60, 62    
   No. of clusters 0 0 0 1 0 0 0 
   No. of studies 0 0 0 2 0 0 0 
   No. of patients 0 0 0 510 0 0 0 
 
Baseline IOP (NTG)
More progression 
No relation 
Less progression 
Significant  Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 4)    10, 30 35, 74   
   No. of clusters 0 0 0 2 2 0 0 
   No. of studies 0 0 0 2 2 0 0 
   No. of patients 0 0 0 196 193 0 0 
Multivariable 
analysis (n = 7) 21   
22, 24, 25, 30, 
74 
  35 
   No. of clusters 1 0 0 3 0 0 1 
   No. of studies 1 0 0 5 0 0 1 
   No. of patients 32 0 0 469 0 0 92 
*Studies comprising a majority of normal-tension glaucoma patients. 
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Diabetes (NTG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 4)   76 26, 30 77   
   No. of clusters 0 0 1 2 1 0 0 
   No. of studies 0 0 1 2 1 0 0 
   No. of patients 0 0 286 219 256 0 0 
Multivariable 
analysis (n = 4)    16, 21, 22, 24    
   No. of clusters 0 0 0 2 0 0 0 
   No. of studies 0 0 0 4 0 0 0 
   No. of patients 0 0 0 268 0 0 0 
 
Migraine (OAG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 7)   60 27, 61, 65 70, 80, 81   
   No. of clusters 0 0 1 3 2 0 0 
   No. of studies 0 0 1 3 3 0 0 
   No. of patients 0 0 255 433 627 0 0 
Multivariable 
analysis (n = 2)    60, 62    
   No. of clusters 0 0 0 1 0 0 0 
   No. of studies 0 0 0 2 0 0 0 
   No. of patients 0 0 0 510 0 0 0 
 
Smoking (OAG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 4)   76* 27, 60, 61    
   No. of clusters 0 0 1 2 0 0 0 
   No. of studies 0 0 1 3 0 0 0 
   No. of patients 0 0 286 580 0 0 0 
Multivariable 
analysis (n = 3)    55, 60, 62    
   No. of clusters 0 0 0 2 0 0 0 
   No. of studies 0 0 0 3 0 0 0 
   No. of patients 0 0 0 1117 0 0 0 
*Studies comprising a majority of normal-tension glaucoma patients. 
 
Prognost ic  factors  for  progress ion 
65 
Diastolic blood 
pressure (NTG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 2)   74 30    
   No. of clusters 0 0 1 1 0 0 0 
   No. of studies 0 0 1 1 0 0 0 
   No. of patients 0 0 101 160 0 0 0 
Multivariable 
analysis (n = 4)   23 22, 24, 25    
   No. of clusters 0 0 1 1 0 0 0 
   No. of studies 0 0 1 3 0 0 0 
   No. of patients 0 0 47 208 0 0 0 
 
Baseline untreat-
ed IOP (NTG) 
More progression 
No relation 
Less progression 
Significant  Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 3)    30 35, 74   
   No. of clusters 0 0 0 1 2 0 0 
   No. of studies 0 0 0 1 2 0 0 
   No. of patients 0 0 0 160 193 0 0 
Multivariable 
analysis (n = 6) 21   22, 24, 30, 74   35 
   No. of clusters 1 0 0 3 0 0 1 
   No. of studies 1 0 0 4 0 0 1 
   No. of patients 32 0 0 441 0 0 92 
 
Mean diurnal IOP 
(OAG) 
More progression 
No relation 
Less progression 
Significant  Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 2)     35, 74   
   No. of clusters 0 0 0 0 2 0 0 
   No. of studies 0 0 0 0 2 0 0 
   No. of patients 0 0 0 0 193 0 0 
Multivariable 
analysis (n = 6) 21   22, 24, 25, 74   35 
   No. of clusters 1 0 0 2 0 0 1 
   No. of studies 1 0 0 4 0 0 1 
   No. of patients 32 0 0 309 0 0 92 
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Low blood 
pressure tendency 
(OAG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 6)    30*, 61 
60, 77*,  
80, 81 
  
   No. of clusters 0 0 0 2 3 0 0 
   No. of studies 0 0 0 2 4 0 0 
   No. of patients 0 0 0 415 880 0 0 
Multivariable 
analysis (n = 1)    60    
   No. of clusters 0 0 0 1 0 0 0 
   No. of studies 0 0 0 1 0 0 0 
   No. of patients 0 0 0 255 0 0 0 
 
Duration of 
disease (OAG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 5) 48  50 10* 47, 66   
   No. of clusters 1 0 1 1 2 0 0 
   No. of studies 1 0 1 1 2 0 0 
   No. of patients 152 0 88 36 119 0 0 
Multivariable 
analysis (n = 3)    47, 66 50   
   No. of clusters 0 0 0 2 1 0 0 
   No. of studies 0 0 0 2 1 0 0 
   No. of patients 0 0 0 119 88 0 0 
 
Diurnal IOP 
fluctuation (OAG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 2)     35, 74   
   No. of clusters 0 0 0 0 2 0 0 
   No. of studies 0 0 0 0 2 0 0 
   No. of patients 0 0 0 0 193 0 0 
Multivariable 
analysis (n = 3)  22 23 24    
   No. of clusters 0 1 1 1 0 0 0 
   No. of studies 0 1 1 1 0 0 0 
   No. of patients 0 110 47 70 0 0 0 
*Studies comprising a majority of normal-tension glaucoma patients. 
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Mean ocular 
perfusion pressure 
(OAG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 4)   74* 61 72, 73   
   No. of clusters 0 0 1 1 1 0 0 
   No. of studies 0 0 1 1 2 0 0 
   No. of patients 0 0 101 255 186 0 0 
Multivariable 
analysis (n = 3)    62, 74* 73   
   No. of clusters 0 0 0 2 1 0 0 
   No. of studies 0 0 0 2 1 0 0 
   No. of patients 0 0 0 356 146 0 0 
 
Right-hand eye 
(OAG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 5)   38, 40, 41 51 32*   
   No. of clusters 0 0 1 1 1 0 0 
   No. of studies 0 0 3 1 1 0 0 
   No. of patients 0 0 863 40 61 0 0 
Multivariable 
analysis (n = 0)        
   No. of clusters 0 0 0 0 0 0 0 
   No. of studies 0 0 0 0 0 0 0 
   No. of patients 0 0 0 0 0 0 0 
 
Lower educational 
level (OAG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 1)   41     
   No. of clusters 0 0 1 0 0 0 0 
   No. of studies 0 0 1 0 0 0 0 
   No. of patients 0 0 401 0 0 0 0 
Multivariable 
analysis (n = 4)   38 39, 55 41   
   No. of clusters 0 0 1 2 1 0 0 
   No. of studies 0 0 1 2 1 0 0 
   No. of patients 0 0 301 1165 401 0 0 
*Studies comprising a majority of normal-tension glaucoma patients. 
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Minimum IOP of 
diurnal variation 
(OAG) 
More progression 
No relation 
Less progression 
Significant  Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 2)     35, 74   
   No. of clusters 0 0 0 0 2 0 0 
   No. of studies 0 0 0 0 2 0 0 
   No. of patients 0 0 0 0 193 0 0 
Multivariable 
analysis (n = 2)    22, 24    
   No. of clusters 0 0 0 1 0 0 0 
   No. of studies 0 0 0 2 0 0 0 
   No. of patients 0 0 0 180 0 0 0 
 
Maximum IOP of 
diurnal variation 
(OAG) 
More progression 
No relation 
Less progression 
Significant  Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 2)     35, 74   
   No. of clusters 0 0 0 0 2 0 0 
   No. of studies 0 0 0 0 2 0 0 
   No. of patients 0 0 0 0 193 0 0 
Multivariable 
analysis (n = 2)    22, 24    
   No. of clusters 0 0 0 1 0 0 0 
   No. of studies 0 0 0 2 0 0 0 
   No. of patients 0 0 0 180 0 0 0 
 
Major hypoten-
sion (OAG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 3)   26* 30* 76*   
   No. of clusters 0 0 1 1 1 0 0 
   No. of studies 0 0 1 1 1 0 0 
   No. of patients 0 0 59 160 286 0 0 
Multivariable 
analysis (n = 1)    62    
   No. of clusters 0 0 0 1 0 0 0 
   No. of studies 0 0 0 1 0 0 0 
   No. of patients 0 0 0 255 0 0 0 
*Studies comprising a majority of normal-tension glaucoma patients. 
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Older age at 
diagnosis (OAG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 3)   47 50 48   
   No. of clusters 0 0 1 1 1 0 0 
   No. of studies 0 0 1 1 1 0 0 
   No. of patients 0 0 48 88 152 0 0 
Multivariable 
analysis (n = 2)    47 50   
   No. of clusters 0 0 0 1 1 0 0 
   No. of studies 0 0 0 1 1 0 0 
   No. of patients 0 0 0 48 88 0 0 
 
Mean arterial 
blood pressure 
(OAG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 2)   74*    73 
   No. of clusters 0 0 1 0 0 0 1 
   No. of studies 0 0 1 0 0 0 1 
   No. of patients 0 0 101 0 0 0 146 
Multivariable 
analysis (n = 2)    21* 73   
   No. of clusters 0 0 0 1 1 0 0 
   No. of studies 0 0 0 1 1 0 0 
   No. of patients 0 0 0 32 146 0 0 
 
Disc size (OAG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 3)   13, 82 30*    
   No. of clusters 0 0 2 1 0 0 0 
   No. of studies 0 0 2 1 0 0 0 
   No. of patients 0 0 275 160 0 0 0 
Multivariable 
analysis (n = 1)    13    
   No. of clusters 0 0 0 1 0 0 0 
   No. of studies 0 0 0 1 0 0 0 
   No. of patients 0 0 0 30 0 0 0 
*Studies comprising a majority of normal-tension glaucoma patients. 
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Threat to fixation 
(OAG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 3)    4, 65 80   
   No. of clusters 0 0 0 2 1 0 0 
   No. of studies 0 0 0 2 1 0 0 
   No. of patients 0 0 0 134 293 0 0 
Multivariable 
analysis (n = 0)        
   No. of clusters 0 0 0 0 0 0 0 
   No. of studies 0 0 0 0 0 0 0 
   No. of patients 0 0 0 0 0 0 0 
 
Cardiac arrhyth-
mia (OAG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 3) 76  77 30    
   No. of clusters 1 0 1 1 0 0 0 
   No. of studies 1 0 1 1 0 0 0 
   No. of patients 286 0 256 160 0 0 0 
Multivariable 
analysis (n = 1)    76    
   No. of clusters 0 0 0 1 0 0 0 
   No. of studies 0 0 0 1 0 0 0 
   No. of patients 0 0 0 286 0 0 0 
 
High cholesterol 
levels (OAG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 3)    27 76*  77* 
   No. of clusters 0 0 0 1 1 0 1 
   No. of studies 0 0 0 1 1 0 1 
   No. of patients 0 0 0 70 286 0 256 
Multivariable 
analysis (n = 1)    77*    
   No. of clusters 0 0 0 1 0 0 0 
   No. of studies 0 0 0 1 0 0 0 
   No. of patients 0 0 0 256 0 0 0 
*Studies comprising a majority of normal-tension glaucoma patients. 
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Focal ischemic 
disc pathology 
(OAG) 
More progression 
No relation 
Less progression 
Significant  
Non-
significant 
Non-
significant 
 Significant 
Univariate 
analysis (n = 1)   45     
   No. of clusters 0 0 1 0 0 0 0 
   No. of studies 0 0 1 0 0 0 0 
   No. of patients 0 0 72 0 0 0 0 
Multivariable 
analysis (n = 2)    22*, 24*    
   No. of clusters 0 0 0 1 0 0 0 
   No. of studies 0 0 0 2 0 0 0 
   No. of patients 0 0 0 180 0 0 0 
*Studies comprising a majority of normal-tension glaucoma patients. 
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ABSTRACT 
Purpose: To develop a prediction model for glaucomatous visual field progression using 
easily accessible baseline clinical data. 
 
Patients and Methods: We collected baseline data of 613 consecutive patients with 
open-angle glaucoma from 2001 to 2003. The rate of visual field progression was 
calculated using the Visual Field Index (VFI) of routine follow-up examinations until 
2010. Baseline data of 333 patients from three hospitals were used to develop a model 
to predict the rate of VFI progression using a linear regression analysis and univariate 
pre-selection (p<0.1) of eight candidate predictors. The performance of the model was 
investigated using R2, the area under the receiver operating characteristic curve (AUC), 
and calibration plots. The prediction model was internally validated using bootstrapping 
and externally validated in 280 patients from two other hospitals. 
 
Results: After a mean follow-up period of 5.8 years of all 613 eyes, the mean rate of VFI 
progression was -1.6% per year. During model development, 10.3% of the observed 
variation in VFI rates was explained by the model. The AUC was 0.76 when the predic-
tion model was used to detect a VFI rate ≤-3% per year, which decreased to 0.71 at 
external validation. The final model contained the following predictors: age, baseline 
intraocular pressure (IOP), and baseline visual field status.  
 
Conclusions: Our prediction model may offer the possibility to indentify subgroups of 
treated patients with high rates of visual field progression, thereby providing an oppor-
tunity for more intensive treatment of those high-risk glaucoma patients. 
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Introduction 
Open-angle glaucoma (OAG) is a chronic, progressive optic neuropathy with a charac-
teristic appearance of the optic nerve and associated visual field defects.1 Glaucoma is 
the second leading cause of blindness worldwide.2 The ability to differentiate rapidly 
progressing patients from slowly progressing patients would give ophthalmologists the 
opportunity to direct more intensive treatment to those who are at a high risk of be-
coming blind, and could additionally prevent adverse events and costs of intensive 
treatment in those at a low risk of blindness.3 One approach to differentiate between 
patients with fast and slow progression is to monitor disease progression. However, this 
consumes time and damage has already occurred before treatment is intensified. 
Another approach is to predict progression.  
 
Currently, an ophthalmologist takes into account the patient’s life expectancy and 
disease stage to estimate the patient’s risk of visual disability. A reliable rate of visual 
field progression should also be estimated for this purpose.4 Knowledge of prognostic 
factors (i.e. predictors of progression) can help the ophthalmologist to identify patients 
at risk of high rates of progression. Combining prognostic factors in a clinical prediction 
model may further quantify the risk and makes it easier for a clinician to aggregate 
knowledge of several prognostic factors.5, 6 However, currently there is no model 
available to predict the rate of glaucomatous visual field progression.  
 
The aim of the present study is to develop a model to predict the rate of visual field 
progression in individual OAG patients by quantifying the contribution of several base-
line prognostic factors. 
Material and methods 
Study population 
We performed a retrospective analysis based on data from a multicentre prospective 
follow-up study. We used the database of the DUtch Research project on treatment 
outcome IN Glaucoma patients (DURING) study to identify OAG patients who were 
consecutively recruited in the latter project from 2001 to 2003.7, 8 All patients were 
treated with topical glaucoma medication at baseline. Patients received routine follow-
up examinations and standard medical care prescribed by their ophthalmologist. In-
formed consent was obtained from all patients. Seventy-nine percent of the invited 
patients eventually participated in the DURING study. For the current study we collect-
ed patients from five out of the nine originally participating Dutch hospitals, including 
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one academic hospital. This study was approved by the local ethics committees and 
conformed to the tenets of the Declaration of Helsinki. All patients gave their informed 
consent prior to inclusion in the study. 
 
A flow chart of the patient selection process is shown in Figure 1. We used 333 patients 
from three hospitals to develop the prediction model (i.e. the development sample in 
Figure 1a) and 280 patients from two other hospitals to validate the model (i.e. the 
validation sample in Figure 1b). We included one eye of each patient. OAG had to be 
diagnosed in the study eye by the ophthalmologist at the baseline visit of the DURING 
study. Eyes diagnosed as having primary open-angle glaucoma (POAG), normal tension 
glaucoma (NTG), pigment glaucoma (PG), or pseudoexfoliation glaucoma (PXG) were 
included. 
 
1089 patients included in the DURING study (from 3 locations)
  
Patients without open-angle glaucoma (n = 430) 
No standard visual fields available at baseline (n = 133) 
No reliable standard SITA visual fields available for follow-up (n = 97) 
Patients without baseline visual field loss (n = 80) 
Manifest learning effect (n = 16) 
 
333 eyes of 333 patients were used in the analyses
 
Figure 1a: Flow chart of the patient selection process for the development sample 
 
1193 patients included in the DURING study (from 2 locations)
  
Patients without open-angle glaucoma (n = 444) 
No standard visual fields available at baseline (n = 122) 
No reliable standard SITA visual fields available for follow-up (n = 150) 
Patients without baseline visual field loss (n = 151) 
Manifest learning effect (n = 46) 
 
280 eyes of 280 patients were used in the analyses
 
Figure 1b: Flow chart of the patient selection process for the validation sample 
DURING = DUtch Research project on treatment outcome IN Glaucoma patients, SITA = Swedish Interactive 
Thresholding Algorithm. 
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Visual fields 
All visual fields in this study were performed with the Humphrey Field Analyzer (HFA) 
(Carl Zeiss Meditec, Dublin, CA, USA). Standard 24-2 or 30-2 visual fields obtained 
earlier or at the same day of the baseline visit of the DURING study had to be available 
for each patient for inclusion (Figure 1). At least two standard Swedish Interactive 
Thresholding Algorithm (SITA) Fast or SITA Standard visual field tests with less than 15% 
false positive answers were required. Baseline visual field loss was required for each 
included eye. This was indicated by a Glaucoma Hemifield Test (GHT) “outside normal 
limits” and/or a significant (p<0.05) deviation of the pattern standard deviation index 
(PSD). If both eyes were diagnosed as having OAG, we selected the most affected eye 
based on the GHT and the PSD. If both eyes of a patient were equally affected, one eye 
was randomly chosen. No manifest learning effect was permitted for patients with only 
two available visual fields (see Figure 1).  
 
All available visual fields were collected until 2010 and the Visual Field Index (VFI) was 
extracted. The VFI is a summary value of all individual test points in one visual field and 
is expressed as a simple percentage, 100% representing a normal visual field. Although 
the VFI may not be suited to detect early visual field damage and has not proven to be 
superior to the mean deviation (MD) index,9 we chose the rate of the VFI as measure of 
visual field progression, because the VFI is corrected for the effect of cataract, is more 
heavily weighted to central areas of the visual field, and is used to calculate a patient’s 
rate of progression in modern HFA software, expressed as percentage of visual field loss 
per year.10 
Candidate predictors 
The following eight candidate predictors, which were available at the baseline visit of 
the DURING study, were included in the initial prediction model: gender, age, mean 
intraocular pressure (IOP) of the last two visits at baseline, MD value of the baseline 
visual field, diagnostic category of OAG, previous disease progression subjectively 
determined by the ophthalmologist, patient’s adherence with medication, and the MD 
difference between the study eye and the fellow eye. IOP and baseline MD were initially 
modeled as continuous variables but were recoded as categorical predictors based on 
hypotheses of a nonlinear relation with progression.11, 12 The effect on R2 was assessed 
and the coding that explained most of the variance was used for the multivariable 
model. Disease progression and adherence were derived from a form filled in by oph-
thalmologists participating in the DURING study at the baseline visit. One of the ques-
tions was “Are you changing therapy?”. If the answer was “yes”, he/she was asked why 
the therapy was changed. Possible answers were “the current therapy has no/little 
effect on IOP”, “target pressure has not been reached”, “adverse effects”, or “because 
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of glaucoma progression”. The patients whose therapy was changed because of glau-
coma progression were labeled progressive at baseline for the current study. Adher-
ence was assessed by the question “When was the last time the patient put drops in his 
eyes?”. Generally, glaucoma eye drops have to be used at least once every 24 hours. 
We therefore labeled the patient as being non-adherent for the current study if the 
answer was “before yesterday morning”. 
Model development 
In the development sample from three of the five hospitals (n=333), we applied a 
multivariable linear regression analysis to develop a model with variables that predict 
the VFI rate over the follow-up period. We applied a univariate pre-selection of the 
eight candidate predictors with linear regression analysis and used p<0.10 to include 
predictors in the multivariable model. As a control analysis, we also applied a forward 
and backward selection approach with an entry criterion of p<0.05 and a removal 
criterion of p<0.10 respectively. 
When patients had missing values for predictors in the univariate analysis, we per-
formed a complete case analysis (i.e. we only included patients with available data in 
the specific analysis). The influence of the following five potentially confounding factors 
was assessed by alternatively adding these factors to the multivariable model: duration 
of follow-up, previous experience with perimetry, number of visual field assessments 
performed, clinical centre where the patient was included, and whether the patient was 
already treated before the baseline visit.  
Model evaluation 
The performance of the model was expressed in terms of explained variation (R2 statis-
tic). Furthermore, the discriminative ability of the model was tested by calculating the 
areas under the receiver operating characteristic (ROC) curves (AUC) for detecting rates 
of progression from -1% to -4% per year. An AUC near 0.5 indicates that the model is no 
better than a coin-flip in identifying progressive patients and a value of 1.0 indicates a 
perfect test.13 We also made contingency tables and calculated the sensitivity, specifici-
ty, and predictive values for different cut-off points on the ROC curves. A calibration 
plot was constructed to make a visual evaluation of the fit of the model in the study 
population.  
 
The clinical prediction model was internally validated using 200 bootstrap samples.14 
We calculated optimism-corrected performance measures. We also calculated the 
optimism-corrected calibration slope and used this as a uniform shrinkage factor for the 
regression coefficients in the multivariable model.15 After shrinkage, we calculated the 
new regression constant by making the mean predicted and observed VFI rate equal.  
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The clinical prediction model was externally validated in a validation sample derived 
from the two other hospitals (n=280). We applied the internally validated model in this 
sample to predict individual VFI rates. The AUC was calculated and a new calibration 
plot was constructed. We also fitted the prediction model in the validation sample, 
compared the new regression coefficients with the coefficients in the development 
sample, and calculated the new R2. We eventually formulated the final regression 
formula based on the entire sample derived from all hospitals (n=613). 
 
Internal model validation was performed using the statistical software R (version 2.9.1). 
For all other analyses we used SPSS for Windows (version 15.0). 
Results 
Study population 
We included 613 eyes of 613 patients. After a mean follow-up period of 5.8 years, a 
mean of 5.0 visual fields were performed. The mean rate of VFI progression was -1.6% 
per year in the entire population. We constructed the prediction model based on 333 
patients from hospitals A, B, and C. The prediction model was externally validated in 
280 patients from hospitals D and E. Table 1 summarizes the descriptive statistics of the 
candidate predictors, the potentially confounding variables, and the outcome measure 
for both groups. For the development sample, the mean observed rate of VFI progres-
sion was -1.9% (standard deviation (SD) ± 3.4) per year. The validation sample had a 
lower mean rate of VFI progression of -1.3% (SD ± 3.2) per year (Table 1). Values for the 
candidate predictors were comparable between both groups, although the validation 
sample had a better baseline visual field (Table 1). 
Model development 
After categorizing the continuous predictor baseline IOP into IOP ≤21 mmHg and IOP 
>21 mmHg, the univariate model R2 improved from 1.1% to 2.6%. This cut-off point also 
had the highest R2 when we varied the cut-off points in the univariate analysis from 18 
to 26 mmHg. Dividing IOP into tertiles did not improve the model. Categorizing the 
continuous predictor baseline MD into tertiles led to an improvement from 1.2% to 
4.0% in the univariate model R2. The group with the best visual fields was selected as 
reference group for the groups with moderate visual field loss (i.e. MD values ≤-4.6 dB 
and >-10.8 dB) and severe visual field loss (i.e. MD values ≤-10.8 dB). The model did not 
further improve when we categorized baseline MD into quartiles.  
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Age, IOP and baseline visual field status were entered into the multivariable model after 
univariate pre-selection of predictors (Table 2). No confounding variables had consider-
able effects on the regression coefficients or the model R2 except baseline experience 
with perimetry. The R2 of the multivariable model changed from 8.7% to 11.2% when a 
dichotomous variable was included that indicated patients with a lack of previous 
perimetric experience as well as only two available visual fields. Therefore, we decided 
to exclude these 16 patients (i.e. indicated by “manifest learning effect” in Figure 1). 
Twenty-five patients with two available visual fields and previous perimetric experience 
remained in the population of 333 patients. Without these patients, R2 of the multivari-
able model changed from 10.3% to 10.6%. We decided to keep these patients in the 
model. With a forward selection approach the same multivariable model was obtained. 
With backward selection, the multivariable model contained adherence as extra predic-
tor (p=0.064). The positive regression coefficient (i.e. 1.853) means that non-adherence 
results in less visual field progression. Because of its borderline statistical significance 
and contra intuitive direction of its relation with progression, we did not include this 
variable in the multivariable model.  
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Table 1: Descriptive statistics of the study population  
Descriptive statistics Development sample
(n = 333) 
Validation sample 
(n = 280) 
Candidate predictors    
Female sex 130 (39%) 138 (49%) 
Age 68.1 years (±10.9) 69.1 years (±9.0) 
Baseline IOP 16.4 mmHg (±3.8) 16.2 mmHg (±3.5) 
Low IOP (≤21 mmHg) 295 (89%) 262 (94%) 
High IOP (>21 mmHg) 38 (11%) 18 (6%) 
Baseline MD -8.9 dB (±6.8) -7.2 dB (±6.6) 
High MD (>-4.6 dB) 111 (33%) 127 (45%) 
Moderate MD (-10.8 dB < MD ≤-4.6 dB) 112 (34%) 87 (31%) 
Low MD (≤-10.8 dB) 110 (33%) 66 (24%) 
Diagnosis   
POAG 280 (84%) 257 (92%) 
NTG 34 (10%) 18 (6%) 
PG 13 (4%) 2 (1%) 
PXG 6 (2%) 3 (1%) 
Subjective progressiona 19 (6%) 3 (1%) 
Last eye drop ≥2 days agob 11 (3%) 3 (1%) 
MD difference between both eyesc -2.5 dB (±8.5) -3.0 dB (±7.1) 
Potentially confounding variables   
Follow-up period 6.2 years (±2.4) 5.3 years (±2.2) 
Previous perimetric experience 266 (80%) 200 (71%) 
Number of visual fields 5.9 (±2.7) 4.0 (±1.7) 
Clinical centre   
A 230 (69%) - 
B 39 (12%) - 
C 64 (19%) - 
D - 93 (33%) 
E - 187 (67%) 
Patients not treated before baseline 7 (2%) 10 (4%) 
Outcome variable   
Observed VFI rate -1.9% (±3.4) -1.3% (±3.2) 
Values are displayed as means and standard deviations or frequencies and percentages. 
aComplete case analysis with 330 patients and 277 patients respectively.  
bComplete case analysis with 315 patients and 267 patients respectively. 
cComplete case analysis with 278 patients and 182 patients respectively; a positive value indicates a worse
fellow eye.  
IOP = intraocular pressure, MD = mean deviation, POAG = primary open-angle glaucoma, NTG = normal-
tension glaucoma, PG = pigment glaucoma, PXG = pseudoexfoliation glaucoma, VFI = Visual Field Index. 
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Table 2: Results of univariate pre-selection of predictors  
Candidate predictors 
Coefficients and model fit 
Beta Confidence interval Significance R2 
Moderate visual field group 
(ref. best visual field group) 
-1.31 -2.18, -0.44 0.003 4.4% 
Poor visual field group 
(ref. best visual field group) 
-1.63 -2.51, -0.76 0.000 4.4% 
High IOP (>21 mmHg) 
(ref. low IOP) 
-1.93 -3.05, -0.80 0.001 3.3% 
Age 
(per year older) 
-0.05 -0.08, -0.01 0.005 2.3% 
Female sex 
(ref. male sex) 
-0.58 -1.32, 0.17 0.127 0.7% 
MD difference in both eyesa 
(per decibel higher) 
0.03 -0.01, 0.08 0.176 0.7% 
Last eye drop ≥2 days agob 
(ref. <2 days ago) 
1.43 -0.57, 3.43 0.161 0.6% 
Normal-tension glaucoma 
(ref. POAG) 
0.29 -0.92, 1.50 0.636 0.5% 
Pigment glaucoma 
(ref. POAG) 
-0.96 -2.85, 0.92 0.315 0.5% 
Pseudoexfoliation glaucoma 
(ref. POAG) 
0.91 -1.83, 3.65 0.516 0.5% 
Subjective progressionc 
(ref. no progression) 
0.71 -0.86, 2.28 0.376 0.2% 
Results of the univariate analyses for 333 eyes of 333 patients. The candidate predictors are ranked according
to their R2 value. Age, IOP and baseline visual field status were eventually selected for the multivariable
analysis.  
aComplete case analysis with 278 patients; a positive value indicates a worse fellow eye.  
bComplete case analysis with 315 patients.  
cComplete case analysis with 330 patients.  
R2 = explained variation, which is a measure of the model fit, ref. = reference group, IOP = intraocular 
pressure, MD = mean deviation, POAG = primary open-angle glaucoma. 
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The multivariable model contained the following predictors and accompanying regres-
sion coefficients: age (-0.04% per year older), baseline IOP  
(-2.18% for IOP values above 21 mmHg), and baseline visual field status (-1.34% for 
moderate and -1.71% for severely affected visual fields). 
Model evaluation in the development sample 
R2 of the multivariable model was 10.3%. The calibration plot is shown in Figure 2a. The 
mean absolute difference between the observed and predicted VFI rate was 1.97% and 
had a positively skewed distribution. 
 
Based on the relatively large scattering in the calibration plot and the relatively high 
absolute difference between the observed and predicted VFI rate, we assessed the 
value of the model in identifying rapidly progressing patients instead of predicting an 
exact VFI rate for individual patients. Therefore, we calculated the AUC for detecting 
different rates of visual field progression (Table 3). The highest AUC (i.e. 0.76) was 
found when the model was used to detect a rate ≤-3% per year. The ROC curve for this 
rate is shown in Figure 3. Seventy-five out of 333 patients (22.5%) had an observed VFI 
rate ≤-3% per year. We calculated the sensitivity, specificity, and predictive values for 
different cut-off points on this ROC curve (Table 4). When using a cut-off point of -3.0% 
on the ROC curve, we found a positive predictive value (PPV) of 0.61 and a negative 
predictive value (NPV) of 0.81 (Table 4). This corresponds to a 61% and 19% chance of 
being rapidly progressive with a positive and negative test result, respectively. 
 
Using 200 bootstrap samples, we estimated the optimism-corrected R2 at 7.2% and the 
AUC at 0.75 for the detection of a rate ≤-3% per year. The uniform shrinkage factor 
estimated with bootstrapping was 0.925, resulting in the following internally validated 
model: 
 
VFI rate = 
2.05 + -0.04 * age + -2.01 * IOP >21 mmHg + -1.24 * moderate MD + -1.58 * low MD 
 
 
Chapter  3  
84 
 
Figure 2a: Calibration plot of the model predicting the rate of progression in the development sample (n=333) 
 
 
 
Figure 2b: Calibration plot of the internally validated model predicting the rate of progression in the validation 
sample (n = 280) 
Each point represents the observed VFI rate and the predicted VFI rate of one of the patients included.  
VFI = Visual Field Index. 
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Figure 3: ROC curve for detecting a VFI rate ≤-3% per year (n=333) 
ROC curve = receiver operating characteristic curve, VFI = Visual Field Index. 
 
Model evaluation in the validation sample 
When we applied the internally validated model to individual patients in the validation 
sample, the mean predicted VFI rate was -1.6% (SD ± 0.9) per year. The accompanying 
calibration plot is shown in Figure 2b. Fifty out of 280 patients (17.9%) in the validation 
sample had an observed VFI rate ≤-3% per year. We found an AUC of 0.71 when we 
applied the internally validated model to detect a VFI rate ≤-3% per year in the valida-
tion sample. 
 
When we fitted the model in the validation sample, R2 was 5.3%. All coefficients were 
closer to zero, except for age: 
VFI rate = 
2.88 + -0.05 * age + 0.07 * IOP >21 mmHg + -0.80 * moderate MD + -1.06 * low MD 
 
The model without IOP had the same R2. The coefficients of age and baseline MD were 
not influenced by the addition of IOP to the model. Therefore, we decided to keep IOP 
in the model.  
Final model 
The final model fitted in the entire population of 613 patients was:  
VFI rate = 
2.43 + -0.05 * age + -1.52 * IOP >21 mmHg + -1.20 * moderate MD + -1.52 * low MD 
R2 of the final model was 7.6%.  
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Table 3: AUCs for detecting different rates of visual field progression (n=333)  
Detected VFI rates Observed cases Prevalence AUC Confidence interval 
≤-1.0% 169 50.8% 0.697 0.640, 0.753 
≤-1.5% 138 41.4% 0.712 0.656, 0.768 
≤-2.0% 110 33.0% 0.743 0.688, 0.798 
≤-2.5% 92 27.6% 0.747 0.690, 0.804 
≤-3.0% 75 22.5% 0.756 0.697, 0.816 
≤-3.5% 67 20.1% 0.755 0.696, 0.813 
≤-4.0% 53 15.9% 0.751 0.687, 0.816 
The number of observed highly progressive cases for each cut-off point with the corresponding prevalence is 
shown in the second and third columns. The AUC and its confidence interval are shown in the last two
columns.  
VFI = Visual Field Index, AUC = the area under the receiver operating characteristic curve. 
 
Table 4: Accuracy measures for different cut-off points on the ROC curve for detecting a VFI rate ≤-3% per 
year (n=333) 
Cut-off point of  
predicted VFI rate 
Predicted  
cases 
True 
positives 
Sensitivity Specificity Predictive values 
Positive Negative 
-1.0% 243 69 0.92 0.33 0.28 0.93 
-1.5% 216 66 0.88 0.42 0.31 0.92 
-2.0% 176 62 0.83 0.56 0.35 0.92 
-2.5% 86 39 0.52 0.82 0.45 0.85 
-3.0% 31 19 0.25 0.95 0.61 0.81 
-3.5% 20 12 0.16 0.97 0.60 0.80 
-4.0% 15 10 0.13 0.98 0.67 0.80 
The total number of observed cases with a VFI rate ≤-3% per year is 75, with a prevalence of 22.5%.  
ROC = receiver operating characteristic, VFI = Visual Field Index. 
Discussion 
Although only a small amount of the variance in visual field progression could be ex-
plained by our prediction model, it may offer the possibility to indentify subgroups of 
treated patients with high rates of glaucomatous visual field progression and provide an 
opportunity for more intensive treatment of these patients. Three out of eight tested 
predictors (i.e. age, IOP, and baseline visual field) significantly improved predictions of 
the VFI rate in the multivariable model. Regression coefficients were consistent at the 
external validation, with the exception of IOP.  
 
However, we feel that our model should not be used to predict an exact VFI rate for an 
individual patient, because we found a large scattering in the calibration plot (Figure 2a) 
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and a relatively high absolute difference between the observed and predicted VFI rate. 
The performance of our prediction model improved when it was used to distinguish 
rapidly progressive and a slowly progressive glaucoma patients. AUCs ranged from 
0.743 to 0.756 when detecting VFI rates ≤-2%, ≤-3%, or ≤-4% per year (Table 3). The 
accuracy measures of Table 4 reflect the potential clinical value of the prediction model. 
Without the use of a prediction model, the probability of a VFI rate ≤-3% for each 
individual patient in the development sample is 22.5% (i.e. the prevalence). With use of 
our prediction model, this chance becomes 61% (i.e. the PPV) and 19% (i.e. 1-NPV) after 
a positive and negative test result, respectively (Table 4). Hence, a positive result of our 
prediction model gives a clinical significant change in a patient’s risk of future rapid 
progression.  
 
In conducting the current study, we applied broad selection criteria to give a good 
representation of patients with OAG in clinical practice. Therefore, we included patients 
who had at least two reliable visual fields available, although we know that rates of 
progression based on a low number of visual fields may be less reliable.16 We found no 
significant effect of the number of visual fields performed on the performance of the 
prediction model (p=0.410). This might be explained by the relatively long follow-up 
period in this study, resulting in higher signal-to-noise ratios for the rate of progression.17 
Furthermore, we excluded no patients because of other ocular pathology, like cataract. 
We used the VFI as outcome measure, which corrects for general visual field depression 
in patients with early and moderate visual field loss.10  
 
In an earlier review, we found 85 studies that investigated prognostic factors for glau-
comatous visual field progression in univariate or multivariable models.18 However, only 
a few models have been assessed for their clinical performance in predicting progres-
sion. Nouri Mahdavi and co-workers used a prediction model with predictors derived 
during the first four years of follow-up to predict visual field progression after eight 
years.19 Sensitivity and specificity of the model were actually quite high (i.e. 0.86 and 
0.73 respectively) at the best cut-off point for visual field progression in the first four 
years.19 The sensitivity and specificity of our model (i.e. 0.83 and 0.56 respectively, as 
shown in Table 4) were lower, probably because we used baseline data instead of data 
collected over a period of four years. In another study, De Moraes and co-workers used 
an independent population for external validation of their prediction model.20 Like in 
the current study, the R2 statistic of their model at external validation (i.e. 14%) was 
low. However, the c-index of their model at external validation was 0.78, which is 
relatively high compared with the analogous AUC of 0.71 in the current study. This may 
be partly explained by the inclusion of prognostic factors in their prediction model that 
were collected during the follow-up period instead of at baseline, like peak IOP and 
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mean IOP.20 Other studies investigated the performance of models to predict conversion 
from ocular hypertension to glaucoma. For example, a prediction model for the five-year 
risk of developing glaucoma in ocular hypertensive patients has been implemented by the 
Ocular Hypertension Treatment Study (OHTS) Group.21 The AUC for this model was 0.76 in 
the development sample and 0.72 at external validation, which are very comparable with 
the values of our model.21 
 
The three predictors in our final model have shown to be among the most consistent 
prognostic factors for OAG progression.18, 22 An elevated IOP is also one of the few 
factors that can be modified by medical or surgical treatment.23 Reducing IOP has been 
shown to slow the onset and progression of OAG.24, 25 Therefore, treatment in clinical 
practice is mainly guided by IOP values. The effect of changing treatment based on IOP 
could dilute and even reverse the relation between IOP and visual field progression. This 
may explain why IOP did not contribute to the model in the external validation of our 
study. Nonetheless, we found a strong effect of baseline IOP with an R2 of 3.3% in the 
univariate analysis of the development sample. We modeled IOP as a dichotomous 
variable and found an optimal cut-off point at 21 mmHg. This cut-off point matches the 
traditional border between normal and abnormal IOP values.26 Baseline MD was also 
modeled as a categorical variable, because earlier studies have shown that the relation 
between visual field progression and baseline visual field loss is not uniform across the 
entire range of visual field loss. Progression is positively related with baseline visual field 
severity in early disease stages and negatively related with visual field severity in ad-
vanced disease stages.12, 27, 28  
 
Five out of eight tested prognostic factors were not included in the final prediction 
model because their p-value in the univariate pre-selection was ≥0.1. Suboptimal 
measurement may have contributed to the lack of significance for some of the predic-
tors. For example, adherence to glaucoma medication was defined as whether a patient 
used eyedrops in the last 24-hours before the baseline visit. There are indications that 
patient adherence improves close to an upcoming visit.29, 30 Therefore, adherence in this 
study may be overestimated. Previous disease progression at baseline was defined as 
subjective progression according to the treating ophthalmologist. It would be better to 
measure previous disease progression more objectively by making visual fields in the 
years before baseline. However, these were not available for most patients in the 
current study. Not all currently known predictors were investigated in our study be-
cause they were not available. For example, we did not study the presence of disc 
hemorrhages, central corneal thickness (CCT), and peripapillary atrophy.18 However, the 
strength of the current model is the use of simple, easily accessible baseline clinical 
data.  
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ABSTRACT 
Purpose: To study and quantify the difference in incidence of progression between 
methods for the assessment of glaucomatous visual field progression. 
 
Methods: We identified 2,450 articles published up to April 2009 in the following data 
sources: PubMed, EMBASE, and Cochrane. Ten studies covering 30 methods were 
included. All studies aimed to compare different methods for the assessment of glau-
comatous visual field progression in the same study population. A network meta-
analysis using a mixed-effects model was performed to combine within-study between-
method comparisons with indirect comparisons from other studies. The summarized 
incidence of progression was calculated for every method and methods were ranked 
according to this incidence.  
 
Results: In total, methods were compared in 1040 eyes of 948 glaucoma patients. On 
average, 21% of the eyes progressed. When all 30 methods were ranked, the incidence 
ranged from 2% to 62%. These incidences are corrected for a baseline mean deviation 
(MD) value of -7 decibels and a mean follow-up time of six years. Besides the assess-
ment method, the incidence was only determined by the follow-up period and baseline 
MD value, leaving no unexplained variance in the incidence of progression.  
 
Conclusion: The incidence of progression varies considerably between different studies. 
This is mainly caused by the variety of methods used to assess progression, but also by 
differences in follow-up time and baseline visual field loss.  
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Introduction 
Monitoring patients with open-angle glaucoma is based on the reliable detection of 
early deterioration of the visual field and subsequent lowering of the intraocular pres-
sure. The aim is to prevent irreversible visual field loss leading to visual disability.1 A 
major problem in the assessment of glaucomatous visual field progression is the lack of 
a gold standard.2 As a consequence, investigators often develop a new method for their 
own purposes. Many different methods have been described, ranging from completely 
subjective to fully automated calculations.3, 4 
 
If studies are using different methods and subsequently have different results, it is hard 
to distinguish the contribution of the chosen method from other study characteristics in 
the quantification of the incidence of progression. This could make studies incompara-
ble to each other. However, the extent to which the use of different methods leads to 
differences in study outcome between similar studies has not yet been investigated. 
What has been investigated is the use of different methods in one study population. 
Most frequently, the mutual agreement of a few methods was investigated by studying 
the difference in the proportion of patients who develop progression and the overlap in 
patients classified as having progressed. However, no studies have been published that 
compare all methods in one study. Therefore, a ranking of methods is missing and it 
remains unclear which methods give a high or a low incidence of progression. The 
interpretation and the possibility to compare studies will improve with a clear ranking. 
For example, it would make a real difference to find a high incidence with a low ranked 
method when compared to finding a low incidence with a high ranked method.  
 
In the present study, firstly all methods to assess glaucomatous visual field progression 
used in different studies were compared. Secondly, these methods were ranked accord-
ing to their incidence of progression and their difference was quantified using a network 
meta-analytic approach. Finally, we also investigated the influence of baseline visual 
field loss and follow-up time and determined the extent to which the incidence of 
progression was explained by these variables.  
Materials and methods 
Search strategy 
A systematic computerized search was performed in PubMed, EMBASE, and all data-
bases and registers of The Cochrane Library, in April 2009. The following keywords were 
used: (glaucoma*) AND (prognos* OR predict* OR progress* OR longitudinal OR cohort 
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OR follow-up) AND (perimetr* OR visual field* OR HFA OR Octopus OR Humphrey (not 
in author)). The search was limited to articles in English, Dutch, French, or German. A 
total of 2,450 articles were identified.  
Selection procedure 
All titles and abstracts were screened and articles were excluded based on predefined 
exclusion criteria. Of the remaining 782 articles that were studied completely, 48 
articles fulfilled the selection criteria (figure 1). The selected studies had to follow 
glaucoma patients for minimally one year with the use of conventional visual field 
examinations. Studies should also directly compare at least two methods to assess 
glaucomatous visual field progression within the same study population. After that, the 
type of perimeter used and a precise description of the methods used for assessment of 
visual field progression were recorded for these studies. In addition, the number of 
participants, duration of follow-up, number of visual field examinations, patient charac-
teristics, incidence of progression, and the publication year were noted. 
 
We combined direct and indirect comparisons of methods in a network meta-analysis. A 
direct comparison is defined as a comparison of methods in one study using exactly the 
same study population during the same study period. Indirect comparisons of two 
methods have not actually been made in one study, but are made in different studies by 
using a common comparator.5 Studies were excluded when no comparisons with other 
methods in the meta-analysis were possible. This led to the sole inclusion of studies that 
applied methods based on the Humphrey Field Analyzer (HFA) (Carl Zeiss Meditec, 
Dublin, CA, USA), since this perimeter was used in most studies on progression and no 
studies were found that directly compared HFA-based methods with methods from 
other perimeters. Furthermore, studies that did not report incidence proportions of 
progression and in which the incidence proportion could not be calculated from the 
data were excluded. We defined the incidence proportion as the proportion of glauco-
ma patients that developed visual field progression during the follow-up period of a 
specific study. Studies with populations that overlapped with other selected studies 
were also excluded to obtain a fair comparison between methods. In these cases, the 
study was chosen that had the most comparisons with methods used in other studies. 
When overlap of study populations was uncertain, more information was retrieved from 
the authors. Finally, two studies were found which investigated a selected group of 
glaucoma patients that was considered to be progressive based on clinical judgement.6, 
7 These studies were excluded, because including them would result in selection bias.8  
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2450 potential relevant articles identified and screened for retrieval
  
Exclusion criteria 
No measurement of visual field progression (n = 471)
Unconventional or single perimetric measurement (n = 434)
No visual field damage at baseline (n = 395)
Patients without glaucomatous disease (n = 244)
No original study (n = 172)
Follow-up of less than one year (n = 124)
Case-reports (n = 80)
Patients younger than 18 years (n = 35)
Animal study (n = 17)
Other languages than English, French, Dutch, or German (n = 8)
Abstracts (n = 23) 
Article not available in the Netherlands (n = 35)
No direct comparisons between methods (n = 364)
 
48 articles fulfilled the selection criteria
  
Additional exclusion criteria for the meta-analysis
No Humphrey Field Analyzer (n = 8)
No reporting of incidence of progression (n = 10)
No connections with the network (n = 5)
Overlap of patients with other studies in the network (n = 10)
Pre-selected progressive patients (n = 2)
Methods were applied on different groups (n = 1)
 
12 articles were included in the meta-analysis
 
Figure 1: Flow chart of the article selection process 
 
Finally, the data of twelve articles were combined in the network meta-analysis (figure 
1).9-20 Three articles were included that studied different methods in the same popula-
tion during the same follow-up period.12-14 Data of these articles were treated as a 
single study. The references of all included articles were additionally screened to identi-
fy more studies. This did not result in additional articles. However, we found one recent 
article that described the same study as one of the included articles.21 Since additional 
methods were applied in this article, we added these methods to the meta-analysis.  
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Statistical analysis 
If not available, incidence proportions of glaucomatous progression were calculated 
from the number of eyes that progressed for each method within each study. All inci-
dence proportions were then combined in a mixed-effects model. More specifically, an 
arm-based network meta-analysis model with dummy variables to identify the various 
methods was used for the analysis.22 The computations for these analyses were per-
formed with the statistical software R (version 2.10.1). An additional complication in the 
analysis arose due to the fact that incidence proportions from the same sample using 
different methods are correlated and therefore cannot be treated as independent 
observations. The magnitude of the correlation between several incidence proportions 
from the same sample can only be calculated if a complete cross-classification table of 
the various methods is provided in an article. Usually, such detailed information was 
unavailable. We therefore used the method suggested by Riley and co-workers.23 This 
method substitutes a single overall correlation parameter for the study-specific individ-
ual correlations.  
 
The model therefore is given by: 
yij = β1 M1,ij + β2 M2,ij + … + βx Mx,ij + uij + εij, 
 
where yij is the observed incidence proportion in study i for method j, M1,ij is a dummy 
variable (i.e., coded 1 or 0), indicating whether yij corresponds to method 1 (and similar-
ly for M2,ij through Mx,ij), the uij values denote the random effects, and the εij values 
denote the sampling errors. The model assumes that the variances of the uij's are equal 
to τ2, denoting the amount of heterogeneity in the true incidence proportions. Fur-
thermore, the correlation between two uij's from the same sample (i.e., study) is denot-
ed by ρ. The variances of the εij values were estimated based on the observed incidence 
proportions and can be denoted by vij. Moreover, two εij values from the same study are 
also assumed to be related to each other with their correlation given by ρ. Finally, 
assuming normality of the uij and εij values, the parameters of the model were then 
estimated using restricted maximum likelihood estimation. As a result, we obtained the 
following estimates from the model: the average incidence proportions for the various 
methods (estimated values of β1 through βx), the amount of heterogeneity in these 
results (estimate of τ2), and an estimate of the correlation for incidence proportions 
arising from the same study (estimate of ρ). The precision of the estimates of β1 
through βx was quantified via corresponding 95% confidence intervals obtained in the 
usual manner (i.e., estimate of β ± 1.96 SE, where SE denotes the standard error of the 
estimate of β). A confidence interval was also obtained for τ2, based on a profile likeli-
hood method.24  
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The mean deviation (MD) value at baseline and the mean follow-up time were also 
included as covariates in the model so that the incidence proportions from the various 
methods could be compared while controlling for the influence of these covariates. We 
included these covariates initially as linear predictors in the model, but also examined 
whether the incidence proportions changed as an accelerating (quadratic) function 
thereof. Another potential covariate was the mean number of visual field examinations 
for the patients in each study. However, this covariate correlated very strongly with the 
mean follow-up time in a study (r=0.79) and therefore it was almost impossible to 
distinguish. We chose to use follow-up time over the number of examinations because 
its influence on the incidence of progression is inherently more logical. 
 
Where possible, we also compared the incidence proportions of two methods from the 
network model with incidence proportions of the same two methods, which were based 
only on direct comparisons. To use a reasonable amount of data for getting more stable 
results, this additional analysis was only done for methods that were directly compared 
in three or more studies. 
Results 
The flow of articles included in this systematic literature review is shown in figure 1. 
Twelve articles that studied 30 methods in ten studies were included in the meta-
analysis. All methods were named and classified in six groups according to their main 
characteristics (table 1).  
Six groups of methods 
The first group consisted of methods based on the Glaucoma Progression Analysis 
(GPA), which is similar to the visual field endpoint in the Early Manifest Glaucoma Trial 
(EMGT).25 We abbreviated this group to "group G", from GPA. The GPA is an event 
analysis based on pattern deviation values and is included in the new HFA software. 
When significant deterioration (p<0.05) is seen on the pattern deviation probability 
maps of the GPA printouts in the same three or more points on three consecutive 
follow-up tests, the software interprets this as likely progression.25 Although some 
studies performed separate analyses after exclusion of eyes with a baseline visual field 
"out of range" according to the GPA printout of the HFA, we used the incidences of 
progression in all study eyes. Group A (A from AGIS) consisted of two methods that 
were based on the Advanced Glaucoma Intervention Study (AGIS).26 Both the AGIS 
method and the Collaborative Initial Glaucoma Treatment Study (CIGTS) method, which 
is derived from the AGIS method, use a scoring system to grade each visual field in the 
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follow-up period. The AGIS score is based on the actual decibel deviations at the total 
deviation plot, while the CIGTS algorithm is based on the p-values obtained from the 
total deviation probability plot. Both scoring systems range from 0 to 20, with 0 repre-
senting no field loss and 20 end-stage disease. Visual field series are considered to be 
progressive if the score has a minimal increase of four (with the AGIS method) or three 
points (with the CIGTS method) and is confirmed by two additional tests.27 In methods 
that are classified as point-wise linear regression (PLR) methods (group P from PLR), a 
linear regression analysis was performed in different individual locations at the visual 
field. Another group of methods was based on a linear regression analysis with visual 
field indices (group I from indices), like the MD and the Visual field index (VFI). The VFI is 
calculated by the new software of the HFA. Each location on the visual field contributes 
to the VFI, although it is more heavily weighted to central areas of the visual field.28 A 
location which is not significantly (p<0.05) depressed on the pattern deviation probabil-
ity map is considered to have a 100% sensitivity. The VFI is expressed as one percent-
age, where 100% represents a normal visual field and 0% represents a perimetrically 
blind eye. The HFA software performs a linear regression analysis of the VFI against 
time.28  
 
Another group of methods was made that combined a PLR and a linear regression 
analysis of the MD value. The methods in this group (group T from TNT) were variants of 
the Threshold Noiseless Trend (TNT) program.29 The TNT program filters perimetric 
results and takes into account dependency relations in the visual field. Moreover, it 
combines linear regression analyses of the MD, the cumulative defect curve, and 
different locations at the visual field. Suspected progression is seen the first time that 
one of these parameters indicates progression. If this result is repeated by two consecu-
tive examinations or if two or more parameters indicate progression, TNT indicates 
definite progression.17 Finally, a clinical group (group C from clinical) comprised meth-
ods based on clinical judgement. Classified in this group were methods based on entire-
ly subjective assessments of visual fields by multiple observers, who had to agree on 
progression while they were blinded for other clinical data. Other methods in this group 
used certain algorithms for the assessment of visual fields, for example based on the 
clinical judgement of scotoma’s.30 One clinical method was based on nonparametric 
ranking of MD values.19 This method objectifies the commonly practised method of 
monitoring glaucoma patients with the use of MD values. A visual field series is consid-
ered progressive as the MD value of a follow-up visual field is worse than the MD of the 
worse of two baseline fields. This has to be confirmed on at least two visual fields.19 We 
did not take into account one subjective method that was based on the experience and 
expertise of only one observer who was not blinded for other clinical information.11  
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Table 1: Description of the 30 methods studied 
 
Methods are classified in six groups according to their main characteristics.  
GPA = Glaucoma Progression Analysis, AGIS = Advanced Glaucoma Intervention Study, CIGTS = Collaborative 
Initial Glaucoma Treatment Study, PLR = point-wise linear regression, dB = decibels, MD = mean deviation, 
CPSD = corrected pattern standard deviation, VFI = Visual Field Index, TNT = Threshold Noiseless Trend  
G Based on Glaucoma Progression Analysis (GPA)
G1 GPA
G2 GPA using total deviation
G3 GPA with 2 follow-up visual fields
G4 Modified GPA; difference between number of improving points and deteriorating points (≥ 3) repeatable at 3 consecutive examinations
G5 Modified GPA using total deviation; difference between number of improving points and deteriorating points (≥ 3) repeatable at 3 consecutive examinations
A Based on Advanced Glaucoma Intervention Study (AGIS) method
A1 AGIS-method
A2 CIGTS-method
P Based on point-wise linear regression analysis (PLR)
P1 PLR with threshold values, using a criterion of p≤0.001 and a cut-off point of ≥ 4 locations
P2 PLR with threshold values, using a criterion of p≤0.001 and a cut-off point of ≥ 3 locations
P3 PLR with threshold values, using a criterion of p≤0.001 and a cut-off point of ≥ 2 locations
P4 PLR with threshold values, using a criterion of p≤0.001 and a cut-off point of ≥ 1 location
P5 Two-omitting PLR with pattern deviation values, using criteria of ≤-1dB per year and p<0.05 and a cut-off point of ≥ 3 locations at 3 consecutive examinations
P6 Two-omitting PLR with total deviation values, using criteria of ≤-1dB per year and p<0.05 and a cut-off point of ≥ 3 locations at 3 consecutive examinations
P7 PLR with total deviation values, using criteria of ≤-1dB per year and p≤0.01 and a cut-off point of ≥ 3 locations at 3 consecutive examinations, with consistent worsening through the end of follow-up
P8 PLR with PROGRESSOR software (threshold values), using criteria of ≤-1dB per year and  p≤0.05 and a cut-off point of ≥ 2 nonedge locations
I Based on linear regression analysis with indices
I1 Linear regression analysis of a Glaucoma Hemifield cluster, using a criterion of p<0.005 and a cut-off point of ≥ 4 clusters
I2 Linear regression analysis of a Glaucoma Hemifield cluster, using a criterion of p<0.005 and a cut-off point of ≥ 3 clusters
I3 Linear regression analysis of a Glaucoma Hemifield cluster, using a criterion of p<0.005 and a cut-off point of ≥ 2 clusters
I4 Linear regression analysis of a Glaucoma Hemifield cluster, using a criterion of p<0.005 and a cut-off point of ≥ 1 cluster
I5 Linear regression analysis of the MD, using a criterion of p<0.025
I6 Linear regression analysis of the MD, using a criterion of p<0.05
I7 Linear regression analysis of the CPSD, using a criterion of p<0.025
I8 Linear regression analysis of the VFI, using a criterion of p<0.05
T Based on PLR and linear regression analysis with indices
T1 Progression according to Threshold Noiseless Trend (TNT) program
T2 Suspected progression according to TNT program
C Based on clinical judgement
C1 Likely progression based on the subjective assessment of Humphrey printouts by multiple observers without using a predefined criterion; observers should reach agreement and were blinded for other clinical information
C2
Likely progression based on the subjective assessment of visual fields by multiple observers using PROGRESSOR 
software without a predefined criterion; observers should reach agreement and were blinded for other clinical 
information
C3 Nonparametric progression analysis based on nonparametric ranking of MD values
C4
At least one of these scotoma criteria: deepening of ≥2 points ≥10dB in the same locations; expansion of ≥2 points 
≥10dB; development of ≥2 adjacent points, not within or adjacent to a baseline scotoma, with p<1% or worse at 
pattern deviation plot or 1 previously normal location in central 10 degrees ≥10dB. Confirmations at the same 
locations on 3 consecutive fields, based on pattern deviation values
C5
At least one of these scotoma criteria: deepening of ≥2 points ≥10dB in the same locations; expansion of ≥2 points 
≥10dB; development of ≥2 adjacent points, not within or adjacent to a baseline scotoma, with p<1% or worse at 
pattern deviation plot or 1 previously normal location in central 10 degrees ≥10dB. Confirmations at the same 
locations on 2 consecutive fields, based on pattern deviation values
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Population characteristics 
In total, 1040 eyes of 948 glaucoma patients were studied in the ten studies included. 
As shown in table 2, all patients were derived from western countries, with mean 
baseline MD values ranging from -3.3 to -10.4 decibel (dB), and mean age ranging from 
57.7 to 72.5 years. An average of 1.7 visual fields per year were analysed in the studies. 
In one study, patients received laser therapy or filtration surgery according to a treat-
ment protocol.15 All other patients received various treatments during the follow-up 
period. An average of six methods was directly compared in the studies included. The 
uncorrected incidence proportions that were given or calculated for the different 
methods in the studies are also shown in table 2. The maximum difference in the 
incidence proportions within a single study was 0.44.  
Ranking of methods 
Figure 2 shows the ranking of the 30 methods according to their incidence proportions 
when combined in the meta-analysis. The mean estimated incidence proportion of 
progression was 0.21 (95% confidence interval (CI) 0.15, 0.26) in 6 years (dashed verti-
cal line in figure 2), indicating that on average 21% of the study eyes progressed in six 
years. The incidence proportions of progression according to 30 methods ranged from 
0.02 (CI -0.02, 0.05) for method P1 to 0.62 (CI 0.47, 0.78) for method P8. A continuous 
vertical line represents the incidence proportion of the GPA (method G1), which was 
the most frequently studied method, with six studies in this meta-analysis. With an 
incidence proportion of 0.16 (CI 0.14, 0.19), the GPA is in the middle of the ranking of all 
30 methods. The AGIS-based methods and most of the methods based on linear regres-
sion analysis with indices showed lower incidence proportions than the GPA method. 
Methods that are based on clinical judgement or the TNT program showed higher 
incidences than the GPA. All incidence proportions shown in figure 2 are the estimated 
rates when the mean follow-up time was set at six years and the mean baseline MD 
value was set at -7 dB. These values were chosen because these were the mean values 
in the ten included studies. Follow-up time was significantly associated with the inci-
dence of progression, with an increase in the incidence proportion of approximately 2.1 
percent points per extra follow-up year (p<0.001). Baseline MD was also significantly 
associated with the incidence of progression, increasing the incidence proportion by 0.9 
percent points per extra dB of MD loss (p=0.025). No accelerating (quadratic) relation-
ships between these two predictors and the incidence proportions were found (p=0.93 
and p=0.77, respectively). 
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Table 2: Characteristics of the ten studies included 
Study  
(year of 
publication) 
Source of the 
study population 
Method Uncorrected 
incidence 
proportion of 
progression 
Maximum 
difference in 
incidence of 
progression 
Number 
of 
patients 
and eyes
Mean 
baseline 
MD value 
(dB) 
Mean 
age 
(years)
Mean 
follow-up 
period 
(years) 
Mean 
number of 
visual field 
examin-
ations 
Number of 
visual 
fields per 
year 
Birch et al. 
 (1995) 
Royal Liverpool 
University 
Hospital, UK 
P8 0.56 0.42 NA 36 -7.5 NA 3.3* 6 1.8 
I6 0.14 
  
 
  
Smith et al.    
(1996) 
Glaucoma 
Service, Wilmer 
Institute, 
Baltimore, 
Maryland, USA 
P1 0.05 0.44 191 191 -8.7 61.8 7.1 9.5 1.3 
P2 0.07 
P3 0.11 
P4 0.19 
I1 0.06 
I2 0.07 
I3 0.09 
I4 0.18 
I5 0.49 
I7 
 
0.14 
Katz et al. 
(1997, 1999, 
2000) 
Glaucoma 
Screening Study, 
Baltimore, 
Maryland, USA 
G1 0.21 0.30 56 67 -7.4 62.0 6.3** 7** 1.1 
G2 0.33 
A1 0.10 
A2 0.19 
P2 0.03 
P3 0.10 
P4 0.22 
I1 0.06 
I2 0.10 
I3 0.12 
I4 0.25 
I5 0.18 
I7 0.07 
C1 
 
0.21 
Lee et al. 
(2002) 
DIGS, University 
of California, San 
Diego (and other 
locations), USA 
G1 0.08 0.09 48 48 -4.7 57.7 2.8 5 1.8 
G2 0.13 
G4 0.08 
G5 0.13 
A1 0.04 
A2 
 
0.04 
Viswanathan 
et al. (2003) 
Moorfields Eye 
Hospital, London, 
UK 
C1 0.19 0.22 27 27 -7.7** 61** 5.7** 16 2.8 
C2 0.48 
  
 
  
Artes et al.     
(2005) 
QEII Health 
Sciences Centre, 
Halifax, Nova 
Scotia, Canada 
G1 0.21 0.15 101 168 -3.3** 61** 10** 21** 2.1 
G2 0.30 
P5 0.24 
P6 0.36 
  
 
  
Nouri-Mahdavi 
et al. (2007) 
Advanced 
Glaucoma 
Intervention 
Study, USA 
G2 0.31 0.13 156 156 -10.4 64.4 8 18** 2.3 
A1 0.22 
P7 0.35 
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Study  
(year of 
publication) 
Source of the 
study population 
Method Uncorrected 
incidence 
proportion of 
progression 
Maximum 
difference in 
incidence of 
progression 
Number 
of 
patients 
and eyes
Mean 
baseline 
MD value 
(dB) 
Mean 
age 
(years)
Mean 
follow-up 
period 
(years) 
Mean 
number of 
visual field 
examin-
ations 
Number of 
visual 
fields per 
year 
Arnalich-
Montiel et al. 
(2009)# 
Ramon y Cajal 
Hospital, Madrid, 
Spain 
G1 0.19 0.18 90 90 -6.3 72.5 5.1 6.2 1.2 
G3 0.31 
I6 0.21 
I8 0.13 
C4 0.19 
C5 
 
0.30 
Diaz-Aleman et 
al. (2009) 
Aberdeen Royal 
Infirmary, 
Aberdeen, UK 
G1 0.11 0.41 42 56 -3.9 68.5 5.5 7.8 1.4 
G3 0.25 
T1 0.43 
T2 0.52 
C1 
 
0.14 
Wesselink et 
al. (2009) 
GLGS, UMCG, 
Groningen, the 
Netherlands 
G1 0.16 0.17 201 201 -9.4## 66.4## 5.3## 7.1## 1.3 
C3 0.33 
    
All data were directly derived from the articles,9-20 but we calculated the number of visual fields per year by 
dividing the number of visual field examinations by the follow-up period.  
* = the follow-up period for the total group of glaucoma patients and patients with ocular hypertension was 
used 
** = median value 
# = data were derived from a more recent article,21 which described the same study 
## = data for the total group of 221 patients was used.  
MD = mean deviation, dB = decibels, NA = data not available, DIGS = Diagnostic Innovations in Glaucoma 
Study, GLGS = Groningen Longitudinal Glaucoma Study, UMCG = University Medical Center Groningen. 
 
Table 2: continued 
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Figure 2: Ranking of 30 methods according to their incidence of visual field progression 
The 30 points represent the estimated incidences of visual field progression with their 95% confidence 
intervals of all methods studied. The incidences are corrected for a mean follow-up period of six years and a 
baseline mean deviation value of -7 decibels. The dashed vertical line represents the mean estimated 
incidence of visual field progression in the ten studies. The continuous vertical line represents the incidence of 
the Glaucoma Progression Analysis (method G1). The methods are grouped according to their main character-
istics: group G = methods based on Glaucoma Progression Analysis, group A = methods based on Advanced 
Glaucoma Intervention Study method, group P = methods based on point-wise linear regression analysis, 
group I = methods based on linear regression analysis with indices, group T = methods based on point-wise 
linear regression analysis and linear regression analysis with indices, group C = methods based on clinical 
judgement. 
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Contribution of methods 
The variance explained by the model can be expressed in terms of the amount of 
heterogeneity as estimated by the model (i.e., the estimate of τ2). After correcting for 
follow-up time and baseline MD, the methods used for assessing progression accounted 
for all the remaining heterogeneity between the estimated incidences of progression in 
studies (CI 0, 0.002). To estimate the contribution of the chosen method in the quantifi-
cation of the incidence of progression, the model in which all methods were assumed to 
have the same average incidence of progression (without including mean follow-up 
time and MD value as covariates) was compared with the model where all methods 
were allowed to have different incidences. The former model yielded an estimated 
amount of heterogeneity (i.e., the estimate of τ2) equal to 0.011 (CI 0.006, 0.022), which 
is decreased to 0.002 (CI <0.001, 0.008) when all methods were allowed to have differ-
ent incidences. Therefore, approximately 82% of the heterogeneity in this analysis can 
be accounted for by the variety of methods used in studies. The rest of the heterogenei-
ty was explained by the mean baseline MD value and the mean follow-up time.  
Additional analysis 
We evaluated the network model with both direct and indirect comparisons of methods 
by performing an additional analysis for the direct comparisons only. This analysis was 
also corrected for the mean follow-up time and the mean baseline MD. Methods G1 
and G2 were the only methods that were directly compared in three or more studies. 
The estimated difference in the incidence proportion between methods G1 and G2 was 
0.081 (CI 0.043, 0.120) in the model with only direct comparisons, while the difference 
in incidence was 0.077 (CI 0.033, 0.121) in the combined direct and indirect model. The 
direction and size of the difference between methods G1 and G2 was approximately the 
same in the direct model as in the combined direct and indirect model, although the 
combined model had a broader confidence interval.  
Discussion 
The mean incidence of glaucomatous visual field progression that we found in the 
literature was 21% in six years. This incidence was based on a large number of patients 
and a large number of methods to assess progression and can be seen as an average 
proportion of eyes that were considered to be progressive. The incidence of visual field 
progression had a large range from 2% to 62% in six years, depending on the method 
that was used. This again confirms the importance of the choice of a method to assess 
glaucomatous visual field progression. We then ranked these methods according to 
their incidence of progression. It is important to note that the incidences that we have 
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found for each method can only be generalized for clinically treated glaucoma patients 
with a mean baseline MD value around -7 dB and a mean follow-up time of six years. 
The estimates of progression should be corrected by adding 0.9% to the incidence or by 
subtracting 0.9% from the incidence, for each dB decrease and increase in baseline MD 
value respectively. In the same way, the incidences should be corrected by adding 2.1% 
for each year extra follow-up. The expected incidence of progression in an article that 
used another method can thus be estimated with the ranking presented in this article.  
 
Together with the range of incidences of progression, we also investigated to what 
extent the use of different methods will lead to differences in results between studies. 
The chosen method accounted for nearly all differences in the incidence of progression 
that we found in the included studies, with the exception of the part that can be ex-
plained by the baseline MD value and the follow-up time. This underscores the im-
portance of taking account of the method used when critically appraising and 
comparing studies on glaucomatous visual field progression. However, the present 
study also underlines the influence of baseline visual field loss and follow-up time on 
the incidence of glaucomatous visual field progression. When clinicians use the same 
method, these factors are even more important in clinical practice than the method 
that is used. Although a longer follow-up period logically leads to an increase in the 
incidence of visual field progression, a worse baseline visual field increases the chance 
of future visual field progression in an individual patient. It has been found in previous 
studies that more advanced baseline visual field loss was an independent predictor of 
future visual field progression.31 However, other studies have found a nonlinear relation 
of baseline visual field and subsequent progression32, 33 or even an opposite relation.34 
The latter finding could be explained by floor effects due to advanced visual field loss of 
the AGIS patients at baseline. This means that no worsening can be observed when 
visual field loss is already advanced, but instead even an improvement of the visual field 
that is most likely the result of regression to the mean. With a mean baseline MD value 
of -7 dB, we assume that floor effects had no major influence on the present results. 
 
Although most meta-analyses use only direct comparisons between treatments or 
diagnostic methods, we also used indirect comparisons. This "network" meta-analysis is 
a method to quantify a rank order, even if no direct comparison between two methods 
has been conducted. By using this method we made optimal use of all available data on 
visual field progression in glaucoma patients. Differences in the incidence proportions 
that are found with direct comparisons can only be explained by the methods that are 
applied, because these comparisons are made in the same population. In contrast, 
indirect comparisons may also be influenced by population differences. Direct compari-
sons between methods can thus be seen as superior to indirect comparisons. However, 
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in this meta-analysis we corrected for follow-up time and baseline MD value, which 
reduced the unexplained heterogeneity between the incidences to zero. Therefore, we 
assume that the results of our meta-analysis provide an adequate approximation of 
direct comparisons between methods that are actually only indirectly compared. An 
additional analysis using only direct comparisons resulted in approximately the same 
incidences as when both direct and indirect comparisons were used.  
 
Remarkably, the incidences in the present study are much lower than the incidences of 
some other well-known studies. These studies were not included in our meta-analysis 
because they did not directly compare two or more methods. For example, 41% of the 
treated patients in EMGT progressed on their visual field in a follow-up period of ap-
proximately six years and with a baseline MD value of -4 dB.35 The incidence that we 
found for the same method (i.e. the GPA method) was only 16%. This large difference 
could partly be explained by the frequent testing protocol of the EMGT, in which visual 
field tests were carried out at 3-month intervals.25 Because of the two required confir-
mations of the GPA method, the availability of at least four visual field tests per year 
leads to an increased chance to detect progression during the follow-up period. Moreo-
ver, a flexible testing protocol resulted in even more available visual fields in the EMGT, 
because additional visual field tests were performed within one month when tentative 
progression occurred. As shown in table 2, this testing frequency is much higher than 
the mean frequency of 1.7 visual fields per year in the studies that were included in our 
meta-analysis. In addition, all studies in our meta-analysis only used a fixed testing 
protocol or no testing protocol. Furthermore, the large difference could also be ex-
plained by 61 patients in the EMGT who had two eligible eyes for the study. These 
patients had a higher chance to be progressive because they were considered to have 
progression when the first eligible eye met the progression criteria.35 An additional 
explanation for the large difference could be that EMGT patients were not treated 
according to current standards. For example, no target pressure was defined for indi-
vidual patients.25 A higher incidence of progression was also found in the Canadian 
Glaucoma Study (CGS).36 The incidence of visual field progression in this study was 31% 
in five years in glaucoma patients with a median baseline MD value of -4 dB. In the CGS, 
a variant of method G2 was used with a slightly stricter cut-off point. The estimated 
incidence of progression of method G2 was only 24% in our meta-analysis. In view of 
the better baseline visual field and shorter follow-up period in the CGS compared with 
the studies in our meta-analysis, one would just expect a lower incidence of progression 
in the CGS. However, the CGS also used a flexible testing protocol with a testing fre-
quency of at least three visual fields per year and a required confirmation of suspected 
progression in ten days.36 Overall, the studies in our meta-analysis better reflect current 
clinical practice than the abovementioned studies. We found incidences that are based 
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on a heterogeneous group of 948 patients. The mean frequency of visual field examina-
tions of around 1.7 visual fields per year in the present meta-analysis also reflects a 
feasible testing frequency in clinical practice.  
 
Our study gives insight into the methods that give either high or low estimates of the 
incidence of glaucomatous visual field progression, but does not solve the problem of 
the lack of a gold standard. Therefore, the definition of "true progression" remains a 
problem. A method may well result in a high incidence proportion without really differ-
entiating between "true progressive" and "true non-progressive" patients. A method 
that correctly classifies a large proportion of the "true progressive" patients as progres-
sive is said to be a method with a high sensitivity. On the other hand, when a method 
classifies a large proportion of the "true non-progressive" patients as non-progressive, it 
is said to be a specific method. The choice of a cut-off point in a particular method is 
generally a trade-off between sensitivity and specificity. In general, we cannot say which 
method is the better one, but we know that sensitivities and specificities differ per 
method in a predictable way when another cut-off point is used. When the cut-off value 
in these methods is less strict, the sensitivity increases while at the same time the 
specificity decreases. Examples in the present meta-analysis are the PLR-based methods 
P1, P2, P3, and P4, which only differ in the number of locations that should meet the 
same criterion. The criterion for a location to be progressive is a statistically significant 
negative linear regression line (p≤0.001). Even without looking at the results of the 
meta-analysis we can assume that method P1, which needs the highest number of 
affected locations for a visual field series to be progressive, is the least sensitive and the 
most specific. The same holds for methods I1, I2, I3, and I4, which differ only in the 
number of progressive clusters that are required to meet the definition of progression. 
It is important to notice that in epidemiologic studies, methods with a high specificity 
are preferred when the true incidence of progression is low. This leads to an estimate of 
the relative risk of the presumed prognostic factor that is closer to the true value of the 
relative risk. In clinical practice, a highly specific method with few false positives is also 
preferred when the treatment of progressive patients has considerable side effects.  
 
We used the results of 30 methods in our meta-analysis, for which a patient could only 
be progressive or non-progressive. However, some methods were originally intended to 
quantify the rate of progression instead of a binary presence or absence of progression. 
These methods are based on indices of the complete tested visual field such as the MD 
(i.e., in methods I5 and I6) and the VFI (i.e., in method I8). In clinical practice, the MD 
index and the VFI are used to quantify the rate of progression on a continuous scale, 
ranging from severe disease progression (e.g., 16% loss in the VFI per year) to slight 
improvement (e.g., 3% increase in the VFI per year).37 Sole statistical significance of the 
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slopes of these indices may be of limited interest for clinical practice, while knowing the 
rate of progression would direct appropriately aggressive treatment to those who are at 
highest risk for visual disability.1 However, when a rate of progression is used to decide 
on changing therapy, it has to be decided which cut-off value for the rate leads to the 
decision to change therapy. Ultimately, even a rate method leads to a dichotomisation 
of the population. Rates of progression should therefore be incorporated in progression 
criteria of methods to determine the presence or absence of progression. For example, 
progression could be defined as a statistically significant decline of the VFI (p<0.05) with 
a rate of at least 3% loss per year. Several PLR methods in the present meta-analysis 
(i.e., P5, P6, P7, and P8) already used statistically and clinically relevant criteria for 
individual visual field locations. Finally, the pattern standard deviation (PSD) or the 
corrected pattern standard deviation (CPSD) indices of the complete tested visual field 
(e.g., in method I7) should generally not be used in methods to assess glaucomatous 
visual field progression. Their values shift to normal values again in more advanced 
glaucoma.38 
 
In conclusion, the incidence of glaucomatous visual field progression varies considerably 
between different studies. This is mainly caused by the variety of methods used to 
assess progression, but also by differences in follow-up time and baseline visual field 
loss. Other factors, like the frequency of visual field examinations and the need for 
confirmation, also seem to be of importance. With a ranking of methods according to 
their incidence of progression, the interpretation and the possibility to compare studies 
are improved. Moreover, in several cases the same method can be used with a more or 
less specific cut-off value, depending on the scientific or clinical goal. An ideal method 
combines statistically and clinically relevant criteria with tailor-made cut-off values. 
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ABSTRACT 
A large number of methods have been developed for assessing glaucomatous visual 
field progression, but their properties have not yet been systematically evaluated. In 
this systematic literature review we summarize the evidence base for selecting a meth-
od by providing answers to ten relevant questions on the variety, validity, and reproduc-
ibility of methods. In total, we found 301 different methods in 412 articles. The majority 
of studies (54%) used the Humphrey Field Analyzer. No data have been published about 
the reproducibility of methods. Although there is no gold standard to assess glaucoma-
tous visual field progression, we found evidence on validity for 48 different methods. 
Some methods were less capable of distinguishing between progressive and non-
progressive patients. Choosing among twelve methods is supported by some evidence 
of their validity. These methods still differ in sensitivity, specificity, and predictive values 
of test results within studies comparing several methods. In conclusion, the current 
evidence base is not perfect. A selection should be made from a limited number of 
methods, according to the clinical purpose of progression assessment. Methods that 
quantify the rate of visual field progression seem to be the most appropriate for guiding 
subsequent medical actions in individual patients. Future studies should investigate 
whether using one method to monitor patients is superior to another method in pre-
venting loss of quality of life. 
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Introduction 
An important goal in the management of open-angle glaucoma is to detect clinically 
relevant visual field progression early and reliably. The methods to assess progression 
however, are a continuing subject of debate.1-6 In the last years, the relevance of moni-
toring the rate of visual field progression has increasingly being recognized.7 Together 
with the patient’s life expectancy and disease stage, the rate of progression can be used 
to estimate individual risk of lifetime visual disability.8 However, from all methods to 
determine visual field progression it may still be difficult to select a specific one. 
 
This paper provides a systematic review of the evidence base for selecting a method to 
assess glaucomatous visual field progression. The clinical use of a good method to 
assess progression should ultimately optimize quality of life (QoL) of glaucoma patients, 
without under- or overtreatment. With this aim in mind we searched the literature to 
provide answers to ten relevant questions.  
Ten questions and answers 
1.  How many methods can we choose from to assess visual field progression? 
A total of 301 different methods were used in 412 articles.  
We classified all methods that we found in the literature. There are 15 different perime-
ters used to assess progression in the literature. A majority of 222 studies (54%) used 
the Humphrey Field Analyzer (HFA) (Carl Zeiss Meditec, Dublin, CA, USA), increasing to 
77% of the articles published since 2000. We therefore focused on methods for the HFA 
for the rest of this article. HFA methods could further be classified into qualitative and 
quantitative methods. A qualitative method implies that the ophthalmologist decides on 
the occurrence of progression, whereas a quantitative method uses numeric units for 
defining progression. Qualitative methods have been used 32 times (8%) and quantita-
tive methods 355 times (92%). Quantitative methods which calculate a rate of progres-
sion were used 166 times (47% of quantitative methods). However, most of these 
studies dichotomized the rate of progression because they aimed to compare different 
progression methods or estimated treatment effects in a large group of patients. 
Therefore, even these methods did not really quantify the rate of progression needed 
for decision making in individual patients. 
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2.  Which method to assess visual field progression can predict loss of QoL? 
The prediction of loss in QoL has not been shown for any method. 
The ultimate goal of glaucoma management is to prevent loss of QoL. A method to 
assess progression should therefore identify patients who will lose vision related QoL in 
the future if treatment is not intensified. Although this constitutes the essential goal of 
monitoring progression it has not been addressed in empirical research. However, its 
clinical relevance is increasingly being recognized.7 Empirical research should ideally 
randomize patients to different monitoring strategies with a subsequent long follow-up 
period to evaluate differences in QoL. Future studies should address this issue with the 
inclusion of methods quantifying the rate of progression. What we do know is that the 
degree of visual field loss and QoL are strongly related.9-13 
3.  What is the gold standard to assess glaucomatous visual field progression? 
There is no gold standard to assess visual field progression. 
A gold standard is a method that is closest to anatomical and consequent functional 
changes, against which new developments should be compared.14 There is no universal-
ly accepted solution in diagnostic research when faced with a missing or an imperfect 
gold standard.15 In the literature about methods to assess glaucomatous visual field 
progression, most studies compared incidences of progression from different methods. 
Although these studies give insight into the methods that give either high or low esti-
mates of the incidence of progression, they do not contribute in the selection of the 
best method. We summarized the results of these studies in an earlier review article.16 
Other studies dealt with the problem of the lack of a gold standard by using another 
reference standard against which methods were compared. Different reference stand-
ards have been used that are of some value to substitute for a gold standard. 
4.  Which methods have been compared with a substitute gold standard of visual 
field progression or stability? 
Several methods have been compared with a substitute gold standard to assess visual 
field progression. In the field of clinimetrics this is termed concurrent validity.17 The 
resulting sensitivities, specificities, positive predictive values (PPVs), negative predictive 
values (NPVs), likelihood ratios (LRs), and diagnostic odds ratios are shown in Table 1.1-6, 
18-28, 30 The first thing to note is that there is a lot of variation in several accuracy 
measures within studies and between studies. There seems to be no superior method, 
although some have a lower diagnostic odds ratio when compared with other methods 
within one study. These methods are less capable to distinguish between progressive 
and non-progressive patients.  
Some studies made use of expert judgment of visual fields series as a substitute for a 
gold standard.3, 6, 19, 20 However, these qualitative judgments can be seen as arbitrary 
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gold standards, because they have not shown to be superior to other methods. If 
subjective judgments are used, it is important that these judgments are masked for 
other clinical information. This was the case in all studies. Three studies calculated 
sensitivities and specificities with use of a preselected sample of unequivocally progres-
sive and non-progressive patients after excluding patients with equivocal results.3, 6, 20 
This may have resulted in overestimated accuracy measures.  
 
Table 1: Accuracy measures of different methods to assess visual field progression 
 
  
Study Reference standard
Number of 
eyes Method Sen Spec PPV NPV LR+ LR- OR
AGIS 0.58 0.98 0.88 0.90 29.0 0.43 67.7
CIGTS 0.75 0.99 0.95 0.94 75.0 0.25 297.0
EMGT 0.96 0.90 0.71 0.99 9.6 0.04 216.0
AGIS 0.36 0.96 0.70 0.86 9.4 0.67 14.1
CIGTS 0.57 0.91 0.60 0.89 6.1 0.47 12.8
EMGT 0.50 0.87 0.49 0.87 3.8 0.58 6.6
GCP (3 points, 3 fields) 0.79 0.79 0.49 0.94 3.8 0.27 14.0
EMGT 0.27 0.95 0.57 0.84 5.4 0.77 7.0
EMGT suspected 
progression 0.53 0.85 0.47 0.88 3.5 0.55 6.0
TNT 0.80 0.71 0.41 0.93 2.8 0.28 9.8
TNT suspected 
progression 0.86 0.60 0.35 0.94 2.2 0.23 9.2
TNT with FI > 40th 
percentile
0.67 0.90 0.63 0.92 6.7 0.37 18.3
PLR according to 
Noureddin et al. (1991) 0.91 0.26 0.24 0.92 1.2 0.33 3.8
PLR according to Fitzke et 
al. (1996) 1.00 0.11 0.22 1.00 1.1 0.00 1173.1
PLR according to Bhandari 
et al. (1997) 0.85 0.72 0.43 0.95 3.0 0.21 14.4
PLR according to Nouri-
Mahdavi et al. (1997) 0.85 0.72 0.43 0.95 3.1 0.21 14.5
MD slope (p<0.1) 0.74 0.89 0.63 0.93 6.9 0.29 23.9
MD slope (p<0.05) 0.52 0.95 0.70 0.89 9.5 0.50 18.9
MD slope (p<0.025) 0.46 0.97 0.80 0.88 16.3 0.56 29.2
Method according to 
Werner et al. (1988) 0.70 0.95 0.76 0.93 12.9 0.32 39.9
AGIS  0.31 1.00 1.00 0.85 3050.0 0.70 4388.1
AGIS (2 fields) 0.47 1.00 0.99 0.88 467.0 0.53 875.3
AGIS - 1.00 - - - - -
CIGTS - 0.97 - - - - -
GCP (4 points, 2 fields) - 0.92 - - - - -
GCP (8 points, 2 fields) - 0.95 - - - - -
GCP (4 points, 3 fields) - 0.99 - - - - -
PLR (2 points, 3 fields) - 0.82 - - - - -
PLR (3 points, 3 fields) - 1.00 - - - - -
AGIS 
(1994)
Stability due to 
short follow-up#
756 AGIS (1 field) - 0.84 - - - - -
Gillespie et 
al. (2003)
Stability due to 
short follow-up#
607 CIGTS (1 field) - 0.90 - - - - -
AGIS (1 field) 0.34 1.00 1.00 0.86 3380.0 0.66 5105.2
CSS 0.59 0.88 0.55 0.90 4.9 0.46 10.6
172
67
47
105
76**
10,000**
Computer 
simulated stability 
for specificities
Progressive optic 
disc cupping
Concurrent validity
Comparisons with other parameters of disease progression
Masked subjective 
judgment
Diaz-
Aleman et 
al. (2009)
Heijl et al. 
(2008)
Katz et al. 
(1999), Katz 
(2000)
Masked subjective 
judgment*
Computer 
simulated stability
(continued)
Comparisons with substitute gold standards of visual field progression and stability
Vesti et al. 
(2003)
Mayama et 
al. (2004)
Masked subjective 
judgment for 
sensitivities*
Masked subjective 
judgment*
47Girkin et al. (2000)
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Table 1: continued 
 
If sensitivities and specificities of methods were available, we calculated positive and negative predictive 
values, likelihood ratios, and odds ratios using formulas that have earlier been described.29 Positive and 
negative predictive values were calculated for a presumed incidence of progression of 20% in six years, based 
on a recent meta-analysis.16 Cut-off points for several methods are shown between brackets (e.g. the number 
of test points or visual fields that had to be progressive before the total visual field series is considered to be 
progressive).  
* These studies used a preselected sample of unequivocally progressive and non-progressive patients after 
excluding patients with equivocal results.  
** Simulated visual field series.  
# Stable eyes are compared with eyes changed in either direction.  
Sen = sensitivity, Spec = specificity, PPV = positive predictive value, which is the probability that a patient has 
"true progression" when the method indicates a patient as progressive, NPV = negative predictive value, 
which is the probability that the patient is "true non-progressive" when the method indicates a patient as 
non-progressive, LR+ = likelihood ratio of a positive test result, which indicates how much a positive test result 
will raise the pretest probability of progression, LR- = likelihood ratio of a negative test result, which indicates 
how much a negative test result will lower the pretest probability of progression, OR = diagnostic odds ratio, 
which describes the odds of a positive test result in patients with progression compared with the odds of a 
positive test result in those without progression, AGIS = Advanced Glaucoma Intervention Study, CIGTS = 
Collaborative Initial Glaucoma Treatment Study, EMGT = Early Manifest Glaucoma Trial, GCP = Glaucoma 
Change Probability, TNT = Threshold Noiseless Trend program, FI = focality index, PLR = pointwise linear 
regression analysis, MD = Mean Deviation, CSS = clinical scoring system based on scotomas, CNTGS = Collabo-
rative Normal-Tension Glaucoma Study 
 
As another substitute for a gold standard, some studies used groups of glaucoma 
patients that were likely to be stable (i.e. not showing progression) to calculate the 
method’s specificity.3, 5, 18, 21 Using a computer simulation, two studies constructed a 
substitute gold standard by simulating stable visual field series with a physiological 
degree of variability.3, 5  
 
Study Reference standard
Number of 
eyes Method Sen Spec PPV NPV LR+ LR- OR
AGIS - - 0.95 - - - -
CIGTS - - 1.00 - - - -
EMGT - - 0.93 - - - -
Modified GCP (1 field) - - 0.26 - - - -
Modified EMGT (1 field) - - 0.31 - - - -
GCP (3 points, 1 field) - - 0.16 - - - -
EMGT (1 field) - - 0.16 - - - -
AGIS (1 field) - - 0.33 - - - -
CIGTS (1 field) - - 0.18 - - - -
AGIS (2 fields) - - 0.45 - - - -
AGIS - - 0.62 - - - -
CNTGS single sequence - - 0.43 - - - -
CNTGS double sequence - - 0.98 - - - -
PLR (3 points, 3 fields) - - 0.91 - - - -
GCP (3 points, 3 fields) - - 0.88 - - - -
AGIS - - 0.80 - - - -
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Two other studies approached a method’s specificity by testing if progression criteria 
were fulfilled within a follow-up period that was too short for the visual field to change 
(i.e. one month).18, 21  
5.  Which methods have been compared with other parameters of disease 
progression? 
We found one study that used progressive optic disc cupping as a reference standard. 
The Advanced Glaucoma Intervention Study (AGIS) method had a very high diagnostic 
odds ratio and a very high likelihood ratio for a positive test result (Table 1).22 
 
Instead of comparing methods to assess glaucomatous visual field progression with a 
substitute gold standard to assess visual field progression, outcomes of methods can 
also be compared with other parameters of disease progression like changes of the 
optic nerve head. This is also a form of concurrent validity.  
6. Which methods give a good prediction of future visual field loss? 
Several methods have a high sustainability. These include the AGIS, Collaborative Initial 
Glaucoma Treatment Study (CIGTS), Early Manifest Glaucoma Trial (EMGT), Collabora-
tive Normal-Tension Glaucoma Study (CNTGS), and pointwise linear regression analysis 
(PLR) methods (Table 1).  
 
When methods have shown progression, they should remain to do so when additional 
follow-up visual fields are acquired since glaucomatous nerve fibre loss is assumed to be 
irreversible. The positive test results must therefore be sustained in future assessments. 
However, the results of assessments that do not show progression are not supposed to 
sustain since the patient could progress afterwards. In clinimetrics this is termed predic-
tive validity, but sustainability is a more appropriate term as used by the authors.17 
  
One way to investigate the sustainability of progression is to use the outcomes after a 
limited number of follow-up years to predict outcomes after a longer period, both using 
the same baseline as a reference.1, 6, 24, 30 Furthermore, another study estimated the 
sustainability of the CNTGS method by a mathematical model based on repeated 
testing.23  
 
Instead of looking at the sustainability of positive test results, Bengtsson and co-workers 
used correlations to validate the continuous Visual Field Index (VFI) rate.31 They investi-
gated if the VFI rate in the initial 3.3 years could reliably predict the VFI after a mean 
follow-up time of 8.2 years. A correlation coefficient of 0.78 was found when the 
predicted VFI was compared with the actual last VFI.31 
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7.  Which methods have shown to be related with a presumed prognostic factor of 
glaucomatous progression? 
In total, 20 different methods have been studied in relation with mean intraocular 
pressure (IOP) in 21 articles. Thirteen methods (65%) found a positive relation between 
mean IOP and glaucomatous visual field progression (Fig. 1).25, 32-52 Six of these methods 
(30%) showed a statistically significant positive difference (p<0.05) in mean IOP be-
tween the progressive and non-progressive groups, including the EMGT method,32 
another method based on pointwise event analysis,40 a method based on PLR,43 and 
three qualitative methods37, 46, 47 (Fig. 1). 
 
A method that is assumed to assess glaucomatous visual field progression should be 
able to find a relation between progression and a presumed risk factor for glaucoma-
tous progression. In clinimetrics this is termed construct validity.53 An example could be 
the relation with mean IOP during the follow-up period. The reason for this is that IOP is 
a consistent prognostic factor for glaucoma and the focus of treatment.54 Although the 
four qualitative methods resulted in a high positive association between mean IOP and 
visual field progression, the outcome assessment in these studies was not masked for 
other clinical information.33, 37, 46, 47 Moreover, two of them included other parameters 
like visual acuity and optic disc criteria in the judgment of progression.46, 47 
8. Which methods have shown to be reproducible? 
To our knowledge, no studies about the reproducibility of methods to assess visual field 
progression have been conducted.  
 
However, we found 21 articles that studied cross-sectional reproducibility of visual field 
measures that were derived from the HFA.21, 55-74 In general, these studies showed that 
Mean Deviation (MD) values have a higher reproducibility than pointwise values. 
9. Taking into account the evidence above, which method should we select from the 
301 available methods? 
The selection from 301 methods is limited to 48 different methods for which data on 
validity was present (see questions 4-7). Excluding the different cut-off points, the 
selection is limited to twelve methods being the AGIS, CIGTS, PLR, MD, Glaucoma 
Change Probability (GCP), EMGT, VFI, Threshold Noiseless Trend (TNT), Werner, clinical 
scoring system (CSS), CNTGS, and subjective methods. It is important to keep in mind 
that methods were validated with use of different reference standards and different 
study designs. 
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Methods based on the AGIS generally have a high discriminative ability, which is shown 
by the high odds ratios in Table 1. However, we found an inverse relation between AGIS 
progression and mean IOP during follow-up (Fig. 1). This is probably a biased result 
since IOP may have been lowered due to changes in treatment among those with 
progression. Moreover, mean IOP during the first follow-up years has earlier shown to 
be associated with subsequent progression on the AGIS score.75 The CIGTS method also 
showed high odds ratios and PPVs. Methods with a high PPV, like the AGIS and the 
CIGTS methods, could for example be used before performing glaucoma surgery, where 
one wants to be certain that a patient is really progressing.  
 
PLR methods showed highly variable accuracy measures ranging from a low odds ratio 
of 3.8 to a much better odds ratio of 1173.1 (Table 1). This is caused by the use of many 
different cut-off points for these methods in the literature. However, PLR, AGIS, or 
CIGTS methods may be impractical in clinical practice, because they are more time-
consuming due to the need to interpret several test locations. These methods could 
possibly be made more usable by computerization of the analysis. 
 
Methods based on the VFI, MD, GCP, or EMGT may be more usable, because the re-
quired information is available on the printed output of the HFA. Among them, the 
EMGT method is the only method that has shown to correlate with mean IOP during 
follow-up (Fig. 1). Methods based on MD and EMGT seem to perform well in the studies 
of Heijl and Mayama, although these studies probably overestimated the method’s 
accuracy (Table 1).3, 6 The odds ratio of the EMGT method was relatively low in the 
other studies.19, 20 
 
Qualitative methods could also be useful, although the interpretation of results is 
dependent on the capacity of the observer. This may cause high inter-observer variabil-
ity.28 Nonetheless, these methods have frequently been used as a substitute for a gold 
standard. In these cases, however, the assessment was based on the judgement of 
more than one observer. Qualitative methods have also shown to correlate well with 
mean IOP, but these findings could be biased because these qualitative assessments 
were not masked for other clinical information.  
10.  In the end, what do we really want to know? 
The current evidence base is not perfect but seems to be fair for a few methods that 
have been validated. Since numerous methods are available, we should probably stop 
developing many new methods to assess visual field progression. The ultimately rele-
vant question, whether using one method to monitor patients is superior to another in 
preventing loss of QoL, has not been answered. Methods that quantify the rate of visual 
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field progression seem to be the most appropriate for guiding subsequent medical 
actions in individual patients, because they can be used to estimate individual risk of 
lifetime visual disability. This should ideally be studied in prospective studies with long 
follow-up periods. If this is not feasible, new research should be directed to other types 
of validation, like the ability of methods to predict future visual field loss and to the 
relation between outcomes of methods and structural progression or prognostic fac-
tors.  
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Figure 1: Difference in mean intraocular pressure between progressive and non-progressive patients accord-
ing to 20 different methods to assess progression 
A positive difference indicates a positive relation between visual field progression and mean intraocular 
pressure during follow-up. The grey bars represent the differences that were tested statistically significant 
while the white bars represent the differences that were not statistically significant. Each bar is labelled by the 
method that was used and by a reference of the study from where we derived the data. When one method 
was investigated in two studies, we calculated the weighted mean difference between the progressive and 
non-progressive groups based on the number of patients in each study. Bars Subj1 to Subj4 represent 
qualitative (i.e. subjective) methods, bars MD1 to MD3 represent methods based on the Mean Deviation 
index, bars PLR1 to PLR2 represent methods based on pointwise linear regression analysis, and bars PWE1 to 
PWE3 represent methods based on pointwise event analysis. Modified Anderson represents a method 
adapted from Chen and Park.36 Blindness represents a method that uses blindness as end-point. Blumenthal 
represents a method derived from Blumenthal and co-workers.52  
IOP = intraocular pressure, EMGT = Early Manifest Glaucoma Trial method, AGIS = Advanced Glaucoma 
Intervention Study method, CIGTS = Collaborative Initial Glaucoma Treatment Study method, GCP = Glaucoma 
Change Probability method 
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PLR2 (Noureddin et al. 1991)
PLR1 (Nouri Mahdavi et al. 2004)
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PWE1 (Zeimer et al. 1991)
MD2 (Kashiwagi et al. 2001)
GCP (Martinez Bello et al. 2000)
MD3 (Yamazaki & Drance 1997)
Blindness (Oliver et al. 2002; Chen 2003)
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PWE3 (Lee et al. 2008)
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Literature search 
To get an overview of all methods to assess glaucomatous visual field progression, we 
performed a systematic literature search in April 2009. We searched in PubMed, EM-
BASE, and all databases and registers of The Cochrane Library with use of the following 
keywords: (Glaucoma*) AND (Prognos* OR Predict* OR Progress* OR Longitudinal OR 
Cohort OR Follow-up) AND (Perimetr* OR Visual Field* OR HFA OR Octopus OR Humph-
rey (not in author)). A total of 2,450 articles were identified. Based on predefined 
exclusion criteria, we selected studies reporting on glaucoma patients who were fol-
lowed for minimally one year with the use of standard visual field examinations, so that 
progression could be assessed (Table 2). We finally included 412 articles (Fig. 2). From 
this search, we also selected 21 articles that used the HFA and studied mean follow-up 
IOP as a prognostic factor for glaucomatous visual field progression.  
 
We studied the reproducibility of progression methods in glaucoma patients by per-
forming a second systematic search in PubMed in April 2009: Glaucoma [Mesh] AND 
Visual fields [Mesh] AND (Observer Variation [Mesh] OR Reproducibility of Results 
[Mesh]).  
 
Table 2: Number of articles excluded according to different criteria 
Exclusion criteria Number
No intention to measure progression of VF damage 471
Unconventional or single perimetric measurement 434
No visual field damage at the beginning of follow-up 395
Patients without glaucomatous disease 244
No original study 172
Perimetric follow-up <1 year (median or mean <1 year) 124
Case-report (<10 patients) 80
Patients aged <18 years 35
Animal study 17
Other languages than English, French, Dutch, or German 8
 
Total 1980
Ten exclusion criteria are listed with their accompanying number of excluded articles.  
VF = visual field 
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Potential relevant articles identified and screened for retrieval (n = 2450)
  
Articles excluded based on title and abstract (n = 1668)
 
Articles selected for more detailed information (n = 782)
  
Abstracts (n = 23) 
 
Articles not available in the Netherlands (n = 35)
 
Articles excluded based on full text (n = 312)
 
Articles included in systematic review (n = 412)
 
Articles using a HFA (n = 222)
 
Figure 2: Flow chart of studies 
The selection process of studies found in the first systematic literature review is shown in this flow chart.  
Four hundred twelve articles were finally included. HFA = Humphrey Field Analyzer 
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ABSTRACT 
Purpose: To present a new strategy to validate different methods to assess visual field 
progression using associations with known prognostic factors.  
 
Methods: We included 177 consecutive open-angle glaucoma patients from 2001 to 
2003. Follow-up visual fields were collected from the Humphrey Field Analyzer until 
2010. Visual field progression was assessed with ten predefined methods and by three 
assessors. Three baseline prognostic factors (i.e. intraocular pressure (IOP), visual field 
mean deviation value, and age) and two follow-up prognostic factors (i.e. mean IOP and 
long-term IOP fluctuation) were considered. The strength of the association between 
the combination of these five factors and visual field progression according to each 
method was investigated by comparing the extent to which progressive and nonpro-
gressive patients could be discriminated by the multivariable prognostic model, ex-
pressed as the area under the receiver operating characteristic curve (AUC). 
 
Results: On average, 7.8 visual fields were performed within a follow-up time of 7.3 
years. The mean incidence of visual field progression for the different methods was 
33.5%, ranging from 12.4% to 59.3%. AUC values ranged from 0.57 to 0.72. Overall, 
three methods had higher AUC values compared with the other methods: assessment 
of visual fields by assessor C, the Advanced Glaucoma Intervention Study method, and 
pointwise linear regression analysis using total deviation values. 
 
Conclusions: The ability to discriminate progressive from nonprogressive patients with 
prognostic factors is variable, depending on the method and cut-off points used to 
assess glaucomatous visual field progression. A high discriminative ability confirms the 
validity of a method. 
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Introduction 
Open-angle glaucoma (OAG) is characterized by visual field progression over months to 
years.1 The general goal of glaucoma management is to maintain the patient’s visual 
function and related quality of life.2 Automated visual field testing is regularly repeated 
to differentiate rapidly progressing patients from slowly progressing patients as a means 
to direct more intensive treatment to those with a high risk of becoming visually im-
paired. A large number of methods to assess visual field progression have been devel-
oped.3 Due to the lack of a gold standard, the relative merits of these methods are 
currently unclear. 
 
Even in the absence of a gold standard, however, diagnostic tests can still be compared 
by following a different strategy.4, 5 For example, the relation between a certain defini-
tion of glaucomatous visual field progression and intraocular pressure (IOP) can be 
investigated. High IOP is among the most consistent prognostic factors for progression 
of glaucoma and is one of the few factors that can be modified by medical or surgical 
treatment to slow down progression.6-8 Therefore, a method that is assumed to assess 
glaucomatous visual field progression should find a relation between progression and 
IOP. When No relation between IOP and glaucomatous progression is found, one should 
question the validity of the assessment method. In clinimetrics, this type of validation is 
termed “construct validation” and the relation between IOP and progression is termed 
a “construct”.9 We defined three additional constructs for this study: more visual field 
progression should be associated with more IOP variation, with more advanced visual 
field loss at baseline, and with higher age. In ophthalmology, the concept of construct 
validity has only been used for the validation of patient questionnaires and training 
tools for ophthalmic surgery.10, 11 However, it has not been applied to validate methods 
to assess visual field progression.  
 
In this study, we present a new strategy to identify the best method for assessing 
glaucomatous visual field progression by comparing the extent to which progressive and 
nonprogressive patients can be discriminated by a multivariable prognostic model 
containing well-known prognostic factors for glaucomatous progression.  
Methods 
Patient selection 
We used the database of the DUtch Research project on treatment outcome IN Glau-
coma patients (DURING) study to identify patients who were consecutively recruited in 
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the latter project from 2001 to 2003.12, 13 All patients were treated with topical glauco-
ma medication at baseline. For the current study we collected information of OAG 
patients from five out of the nine originally participating Dutch hospitals, including one 
academic hospital. There were 185 patients who were diagnosed by a participating 
ophthalmologist as having OAG at the baseline visit of the DURING study and had 
confirmed visual field loss. The baseline Humphrey Field Analyzer (HFA) (Carl Zeiss 
Meditec, Dublin, CA, USA) 24-2 or 30-2 visual field should have a Glaucoma Hemifield 
Test (GHT) “outside normal limits” and/or a significant (p<0.05) deviation of the pattern 
standard deviation (PSD) index. At least six reliable Swedish Interactive Thresholding 
Algorithm (SITA) Fast or SITA Standard visual field tests with <15% false positive an-
swers, <15% false negative answers and <20% fixation losses were available for each 
patient, excluding the first visual field to reduce possible learning effects. We checked 
all patient records to rule out other ocular comorbidity that could have caused visual 
field deterioration during the follow-up period and excluded eight patients for this 
reason. Therefore, 177 patients were eligible for inclusion in this study. 
 
We selected the most severely affected eye based on the GHT and PSD criteria de-
scribed before. If both eyes were equally affected one eye from each patient was 
randomly chosen. All available visual fields were collected until 2010.  
 
This study was approved by the local ethics committees and conformed to the tenets of 
the Declaration of Helsinki. All patients gave their informed consent prior to inclusion. 
Methods to assess visual field progression 
Visual field progression was assessed with ten predefined methods and by three asses-
sors. An overview of these methods is shown in Table 1. These ten methods were 
chosen because they have been frequently studied in the literature and were included 
in our previous meta-analysis about the incidence of progression according to different 
methods to assess progression.14 
 
For the fist two methods, we calculated the rate of progression according to frequently 
used visual field indices from the HFA: the mean deviation (MD) and the visual field 
index (VFI). Both indices are expressed as a mean value of individual test points in one 
visual field, but the VFI is more heavily weighted to central visual field areas.15 For each 
patient, we performed a linear regression analysis of the MD and VFI against time. We 
used a significant deterioration of the visual field as a definition for visual field progres-
sion (p<0.05). In an additional analysis, we added “rate of progression” as criterion for 
visual field progression and varied its cut-off point. 
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The Nonparametric Progression Analysis (NPA) is based on nonparametric ranking of 
MD values.16 This method objectifies the commonly practised method of monitoring 
glaucoma patients with the use of MD values. A visual field series is considered progres-
sive as the MD value of a follow-up visual field is worse than the MD of the worst of two 
baseline fields. This has to be confirmed on at least two consecutive visual fields and 
has to be consistent until the end of the follow-up period.16  
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Table 1: Overview of methods used to assess glaucomatous visual field progression 
Method Description of the method 
Incidence of 
progression 
AGIS AGIS-method 22 (12.4%) 
CIGTS CIGTS-method 26 (14.7%) 
PLR PD 
Two-omitting PLR with pattern deviation values, using criteria of <-1dB per year 
and p<0.05 and a cut-off point of ≥3 locations at 3 consecutive examinations 26 (14.7%) 
Boden 
At least one of these scotoma criteria: deepening of ≥2 points ≥10dB in the same 
locations; expansion of ≥2 points ≥10dB; development of ≥2 adjacent points, not 
within or adjacent to a baseline scotoma, with p<1% or worse at pattern deviation 
plot or 1 previously normal location in central 10 degrees ≥10dB. Confirmations at 
the same locations on 3 consecutive fields, based on pattern deviation values 
38 (21.5%) 
GPA Glaucoma Progression Analysis 35 (22.5%)* 
PLR TD 
Two-omitting PLR with total deviation values, using criteria of <-1dB per year and 
p<0.05 and a cut-off point of ≥3 locations at 3 consecutive examinations 42 (23.7%) 
SubjA Blinded subjective assessment of Humphrey overview printouts by assessor A 65 (36.7%) 
SubjC Blinded subjective assessment of Humphrey overview printouts by assessor C 70 (39.5%) 
Subj 
Likely progression based on the subjective assessment of Humphrey overview 
printouts by observers who were blinded for other clinical information and did not 
use a predefined criterion of progression; two out of three observers had to assign 
a series as progressive 
74 (41.8%) 
VFI Linear regression analysis of the VFI, using a criterion of p<0.05 83 (46.9%) 
MD Linear regression analysis of the MD, using a criterion of p<0.05 85 (48.0%) 
NPA Nonparametric progression analysis based on nonparametric ranking of MD values 96 (54.2%) 
SubjB Blinded subjective assessment of Humphrey overview printouts by assessor B 105 (59.3%) 
The ten methods to assess progression and the three assessors are ranked according to the incidence of visual
field progression as shown in the third column.  
*Excluding 22 eyes that had no possibility to fulfill the progression criteria according to the Glaucoma
Progression Analysis.  
AGIS = Advanced Glaucoma Intervention Study, CIGTS = Collaborative Initial Glaucoma Treatment Study, PLR
PD = pointwise linear regression analysis based on pattern deviation values, Boden = method according to
Boden et al., GPA = Glaucoma Progression Analysis, PLR TD = pointwise linear regression analysis based on
total deviation values, SubjA to SubjC = subjective method according to assessor A to C, Subj = subjective
method according to the three assessors, VFI = visual field index, MD = mean deviation, NPA = nonparametric
progression analysis, dB = decibels. 
 
The fourth method is the Glaucoma Progression Analysis (GPA), which is similar to the 
visual field endpoint in the Early Manifest Glaucoma Trial (EMGT).17 The GPA is an event 
analysis based on pattern deviation values and is included in the new HFA software. 
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When significant deterioration (p<0.05) is seen on the pattern deviation probability 
maps of the GPA printouts in the same three or more points on three consecutive 
follow-up tests, the software interprets this as likely progression.17 We performed the 
analyses after exclusion of eyes that had no possibility to fulfil GPA progression criteria 
due to exclusion of visual fields with advanced loss or different perimetric strategies.  
We performed two pointwise linear regression analyses (PLR), one using total and the 
other using pattern deviation values of individual test points (i.e. PLR TD and PLR PD 
respectively).18 Individual total deviation values were derived by conversion of serial 
HFA output with the MSDOS version of PeriData (PeriData Software GmbH, Huerth, 
Germany). Total deviation values in PeriData are slightly different from HFA values due 
to different reference groups used for calculation of these values. We also calculated 
pattern deviation values for each test point by subtracting the total deviation value of 
the 7th best point of the 24-2 total deviation visual field from the total deviation values 
of all other points.19 We performed a linear regression analysis of the total deviation 
and pattern deviation values of each individual test location of the 24-2 visual field. 
 
The Advanced Glaucoma Intervention Study (AGIS) method and the Collaborative Initial 
Glaucoma Treatment Study (CIGTS) method are both based on the AGIS study.20 Both 
the AGIS method and the CIGTS method use a scoring system to grade each visual field 
in the follow-up period. The AGIS score is based on the actual decibel deviations at the 
total deviation plot of the 24-2 visual field, while the CIGTS algorithm is based on the p-
values obtained from the total deviation probability plot. Both scoring systems range 
from 0 to 20, with 0 representing no field loss and 20 end-stage disease. Visual field 
series are considered to be progressive if the score has increased by four or more from 
the baseline reference field (with the AGIS method) or three or more compared with 
the average score of two baseline fields (with the CIGTS method). With both methods, 
progression has to be confirmed by two additional tests.21 We calculated the CIGTS 
score for each visual field on the printouts of total deviation probability plot and we 
calculated the AGIS score using the total deviation values derived with PeriData. 
 
We also performed a blinded subjective assessment of the series of visual fields (i.e. 
method Subj). Three authors (CAW, HJB, JSS), who are ophthalmologists including two 
glaucoma specialists, independently judged if a visual field series was not progressive, 
possibly progressive, probably progressive, or definitely progressive due to glaucoma. 
The assessors used overview printouts of the HFA and were blinded for the patient’s 
name and other clinical information. They received no instructions for analyzing the 
series of visual fields to give a good representation of subjective assessment in daily 
clinical practice. For defining a visual field series as progressive, at least two assessors 
had to assign a series as definitely or probably progressive. 
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Finally, the method of Boden and co-workers is a progression algorithm based on the 
clinical judgement of scotomas.22 The development, expansion, and the deepening of 
scotomas is determined with use of pattern deviation values and is also based on the 
24-2 visual field.22 Pattern deviation values were derived with PeriData. 
Prognostic factors for progression 
We used the following three baseline prognostic factors for validating the methods: 
baseline MD value, baseline age, and baseline IOP.6 IOP values were derived from case 
records. We defined baseline IOP as the mean of the last two IOPs up to and including 
the baseline visit. We categorized baseline MD value in tertiles, because earlier studies 
have shown that the relation between visual field progression and baseline visual field 
loss is not uniform across the entire range of visual field loss. Progression is positively 
related with baseline visual field severity in early disease stages and negatively related 
with visual field severity in advanced disease stages.23-25 The group with the best visual 
field was selected as reference group for the groups with moderate visual field loss (i.e. 
MD values ≤-4.0 decibels (dB) and >-10.2 dB) and severe visual field loss (i.e. MD values 
≤-10.2 dB).  
 
We also used two prognostic factors that were collected during the follow-up period: 
mean IOP and long-term IOP fluctuation.26, 27 We used follow-up IOP values from the 
baseline visit to the date of the last visual field. IOP values within one month after 
filtration or cataract surgery were excluded from the analysis. In order to control for the 
different time intervals between follow-up visits, we calculated a weighted mean IOP 
according to Harju.28 IOP fluctuation was defined as the standard deviation of follow-up 
IOP values. 
Statistical analyses 
First, we calculated the incidence of glaucomatous visual field progression in our popu-
lation during the follow-up period according to each method. Kappa (κ) statistics were 
calculated to assess agreement between the ten methods and between the subjective 
assessments of the three assessors.  
 
We validated the methods with a prognostic model by performing a multivariable 
logistic regression analysis for each method. We used the binary outcome of the meth-
od to assess visual field progression as the dependent variable and the five prognostic 
factors as the independent variables in the analysis. With the predicted probabilities 
derived from the logistic regression analysis, we created receiver operating characteris-
tic (ROC) curves to assess the association of each method with the combination of 
factors. We calculated the area under the ROC curve (AUC) for comparing the associa-
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tions found with the different methods. An AUC near 0.5 indicates that there is no 
association between the method and the prognostic model and a value of 1.0 indicates 
a perfect association.29 Thus, the method with the highest area under the ROC curve 
was assumed to be a more valid method to assess visual field progression. The individu-
al contribution of the five factors in the multivariable model was also assessed by the 
odds ratio and the accompanying statistical significance.  
 
In an additional analysis, we investigated the influence of “rate of progression” as an 
extra criterion for visual field progression according to the MD and VFI methods that 
were solely based on the statistical significance of progression. We used a rate of 
progression <-1 dB per year for the MD method and <-3% per year for the VFI method 
as cut-off points. To investigate the influence of different cut-off points on AUC values, 
we also varied this “rate of progression” criterion for both methods. 
Results 
Descriptive statistics of the study population are summarized in Table 2. The mean 
baseline MD value was -8.2 dB and the mean age at baseline was 65 years. A mean of 
7.8 reliable visual fields were performed during a mean follow-up time of 7.3 years.  
Visual field progression 
The mean MD rate of progression was -0.46 dB per year. Table 1 shows the incidence of 
visual field progression according to the ten different methods to assess progression 
and for each of the three assessors. The mean incidence of progression was 33.5% 
(standard deviation (SD) ±16.1), which ranged from 12.4% for the AGIS method to 
59.3% for the subjective assessment of visual fields by assessor B.  
 
For the GPA method, several visual field examinations could not be used either because 
of a different test strategy compared with the rest of the series of examinations (n=49) 
or a too severely depressed visual field as indicated by the HFA software (n=115). 
Therefore, 22 patients had no possibility to fulfill the progression criteria for the GPA. 
We analyzed the GPA strategy without these 22 patients.  
 
The mean κ value of the ten methods was 0.35 (SD ±0.15), ranging from 0.74 for the 
agreement between the NPA and MD method to 0.15 for the NPA and AGIS method. 
The interobserver agreement between the three ophthalmologists, expressed as κ 
values, was 0.44 for assessor A versus B, 0.58 for assessor A versus C, 0.47 for assessor 
B versus C. 
Chapter  6  
138 
Prognostic factors 
For each method, the coefficients and statistical significance of the five prognostic 
factors in the multivariable analysis are shown in Table 3. The most consistently related 
prognostic factors with progression were IOP fluctuation and age, with six and four 
statistically significant (p<0.05) associations respectively. A larger IOP fluctuation and a 
higher age resulted in more progression. A higher baseline IOP also consistently result-
ed in more progression, but only one method resulted in a statistically significant 
association in the multivariable analysis. More advanced baseline visual field loss result-
ed in more progression for all methods except the AGIS method and the GPA method. 
With three positive and ten negative associations and a lack of statistical significance for 
all methods, the relation of mean IOP with progression was the least consistent among 
the different methods (Table 3).  
Validation of methods 
The results of the logistic regression analyses are shown in the last column of Table 3. 
The mean AUC of the ten methods and the three assessors was 0.66 (SD ±0.04). AUC 
ranged from 0.57 (confidence interval (CI) 0.46, 0.67) for the GPA method to 0.72 (CI 
0.64, 0.80) for assessor C. Overall, three methods had higher AUC values compared with 
the other methods: assessor C, AGIS, and PLR TD. Two methods had a weaker associa-
tion with prognostic factors compared to the other methods: the MD and GPA. All other 
methods had AUC values around 0.66 (Table 3). 
 
When we added <-1 dB per year for the MD method and <-3% per year for the VFI 
method as progression criteria, the AUC improved from 0.61 to 0.77 (CI 0.66, 0.88) and 
from 0.65 to 0.77 (CI 0.65, 0.88) respectively. Figure 1 shows the ROC curve for the MD 
method and ROC curves for the MD method with the addition of different criteria for 
the rate of progression. The AUC for the MD method increased when stricter criteria for 
progression were used. For the <-0.5 dB, <-1.5 dB, and <-2 dB per year criteria, the 
AUCs were 0.71 (CI 0.62, 0.79), 0.83 (CI 0.66, 1.00), and 0.95 (CI 0.86, 1.00), respective-
ly. We found analogous results for the VFI method. 
  
Val idat ion of  progress ion methods 
139 
Table 2: Descriptive statistics of the study population 
Descriptive statistics Values in the study population (n = 177) 
Follow-up period 7.3 years (±1.2) 
Number of visual fields 7.8 (±1.9) 
Clinical centre  
A 109 (61.5%) 
B 16 (9%) 
C 14 (8%) 
D 16 (9%) 
E 22 (12.5%) 
Female sex 75 (42%) 
Diagnosis  
POAG 141 (79.5%) 
NTG 28 (16%) 
PG 5 (3%) 
PXG 3 (1.5%) 
Cataract surgery during follow-up 29 (16%) 
Filtration surgery during follow-up 13 (7%) 
Prognostic Factors in the Study Eye  
Baseline age 64.8 years (±9.5) 
Baseline IOP 15.5 mmHg (±3.4) 
Baseline visual field MD -8.2 dB (±6.5) 
MD >-4.0dB 59 (33.3%) 
MD ≤-4.0dB and >-10.2dB 59 (33.3%) 
MD ≤-10.2dB 59 (33.3%) 
Follow-up weighted mean IOP 14.7 (±2.8) 
Follow-up IOP standard deviation 2.4 (±1.1) 
Visual field progression  
Observed MD rate in the study eye -0.46 dB/year (±0.59) 
Values are displayed as means and standard deviations or frequencies and percentages. 
POAG = primary open-angle glaucoma, NTG = normal-tension glaucoma, PG = pigment glaucoma, PXG =
pseudoexfoliation glaucoma, IOP = intraocular pressure, MD = mean deviation, dB = decibels. 
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Figure 1 
Receiver operating characteristic curves for different cut-off points of the mean deviation (MD) method. The 
area under the receiver operating characteristic curve (AUC) increases with stricter rate of progression criteria 
for the MD. The AUC ranges from 0.61 for the MD method with statistical significance (p<0.05) as criterion, to 
0.95 when adding the stricter criterion of a rate of progression <-2dB per year alongside the statistical 
significance criterion.  
dB/year = decibels per year. 
Discussion 
In this study, the following methods to assess glaucomatous visual field progression had 
a relatively high ability to discriminate progressive and nonprogressive patients with 
well-known prognostic factors: assessor C, the AGIS method, and PLR using total devia-
tion values. The results of the current validation study are an argument to prefer one of 
these methods. However, validation of methods is a continuous process, should include 
comparisons with other variables, and should be performed in different populations.9 
Ultimately, comparisons should include patient-centered outcome measures, like 
quality-of-life. For example, one study performed a validation of the change in MD 
values over four years and related it with the minimal clinically important difference in 
vision-specific health-related quality of life.30 
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In the current study, direct comparisons between methods to assess glaucomatous 
visual field progression show that there is a high variability in the incidence of progres-
sion between methods. This variability is comparable with our recent network meta-
analysis that ranked methods according to their incidence of progression based on 
direct and indirect comparisons.14 The present ranking of incidences largely correspond 
with the ranking in the meta-analysis, although MD and VFI methods had relatively 
higher incidences and PLR TD and PLR PD methods had relatively lower incidences.14 
This may be explained by the shorter follow-up time of the two studies that studied the 
MD and VFI methods in the meta-analysis (i.e. 3.3 and 5.1 years) and the higher number 
of visual fields of the study that studied the PLR methods (i.e. 21 visual fields), for which 
was only partially adjusted.14, 18, 31, 32 The incidence of progression with the GPA in the 
current study was also higher, mainly because we analyzed the GPA strategy without 22 
patients who had no possibility to fulfill the progression criteria for the GPA. The mod-
erate agreement we found between methods and between different ophthalmologists 
has also been previously described.33-35 
 
It has been shown earlier that the relation between a prognostic factor and visual field 
progression is dependent on the method used to assess visual field progression and the 
statistical analysis that is used.36 We applied the same statistical analysis, but varied the 
method to assess visual field progression. We found a large variability in the coefficients 
and statistical significance of the tested prognostic factors, depending on the method 
used to assess progression. No prognostic factor was tested statistically significant for 
all methods. Mean IOP was the prognostic factor that had the weakest relation with 
visual field progression in our study. The reason for this may be that treatment in 
clinical practice is mainly guided by IOP values. In an observational study, the effect of 
changing treatment based on IOP could dilute and even reverse the relation between 
IOP and visual field progression. IOP fluctuation was the strongest prognostic factor, 
which is in line with recent evidence from the Collaborative Initial Glaucoma Treatment 
Study.37  
 
Unlike more complicated methods, the MD and VFI index are often used for visual field 
assessment in clinical practice. For example, all three assessors have indicated that they 
used the MD index and two of them used the VFI for their blinded subjective assess-
ment of visual field series in this study. Interestingly, we found that progressive and 
nonprogressive patients according to the MD and VFI methods were poorly discriminat-
ed by the multivariable prognostic model. This may be explained by the definition of 
both methods, which only included statistical significance of the progression. Besides 
the severity of visual field progression, statistical significance is also dependent on the 
number of visual fields available. This implies that even a low rate of visual field pro-
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gression could be statistically significant when many visual fields are included in the 
assessment. Therefore, we repeated the analysis after addition of “rate of progression” 
as criterion for visual field progression. A combination of statistical and rate criteria for 
the MD and VFI methods resulted in the highest discriminative ability of all methods in 
this study. Moreover, when stricter criteria for visual field progression were used for the 
MD and VFI methods, stronger associations were found with the combination of prog-
nostic factors. Stricter progression criteria assign progression to a smaller group of 
patients who have more characteristics of typical progressive patients. Therefore, 
applying stricter progression criteria enhances the contrast in prognostic factors be-
tween the progressive and nonprogressive groups which is shown by the larger AUC 
values. It also shows that a more valid method to assess progression may not be only 
achieved by choosing a different method but also by considering a different cut-off 
point. This is akin to clinical practice were a patient with More progression on a scale is 
more likely to be considered to be really progressing. 
 
In conclusion, the relation between glaucomatous visual field progression and prognos-
tic factors is dependent on the method used to assess progression. No prognostic factor 
was tested statistically significant for all methods. The other way round, the ability of a 
progression method to discriminate progressive from nonprogressive patients with a 
combination of well-known prognostic factors is variable. This can be used to validate 
methods to assess progression, where a high discriminative ability confirms the validity 
of a method. 
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ABSTRACT 
Purpose: To assess the prevalence of end-of-life visual impairment in patients followed 
for glaucoma. 
 
Methods: Data of 122 patients followed for glaucoma who had died between July 2008 
and July 2010 and who had visited the ophthalmology outpatient department of a large 
non-academic Dutch hospital were collected from the medical files. Sixty-one patients 
had open-angle glaucoma (OAG) and 61 patients were suspect for glaucoma or had 
ocular hypertension (OHT). Visual impairment was defined as a Mean Deviation value <-
15 dB or a Snellen visual acuity <0.3 (20/60) of the better eye. We determined the 
number of patients with visual impairment on the last patient visit before death and 
investigated its main explanations. 
 
Results: Overall, the mean age at death was 81.8 years after a mean follow-up period of 
9.2 years. Seventy-three percent of all patients had their last visit in the year preceding 
death. In OAG, 16 patients (26%) had an end-of-life visual impairment. In nine patients 
(15%) this was caused by glaucoma. Eight of them had substantial visual loss at the 
initial visit. Six (10%) impaired OAG cases were mainly explained by ocular comorbidity 
and there was an equal contribution of comorbidity and glaucoma in one case. Five 
glaucoma suspects or patients with OHT (8%) were visually impaired at death and these 
were all caused by ocular comorbidity.  
 
Conclusion: The prevalence of end-of-life visual impairment is considerable in OAG 
patients. Substantial visual loss at baseline is an important contributing factor. In glau-
coma suspects or patients with OHT the prevalence is lower and can be attributed to 
ocular comorbidity.  
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Introduction 
The goal of glaucoma management is to maintain visual function and related quality-of-
life (QoL) throughout the patient’s life. To reach this goal, glaucoma patients should be 
identified and treated based on the individual risk of visual disability.1  
 
Current identification of glaucoma patients is not optimal because a large number of 
prevalent cases are undiagnosed.2, 3 Undiagnosed patients could be identified by rou-
tine screening of the general population, but population-based screening for open-
angle glaucoma (OAG) is not considered to be efficient.4 Other screening strategies 
have been proposed, like case finding during regular optician visits.5 On the other hand, 
we know that some glaucoma patients become blind despite timely treatment.6 Deter-
mination of rate of visual field progression is increasingly being recognized as an im-
portant tool to identify patients who need more intensive treatment to slow down 
disease progression.7 The effectiveness of current screening and treatment regimes 
should ideally be judged on the basis of visual function and QoL at the end of glaucoma 
patients’ life. 
 
The aim of the present study is to evaluate current glaucoma management strategies by 
assessing the prevalence of end-of-life visual impairment in a large non-academic Dutch 
hospital. In cases with an end-of-life visual impairment, we determined whether this 
was mainly explained by glaucoma or ocular comorbidity.  
Methods 
Patient selection 
For this study, we performed a retrospective observational case review. We searched 
for all patients diagnosed with glaucoma, ocular hypertension (OHT), or suspected 
glaucoma who were seen at the outpatient ophthalmology department of Catharina 
Hospital Eindhoven between 2003 and 2010. Catharina Hospital Eindhoven is a large 
non-academic referral hospital with six ophthalmologists. To find eligible patients, we 
used the Diagnose Behandel Combinatie-system (DBC-system, DBC-Onderhoud, 
Utrecht, the Netherlands), which has been developed for registration and payment for 
delivered care in the Netherlands. Subsequently, the Dutch Health Insurance Database 
(VECOZO, Tilburg, the Netherlands) was used to retrieve patients who had died. The 
VECOZO database covers more than 99% of all people who are insured for health 
services in the Netherlands. Less than 1% of the total population in the Netherlands is 
currently uninsured.8 In July 2010, we linked the DBC-system with the VECOZO database 
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to retrieve all patients who had glaucoma-related problems and were deceased during 
the past two years. This search resulted in 158 patients (Fig. 1). After studying patient 
records, 135 patients with confirmed glaucoma-related problems and at least two visits 
at the outpatient department were found. This study conformed to the tenets of the 
Declaration of Helsinki and all national laws of the Netherlands, when applicable. 
Data collection 
For each patient, we collected data from the first glaucoma-related visit to the last visit 
at the outpatient department (i.e. the follow-up period). The first glaucoma-related visit 
was defined as the first visit in which a patient presented with an elevated intraocular 
pressure (IOP) or other clinical features related to glaucoma.  
 
Visual function was assessed by Snellen visual acuity and visual field tests (Humphrey 
Field Analyzer (HFA) (Carl Zeiss Meditec, Dublin, CA, USA)). The Mean Deviation (MD) 
index of a standard 24-2 or 30-2 HFA visual field was used as a measure of the overall 
visual field status. SITA visual fields as well as Fastpac visual field tests were performed. 
If not available, screening or 10-2 visual fields were used. Reliable HFA visual fields were 
defined as visual fields having less than 15% false positive answers. Visual fields before 
the year 1996 were performed with Peritest semi-automated static perimetry. Since 
2006, optic nerve imaging was performed additionally to visual field testing using 
scanning laser polarimetry (SLP) (Gdx VCC, Carl Zeiss Meditec, Dublin, CA, USA). We 
used monocular best corrected Snellen visual acuity measurements in the analyses. 
 
Diagnoses were set retrospectively after studying patient records. All diagnoses were 
verified by two authors, including one glaucoma specialist (MJWB and PJGE). OAG 
(n=61) was diagnosed if there was a glaucomatous visual field defect in one or both 
eyes. The OAG group consisted of primary open-angle glaucoma (POAG) (n=53), normal-
tension glaucoma (NTG) (n=7), and pseudoexfoliation glaucoma (PXG) (n=1). NTG was 
diagnosed in patients with IOP always below 21 mmHg. In six POAG patients, the diag-
nosis relied on imaging of the optic nerve because of absence of visual fields. Glaucoma 
suspects (n=9) had normal visual fields but other signs suggestive for glaucoma. OHT 
(n=52) was defined when IOP was >21 mmHg, without damage of the visual field, SLP, 
or optic disc. Glaucomas associated with, or subsequent to other ocular or systemic 
disorders (n=10) or where a narrow angle was likely to be responsible for the optic 
nerve damage (n=3) were excluded (Fig. 1).  
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4711 patients identified in the DBC system
 
158 patients have been deceased in the last two years
  
Exclusion criteria  
Only one visit at the outpatient department (n = 9)
No glaucoma-related problems found in the records (n = 14)
Secondary or angle-closure glaucoma (n = 13)
 
122 patients were used in the analyses
 
Group 1 (n=61) 
53 POAG, 7 NTG, 1 PXG 
Group 2 (n=61)
52 OHT, 9 glaucoma suspect
 
Figure 1 Flow chart of the patient selection process 
DBC = Diagnose Behandel Combinatie, POAG = primary open-angle glaucoma, NTG = normal-tension glauco-
ma, PXG = pseudoexfoliation glaucoma, OHT = ocular hypertension. 
Data analysis 
To analyze end-of-life visual function, we used the last available and reliable visual field 
MD value and the last available Snellen visual acuity for the better eye of each patient. 
The functional status of the better eye has shown to have the highest correlation with 
QoL.9, 10 If data were only available for one eye, this was always the better eye. 
 
We defined visual impairment according to the tenth edition of the International 
Classification of Diseases (ICD-10) of the World Health Organization (WHO).11 We 
considered patients as being visually impaired when they had binocular moderate visual 
impairment category 1 in the ICD-10 (i.e. H54.2), or more. Based on Snellen visual 
acuity, this means a cut-off point of <0.3 (20/60) for the better eye. This cut-off is 
related to substantial loss of QoL (i.e. utilities <0.6).12, 13 A visual acuity <0.5 (20/40) of 
the better eye was used too as a more liberal cut-off point for end-of-life visual impair-
ment. When analyzing visual acuities, Snellen fraction notations were converted to 
logMAR values using conversion tables.14 After the calculations, logMAR values were 
converted back to Snellen values.  
 
We also included visual field loss in the definition of visual impairment, because, com-
pared to visual acuity, visual fields are affected in earlier stages of glaucoma. Moreover, 
the number of patients with impairment from glaucoma is greatly underestimated 
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when the evaluation is based solely on visual acuity.15 Various studies have shown a 
linear relationship between visual field status and vision-targeted QoL, even present at 
early disease stages.16, 17 We chose an MD cut-off point of <-15 dB for the better eye to 
define end-of-life visual impairment. Rein and co-workers estimated that a Snellen 
visual acuity of 20/70 resulted in the same loss in QoL as an MD value of -17 dB.18 The 
ICD-10 only uses visual fields in the definition of blindness. Patients with a visual field of 
the better eye not greater than 10° in radius around central fixation are defined as blind 
according to this definition.11 In order to enable comparisons with other study popula-
tions, we also applied this definition for end-of-life visual impairment in our study. 
When there were test points with very significant loss (p<0.005) on the pattern devia-
tion probability plot within 10° around central fixation of the best eye visual field, we 
defined patients as visually impaired according to this definition. In case only screening 
HFA (n=1) or Peritest visual fields (n=5) were available, visual impairment was defined as 
at least one test point with an absolute defect within the central 10° in radius around 
central fixation (i.e. the WHO definition). Visual impairment in patients with only unreli-
able visual fields (n=2) was clinically judged by two authors (MJWB and PJGE) using all 
other available clinical data too.  
 
The cause of end-of-life visual impairment was considered to be the first ophthalmic 
disorder which permanently reduced visual acuity or the MD value. If glaucomatous 
damage was judged to be the cause, we subsequently analyzed whether there was 
already substantial visual loss at the initial visit. This was defined as a visual field equal 
to an MD value <-10 dB of the better eye and/or a Snellen visual acuity <0.5 (20/40) of 
the better eye. Substantial visual loss at the initial visit could indicate a delayed presen-
tation of glaucoma to the ophthalmologist. 
Results 
Population characteristics 
Descriptive statistics of the 122 included patients are described in Table 1. The mean 
age at death was 79.6 and 84.0 years for the men and women in our study population 
respectively. The mean follow-up period was 9.2 years. No patients were lost to follow-
up due to referral to another hospital or academic centre. Seventy-three percent of all 
patients had their last visit in the year before they died. One hundred fifteen patients 
(94%) were treated with glaucoma medication and five patients (4%) underwent filtra-
tion surgery (Table1). We divided the population into patients initially diagnosed as 
having OAG (i.e. group 1, n=61) and patients initially suspect of having glaucoma or had 
OHT (i.e. group 2, n=61).  
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Table 1: Descriptive statistics of the study population 
Descriptive variables 
Open-angle glaucoma  
(n = 61) 
OHT or glaucoma suspect  
(n = 61) 
General patient characteristics     
Female sex 29 (48%) 32 (53%) 
Age at first visit (years) 73.8 (±10.0) 69.5 (±11.2) 
Age at death (years) 82.9 (±8.4) 80.7 (±9.6) 
Follow-up period (years) 8.3 (±7.0) 10.1 (±7.2) 
Time between last visit and death (years) 0.8 (±0.9) 1.0 (±1.0) 
Treatment     
Topical glaucoma medication during life  59 (97%) 56 (92%) 
Cataract extraction during life 36 (59%) 36 (59%) 
Laser trabeculoplasty performed during life 15 (25%) 7 (12%) 
Trabeculectomy performed during life 5 (8%) 0 (0%) 
Visual field     
Patients with VFs available 55 (90%) 42 (69%) 
Time between last VF and death (years)a 3.9 (±3.4) 6.5 (±3.4) 
Patients with reliable standard VFs available 51 (84%) 38 (62%) 
End MD value of better eye (dB)b -6.9 (±6.4) -2.1 (±2.8) 
End MD value of worse eye (dB)c -14.9 (±8.6) -5.1 (±6.1) 
Visual acuity     
Patients with VA available 61 (100%) 61 (100%) 
Time between last VA and death (years) 1.3 (±1.1) 1.3 (±1.1) 
Starting VA of better eye (Snellen) 0.64 (±0.23) 0.73 (±0.23) 
Starting VA of worse eye (Snellen)d 0.28 (±0.44) 0.51 (±0.32) 
End VA of better eye (Snellen) 0.47 (±0.40) 0.61 (±0.28) 
End VA of worse eye (Snellen)d 0.11 (±0.22) 0.36 (±0.36) 
Values are displayed as means and standard deviations or as frequencies and percentages.  
aFor the 97 patients with visual fields available. 
bFor the 89 patients with available reliable standard 24-2 or 30-2 Humphrey visual fields.  
cFor the 80 patients with bilateral reliable standard 24-2 or 30-2 Humphrey visual fields available.  
dExcluding two totally blind eyes at the start of the follow-up period and three at the last visit.  
OHT = ocular hypertension, VF = visual field, VA = visual acuity, MD = Mean Deviation, dB = decibels. 
 
Visual fields were available from 55 OAG patients (90%) and 42 OHT patients or glau-
coma suspects (69%). No visual fields were obtained from the remaining 25 patients 
due to various reasons. Advanced patient’s age and a short follow-up period were the 
main reasons for not performing visual field tests. Patients with at least one visual field 
available had a mean initial age of 70.4 years and a mean follow-up period of 10.7 years, 
compared with 76.6 years and 3.3 years in patients without visual fields respectively. 
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Eighty-nine patients had reliable standard HFA visual fields available. Because the mean 
number of reliable standard visual fields per eye was 2.6, a rate of visual field progres-
sion could not be estimated reliably. All 122 patients had visual acuity available for both 
eyes. Two eyes of two patients were totally blind at the start and three eyes of three 
patients were totally blind (i.e. with ot without light perception) at the end of the 
follow-up period. None of them were caused by glaucoma. 
Visual impairment 
Sixteen OAG patients (26%) and five patients with OHT or suspect for glaucoma (8%) 
had an end-of-life visual impairment. All 21 visually impaired cases were confirmed by 
studying their patient records. Moreover, 11 of the 21 patients were referred to a 
multidisciplinary low vision rehabilitation centre to help them cope with their visual 
impairment.  
 
Eight (15%) out of all 55 OAG patients with visual fields available had an end-of-life 
visual impairment due to visual field loss (Table 2A). In two of these patients, visual 
impairment was based on screening or Peritest visual fields (i.e. patients 2 and 3 in 
Table 2A). None of the 42 patients with fields available in group 2 had visual impairment 
due to visual field loss. Using the WHO criterion of visual loss within 10° in radius 
around central fixation, 29 (53%) out of 55 patients in group 1 and 8 (19%) out of 42 
patients in group 2 were visually impaired based on visual fields at the end of life. All 
impaired patients based on the MD criterion were also impaired based on the WHO 
criterion. 
 
Ten (16%) out of all OAG patients had an end-of-life visual impairment due to loss in 
visual acuity (Table 2B). Two of them were also visually impaired based on visual fields 
(i.e. patients 1 and 2 in Table 2A and Table 2B). Five (8%) patients in group 2 were 
impaired based on visual acuity. Using the more liberal cut-off point of an end-of-life 
visual acuity <0.5 (20/40) of the better eye, we found 17 patients (28%) and 8 patients 
(13%) with a visual impairment based on visual acuity in groups 1 and 2 respectively. 
The distribution of end-of-life MD and visual acuity values of the better eyes is shown 
for both diagnostic groups in Fig. 2. 
Explanations of visual impairment 
The individual explanations of end-of-life visual impairment are shown in the last col-
umn of Table 2. Among the OAG patients, nine (15%) impaired cases were caused by 
glaucomatous disease (Table 2). Eight of them had substantial visual loss at the initial 
visit. Seven of these cases also had glaucoma-related visual complaints at the initial visit. 
Six (10%) impaired OAG cases were mainly explained by ocular comorbidity. Comorbidi-
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ty and glaucoma contributed equally to the visual impairment in one case (i.e. case 10 in 
Table 2B). All impaired cases in group 2 were explained by ocular comorbidity, mainly 
age-related macular degeneration (AMD). Overall, all end-of-life visual impairments 
based on visual fields were explained by glaucomatous disease (Table 2A). When based 
on visual acuity, only three out of 15 impaired cases were explained by glaucoma (Table 
2B). 
 
 
Figure 2 Histograms of the visual fields and visual acuities of the better eye before death 
The vertical lines indicate the cut-off points which are used in this study to define visual impairment. The 
percentage of patients in each diagnostic group falling beneath this cut-off point is shown in the histograms. 
Two additional patients, who are not shown in this figure, had an end-of-life visual impairment based on 
screening or Peritest visual fields. 
Group 1 = open-angle glaucoma, group 2 = ocular hypertension or glaucoma suspect. 
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Discussion 
Few studies previously investigated end-of-life visual impairment in glaucoma 
patients.19, 20 Forsman and colleagues studied 66 OAG patients and 40 OHT patients 
who had died between 1991 and 2002 of which sixteen percent were visually impaired 
at the last visit.19 However, visual field results were not used in their definition of visual 
impairment, which was defined as a Snellen visual acuity <20/60 of the better eye.19 
Since we found that visual fields were the most sensitive in tracing glaucoma-related 
visual impairment, Forsman and co-workers are likely to have underestimated the 
number of patients with visual impairment. The higher prevalence of exfoliation syn-
drome (42%) in their study may be one of the explaining factors for their higher true 
percentage of end-of-life visual impairment.19 In another study, end-of-life visual func-
tion of OAG patients was defined by binocular criteria derived from driving license 
criteria (i.e. Snellen visual acuity ≤20/40 and no significant loss within the central visual 
field) and partial sight certifications (i.e. Snellen visual acuity <20/200, or <20/60 with a 
gross field defect).20 Based on these definitions, 18.2% and 6.6% of patients had an end-
of-life visual impairment caused by glaucoma alone, respectively. The 15% of OAG 
patients with end-of-life visual impairment caused by glaucoma in our study lies be-
tween their more liberal and more conservative criteria of visual impairment.20  
 
Most cases of end-of-life visual impairments in this study were caused by ocular comor-
bidity. Not surprisingly, AMD was found in this study as the most important ocular 
comorbidity causing a visual acuity <0.3 (20/60). Using a mathematical model, a recent 
study estimated AMD as the most important cause of a visual acuity <20/60 of the 
better eye in the Dutch elderly in 2008.21 Glaucomatous disease followed on the sixth 
place. The prevalence of visual impairment for persons above 50 years from Western 
descent in the Netherlands was estimated in the same paper at 3.8%.21 We found a 
much higher lifetime prevalence of visual impairment, because our population had an 
older age and all patients visited the ophthalmologist for ocular disease. We also judged 
visual impairment based on visual fields which may have resulted in extra visually 
impaired cases. 
 
This study shows that the eventual risk for visual impairment is considerable for patients 
followed for glaucoma. Most patients with an end-of-life visual impairment caused by 
glaucoma had already substantial visual loss at the initial visit. This indicates a delayed 
presentation of glaucoma to the ophthalmologist with a subsequent delay in glaucoma 
treatment. Evaluation of the last visual field before death detected more cases of 
impairment due to glaucoma than visual acuity. From 25 patients, no visual fields were 
available. We found that these patients were older than patients with available visual 
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fields. Older age is one of the most important factors that is associated with conversion 
to glaucoma and glaucoma progression.22 For these reasons, the current estimation of 
visually impaired patients is a lower limit.  
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Context of glaucomatous visual field progression 
The central topic of the research presented in this doctoral thesis is visual field progres-
sion in patients with open-angle glaucoma (OAG). OAG is a lifelong disease with usually 
slow visual field progression over months to years.1 The goal of glaucoma treatment is 
to maintain the patient’s visual function and related quality-of-life, at a sustainable 
cost.2 Cure of lost nerve fibers is not possible. The treatment of OAG patients (i.e. 
lowering of intraocular pressure (IOP)) appears to be cost-effective compared with no 
treatment.3  
 
Treatment decisions should be made with regard to the patient’s individual characteris-
tics, taking into account baseline stage of disease and the (expected) rate of disease 
progression in the light of age-adjusted life expectancy.4 Clinical judgment leads to the 
decision to initiate (aggressive) treatment (i.e. mostly lowering of IOP) when current 
disease stage is advanced, a high disease progression is expected, and/or when life 
expectancy is long. In contrast, the decision to refrain from treatment, or certainly not 
treat aggressively, is made when current disease stage is only mild, predicted disease 
progression is low, and/or life expectancy is short. Personalized care is the result of the 
best balance between benefits and adverse events of treatment and monitoring. Recent 
research has shown that especially the rate of disease progression and the duration of 
life are of importance in making cost-effective treatment decisions for individual pa-
tients (i.e. determinants of the expected value of individualized care).5 
 
Assessment of visual field progression is thus a central aspect of glaucoma manage-
ment. The ability to identify rapidly progressing patients enables ophthalmologists to 
direct more intensive treatment to those who are at a high risk of becoming blind, and 
to refrain from intensifying potentially harmful treatment in those who have no pro-
gression. In clinical practice this can be achieved either by predicting progression or by 
monitoring progression. This thesis is focused on both approaches.  
Prediction of glaucomatous visual field progression 
If a patient is diagnosed with glaucoma, it has to be decided whether to treat, how to 
treat and how intense to treat. The prognosis of a patient forms the point of departure 
for these aspects of patient management.6 Prediction is focused on visual field progres-
sion in glaucoma management, since it gives the opportunity to intervene at an earlier 
stage instead of a wait-and-see strategy, thus preventing further visual field loss. Fur-
thermore, intensive treatment can thus be avoided in patients who are unlikely to 
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progress. We therefore wanted to know if and how progression can be predicted. We 
summarized the results from 85 studies about factors that predict glaucomatous visual 
field progression and ranked all factors according to their likelihood of being a prognos-
tic factor in Chapter 2. All studied factors were classified as definite, possible and 
probable prognostic factors with use of a semi-quantitative approach by masked asses-
sors. Based on the results, we advise to use the following eight factors when making 
decisions about treatment and monitoring strategies in glaucoma patients: age, disc 
hemorrhages (only for the subgroup of patients with normal-tension glaucoma (NTG)), 
baseline visual field loss, baseline IOP, exfoliation syndrome, central corneal thickness, 
peripapillary atrophy (only for the subgroup of patients with NTG), and proven previous 
visual field progression.  
 
Knowing the most important prognostic factors, it would be interesting to know how 
accurately glaucomatous visual field progression can be predicted. Only a few prognos-
tic models for glaucomatous visual field progression have been described.7, 8 We tested 
the predictive ability of a combination of prognostic factors in our own population of 
patients with OAG in Chapter 3. A clinical prediction model was developed to predict 
the rate of visual field progression with the use of baseline age, IOP, and visual field 
status. The accuracy of a prediction model is described as explained variance (i.e. R2) or 
as the area under the receiver operating characteristic (ROC) curve (AUC).9 During 
model development the R2 of our prediction model was 10.3%, which decreased to 
5.3% at external validation. Our model and those of others have a mediocre accuracy in 
predicting an exact rate of visual field progression for individual patients. For example, 
the R2 statistic of the model of De Moraes and co-workers was 14% at external valida-
tion.7 As can be seen from their calibration plot and the calibration plots of our predic-
tion model in Chapter 3, only a small amount of the variance in visual field progression 
can be explained by these models.10  
 
This approach may not be appropriate to improve glaucoma care. Although a prediction 
model does not give a high R2, it may still be possible to distinguish two or more groups 
in which monitoring frequency and treatment intensity can be differentiated with more 
benefits than universally monitoring and/or treating all patients.  
 
The AUC of the model of De Moraes at external validation was 0.78.7 In comparison, the 
AUC of our prediction model was 0.76 when the model was used to detect a VFI rate ≤-
3% per year, which decreased to 0.71 at external validation. In clinical terms, the pre-
test probability of a high rate of visual field progression was 22.5% (i.e. the prevalence) 
in the population described in Chapter 3. This increased to 61% after a positive result of 
our prediction model and decreased to 19% after a negative test result, respectively. 
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Hence, a positive result of our prediction model gives a clinical significant change in a 
patient’s risk of future rapid progression. Prediction of progression may thus have 
additional value in identifying subgroups of patients with high and low rates of visual 
field progression. Groups of rapidly progressing patients who are detected by using the 
model should thus receive more intensive treatment compared with standard treat-
ment regimes. For example, their target IOP could be estimated at lower levels than 
would usually have been done. 
Monitoring of glaucomatous visual field progression 
For the second approach to identify rapidly progressing glaucoma patients (i.e. monitor-
ing progression), it was firstly studied how the chosen method to assess glaucomatous 
visual field progression influences the incidence of visual progression in patients diag-
nosed with OAG in the literature (see Chapter 4). This has direct consequences for the 
number of patients that need to be treated more intensively. We used a relatively new 
statistical approach (i.e. a network meta-analysis) with which it is possible to combine 
direct and indirect comparisons of methods from different studies to study the influ-
ence of a method on the incidence of progression. Corrected for baseline visual field 
loss and mean follow-up time, the mean incidence of progression of the 30 methods 
was 21% in six years. This ranged from 2% to 62%, depending on the method used to 
assess progression. The chosen method accounted for nearly all heterogeneity in the 
incidence of progression (i.e. 82%), and therefore strongly determines the number of 
glaucoma patients that are reported to have progressive disease. As expected, the cut-
off point to decide whether progression had occurred also had a strong influence on the 
incidence of progression.  
 
Although the method influences the number of patients reported with progression of 
visual field loss, it may not be true that a method with a high incidence is better in 
identifying patients with true progression or to differentiate better between those with 
and those without progression. The incidence may be unrelated to the validity of a 
method. To address this issue, a systematic review was conducted to identify all the 
methods and to show what is known about these methods, especially its validity (Chap-
ter 5). We found 301 different methods in the literature to monitor patients for visual 
field progression. We found no evidence for advising one method over all others to 
assess visual field progression in all circumstances. However, the evidence seems to be 
fair for twelve methods that have been validated to some extent: the Advanced Glau-
coma Intervention Study (AGIS), Collaborative Initial Glaucoma Treatment Study, 
pointwise linear regression analysis (PLR), mean deviation (MD), Glaucoma Change 
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Probability, Early Manifest Glaucoma Treatment, Visual Field Index (VFI), Threshold 
Noiseless Trend, Werner, clinical scoring system, Collaborative Normal-Tension Glau-
coma Study, and subjective methods. Based on these findings, a selection from one of 
these methods would therefore be preferable with little need to develop new methods 
to assess visual field progression. A difficulty in a study on the validity of a method to 
assess glaucomatous progression, however, is the lack of a gold standard.  
 
To overcome this problem, the construct validity of the methods to assess glaucoma-
tous visual field progression was investigated for ten commonly used methods (see 
Chapter 6). Construct validity requires a construct known to be valid.11 For example, the 
relation between a certain definition of glaucomatous visual field progression and IOP 
can be investigated. High IOP is among the most consistent prognostic factors for 
progression of glaucoma and is one of the few factors that can be modified by medical 
or surgical treatment to slow down progression.12, 13 Therefore, a method that is as-
sumed to assess glaucomatous visual field progression should find a relation between 
progression and IOP. When No relation between IOP and glaucomatous progression is 
found, one should question the validity of the assessment method. In Chapter 6, the 
method that had the highest association with the combination of five well-known 
prognostic factors in a multivariable logistic regression model was presumed to be the 
most valid method to assess glaucomatous visual field progression. All methods showed 
some degree of construct validity, although to a different extent. Expressed as AUC, the 
value ranged from 0.57 to 0.72. Three methods had higher construct validity compared 
with the other methods: blinded subjective assessment of visual fields by “assessor C”, 
the AGIS method, and PLR analysis using total deviation values. Within the same meth-
od, stricter progression criteria (i.e. a higher cut-off point) resulted in a stronger associ-
ation with the combination of prognostic factors. This implies that in this study stricter 
methods are more valid methods to assess glaucomatous visual field progression, likely 
because the progressive patients according to highly specific methods were more 
“really” progressing patients. A better construct validity can therefore not only be 
achieved by choosing another method but also by changing the criteria for progression.  
 
Beside the differences between progression methods in the incidence of progression 
and the validity, the agreement between different methods has shown to be disap-
pointing.14-16 In Chapter 6 we confirmed this finding by reporting a mean kappa value of 
0.35 (SD ±0.15) as a measure of agreement between ten different methods to assess 
visual field progression. 
 
In recent literature (Chapter 5), many studies stress the importance of determining a 
rate of visual field progression instead of treating glaucomatous visual field progression 
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as a dichotomous event.17 This is important because the rate of progression is more 
suitable for personalized care, as explained above. However, most studies that were 
included in our reviews as described in Chapter 4 and Chapter 5 treated progression as 
a dichotomous event (i.e. yes or no). This can be explained by the fact that, when a rate 
of progression is used to decide on changing therapy in clinical practice, it has to be 
decided which cut-off value for the rate leads to the decision to change therapy. There-
fore, even a rate method leads to a dichotomisation of the population in those who 
progressed and need more intense treatment and those who did not. Nevertheless, it is 
of clinical importance to also incorporate a rate component in a dichotomous method 
to assess progression. Addition of a rate of progression criterion will indicate the clinical 
relevance of progression. This is demonstrated in the research described in Chapter 6, 
where the addition of a rate component to the MD or the VFI methods increased the 
AUC (i.e. a measure of the presumed validity of a method) to much higher levels.  
 
The rate of visual field progression is highly variable among patients with OAG.18 Our 
empirical studies as described in Chapters 3 and 6 confirmed this finding. The rate of 
visual field progression according to the VFI rate ranged from -22.10% to 16.51% per 
year in Chapter 3 and -13.96% to 1.98% per year in Chapter 6. For the monitoring of 
patients, the high variability of progression among patients improves the possibility for 
progression methods to discriminate between the risk profile of patients, and thus 
enabling different treatment modalities.19 
End-of-life visual impairment in glaucoma 
Finally, does it all matter? The ultimate goal of glaucoma management is to prevent 
visual impairment and to preserve the patient’s quality-of-life. In the last decades, 
glaucoma-related blindness has decreased,20 but despite current treatment modalities, 
the prevalence of visual impairment in patients with glaucoma at the end of their life is 
still considerable. We assessed the prevalence of severe end-of-life visual impairment in 
a small population of deceased glaucoma patients in Chapter 7. In OAG, 26% of patients 
had a severe end-of-life visual impairment, which was defined as a MD value <-15 
decibels or a Snellen visual acuity <0.3 (20/60) of the better eye. Fifteen percent of the 
OAG patients had an end-of-life visual impairment that was caused by glaucoma. When 
also taking other studies into account, the prevalence of end-of-life visual impairment 
caused by glaucoma varies from 9% to 15%.21-23  
 
Our study also gave the opportunity to study whether disease progression was the 
cause of end-of-life visual disability. However, we found that an initial late presentation 
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of these glaucoma patients to the ophthalmologist was the most common contributing 
factor for their loss of vision, and age-related macular degeneration was the second 
most common cause. Disease progression after diagnosis was the cause of end-of-life 
visual impairment in only one glaucoma patient. This patient did not visit the ophthal-
mologist and had not used his glaucoma medication for years. One large recent study 
systematically investigated prognostic factors associated with the lifetime risk of OAG 
blindness. IOP at diagnosis, worse visual field status at baseline and age at death were 
the most important risk factors for end-of-life blindness in this study.24 Similar to our 
study, visual field progression was not taken into account in the analysis.  
 
Although the study described in Chapter 7 is small, its concept and results are relevant. 
This finding may mitigate the need to search for a perfect method to assess glaucoma-
tous visual field progression and it shows that further improvements would be desirable 
for earlier detection of patients with glaucoma. Ophthalmologists are able to prevent 
glaucoma blindness to a large extent if the patients is diagnosed at an early stage.24 
Current practice with a limited frequency of visual field examination and subjective 
judgement of progression seems to suffice to prevent blindness to a large extent. The 
need to monitor is further limited if treatment is intense from diagnosis. This gives a 
maximal effect when applied over an extended period of time. Monitoring progression 
will then still be necessary to determine the need for surgery, which has potentially 
more serious adverse events. This approach has earlier been quantified in a cost-
effectiveness model. This discrete event simulation model showed that the most cost-
effective strategy was to aim for an IOP below 15 mmHg in all glaucoma patients from 
the moment of diagnosis as compared with waiting to intensify treatment until progres-
sion has occurred.25, 26 This strategy may be at the expense of individual patients who 
experience adverse events of treatment despite a low risk of end-of-life visual impair-
ment. Ultimately, personalized care should be implemented in dialogue with the indi-
vidual patient. 
Clinical recommendations 
This thesis was focused on prediction and monitoring of progression of glaucoma. 
Treatment decisions to prevent severe visual field loss, glaucoma-related impairment 
and related loss of quality-of-life should be based on their estimated risks. This risk is 
determined by the baseline visual field loss, rate of visual field progression and life 
expectancy. The reduction of this risk is affected by the intensity of treatment and 
factors that modify the effect of treatment.  
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Treatment needs to be started in every glaucoma patient. Its intensity depends on the 
risk of future severity of visual field loss. Current drug and laser treatment have few 
adverse events. Irrespective of the future risk it can thus be intensive. Monitoring is 
then reserved to determine the timing of surgery. A far as visual field monitoring is 
concerned, subjective assessment of progression combined with changes in VFI and MD 
seem to be valid enough to be used.  
 
Summarizing, from our studies several practical advices for clinicians can be given: 
-  Choose one of the methods to assess glaucomatous visual field progression that 
have been validated in the literature and know the properties of the specific method 
used. 
-  Incorporate the rate of visual field progression into your methods to assess progres-
sion, because this information is needed to estimate the individual risk of end-of-life 
visual impairment from glaucoma. 
-  Use a combination of available prognostic factors for glaucomatous visual field 
progression to estimate the individual risk of accelerated visual field progression and 
modify follow-up frequency and treatment accordingly. 
-  When evaluating studies on diagnostic methods, critically evaluate the gold standard 
to which different methods have been compared. Search for studies that investigat-
ed the construct validity of a method when the choice of a gold standard is arbitrary. 
-  Prevention of end-of-life visual impairment due to glaucoma, taking into account 
current practice and opportunities for treatment, should focus on earlier detection 
of patients with glaucoma to achieve less visual impairment.  
Future research 
Current methods of diagnosing, monitoring and treating patients with OAG have a large 
impact on the prevention of glaucoma-related impairment. However, not all glaucoma 
blindness can currently be prevented. A further reduction in blindness could be 
achieved if patients with glaucoma are detected at an earlier stage. General population-
based screening has not shown to be cost-effective, whereas targeting specific high-risk 
groups may be more effective. The best way to achieve this goal needs to be investigat-
ed.27 
 
Further research on causes of glaucoma-related impairment is needed. This can be 
achieved by studying blind glaucoma patients or those with fast progression of the 
disease. A larger study of deceased glaucoma patients can give more accurate estimates 
of the contribution of baseline visual field loss, progression of glaucoma and ocular 
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comorbidity that lead to the occurrence of blindness. Clinical variables that can be 
improved to prevent blindness could be identified. 
 
In the end, visual field progression is an indirect outcome measure of the loss of retinal 
ganglion cells, which is the pathogenic mechanism of glaucomatous damage. The 
relation between visual field loss and retinal ganglion cell loss is probably nonlinear due 
to the logarithmic transformation of visual field sensitivities.28 This can be an explana-
tion for baseline visual field loss to be an important prognostic factor for glaucomatous 
visual field progression, as we found in the studies described in Chapter 2, 3, 4 and 6. In 
eyes with more advanced damage, a smaller number of retinal ganglion cells losses 
would produce relatively larger changes in MD compared with eyes with early 
damage.28 Therefore, it is also important to measure structural changes in OAG pa-
tients, especially in early disease. The interest in using retinal nerve fiber layer thickness 
for assessing disease progression has recently been increased. Optical coherence 
tomography is one of the most promising tools in this respect.29 Unfortunately, agree-
ment between structural and functional disease progression has shown to be poor.29, 30 
Therefore, the structure-function debate should be fuelled with more research on the 
construct validity of methods to assess structural changes of the optic nerve. Both 
structure and function should be studied over time to assess the conditional risk of 
disease progression (e.g. structural loss as a prognostic factor for visual field loss). It 
may also reveal at what point in time progressive patients are diagnosed as such, after it 
had been decided at an earlier time point that they did not show progression. A ran-
domised controlled trial to compare different monitoring strategies may further opti-
mize clinical practice. 
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Valorization is the process of creating value from knowledge, by making knowledge 
suitable or available for social or economic use and by making knowledge suitable for 
translation into competitive products, services, processes and new commercial activi-
ties. 
 
Adding value to what has value is therefore the starting point to reflect on the valoriza-
tion of the knowledge gained in this thesis, and additionally pointing out the ways to 
improve clinical practice for ophthalmologists but, above all, for our patients.  
 
For those who need to care about finances, it also has economic value. It is well known 
that many ophthalmic interventions are cost-effective. In a recent paper by Brown and 
co-workers, it was estimated that taking into account all direct medical costs saved and 
expended, direct nonmedical costs saved and indirect medical costs saved, the return-
on-investment of the treatment of glaucoma with a simple drug as timolol is 3957%.1 
The yearly savings of treating glaucoma patients in a usual care scenario saves at least 
over 180 million Euros in the Netherlands when compared to not treating these pa-
tients.2,3 Improving glaucoma care and preventing glaucoma blindness will further 
increase the savings and return-on-investment. 
 
To improve clinical practice, we have formulated five practical advices for clinicians in 
the Summarizing discussion of this thesis. In the Summarizing discussion we also sug-
gest directions of future research based on the research in this thesis. 
 
In this chapter about valorization, we further discuss the societal perspective and 
practical implications of the presented research. Medical management of glaucoma is 
based on monitoring of glaucoma patients for many years. A change in treatment is 
based on predicted disease progression or monitored disease progression (see Summa-
rizing discussion).  
 
Monitoring of glaucoma patients encompasses a large burden of the work at the outpa-
tients’ department. It is undertaken to assess the effect of treatment, adverse events of 
treatment, or complications of the disease. Its aim is to timely initiate or change treat-
ment to improve the outcome of the disease. Monitoring requires answers to the 
questions of what to monitor, how to monitor, and how frequent to monitor. A basic 
assumption is that the outcome is improved when monitoring is undertaken as com-
pared to no monitoring. However, “despite the considerable staff time and resources 
involved, monitoring is a surprisingly understudied area.”4 This thesis adds value to this 
neglected area of research.  
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Monitoring is also about individualizing or even personalizing care (see also Summariz-
ing discussion). This individualization of health care or personalized medicine is inevita-
ble given the increase in diagnostic possibilities, prognostic factors and new 
interventions. Moreover, efficiency is improved if choices between management strate-
gies are individualized.5 Such an approach fits the needed reform in health care to lower 
cost and improve outcome by improving quality of care. As formulated in an article in 
Harvard Business review: “It’s time for a fundamentally new strategy. At its core is 
maximizing value for patients: that is, achieving the best outcomes at the lowest cost.”6 
This guiding principle has shown to account for already a great deal of current glaucoma 
care that saves sight as well as money.2 
 
This thesis contributes to the societal debate on personalized medicine. It shows that 
the selection of subjects who need more intensive treatment to reduce their risk of 
glaucoma blindness based on the occurrence of progression is strongly influenced by 
the choice of the method to detect progression. Its implications for clinical practice and 
patients are enormous.  
 
The percentage of patients needing additional treatment in glaucoma ranges from 2% 
to 62% depending on the method used to assess progression. This implies a wide range 
in the number of patients who need a change in therapy. If these are to be surgical 
interventions an enormous number of extra operations need to be conducted. Moreo-
ver, the choice of the criterion or cut-off point for one method strongly influences the 
number of patients who need a change in therapy. 
 
Also with regard to the costs of glaucoma treatment, the aim of current health policy in 
the Netherlands is to promote the influence of health care insurance companies. They 
may request transparency of the care process comprising the number of interventions 
(e.g. operations), before reimbursement of the ophthalmological practice is initiated. In 
this context, ophthalmologists may be conservative in their decisions on the number of 
operations and the criteria to decide on an operation. Both need to know the impact of 
criteria on progression in this regard.  
 
The situation is even worse than suggested by the wide range of 2% tot 62% that show 
progression. Chapter 5 in this thesis shows that there are many more methods, 301 to 
be exact, with which glaucomatous visual field progression can be assessed. These 
methods have been used in research or clinical practice despite that only 48 (16%) have 
been validated to some extent. However, the most important question as to what 
extent the method predicts blindness is not known. Moreover, reproducibility studies 
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have not been conducted; implying that one moment a patient may be classified as 
having progressive glaucoma and on another moment as not.  
 
Ophthalmologists and patients are therefore left with methods to assess progression of 
which the consequences are not exactly known. The impact on the budget, in a time of 
budget constraints, is also unknown.  
 
Monitoring is a form of screening and clinicians may not have viewed examinations of 
their patients in this way. This is, however, important. The criteria of Wilson and 
Jungner are used to justify screening in the general population.7 In clinical practice no 
such criteria are used. When we apply these criteria to the monitoring of glaucoma 
patients, all criteria are fulfilled except that there are no clear criteria to assess glauco-
matous progression. 
 
Screening should be compared with no screening. In the latter case patients are sent 
home and asked to return when they notice a change. In glaucoma this will lead to a 
considerably number of cases with advanced visual field loss, since patients do not 
notice any change until a late stage of the disease. Based on this thesis, monitoring 
should be addressed in a more systematic way in daily practice by viewing it as a form 
of screening.  
 
Eight prognostic factors were found to be clearly associated with glaucomatous visual 
field progression. Clinicians could directly use these factors to make their own risk 
estimations. These factors could also serve as starting point for the development of new 
clinical prediction models. Chapter 3 presents a prediction model for visual field pro-
gression. This model can already be used to identify a group of patients with a high rate 
of future visual field progression. It can also serve as a starting point for the develop-
ment of more accurate clinical prediction models. For example, such a prediction model 
can be put online to provide access for all ophthalmologists. It can automatically calcu-
late the risk of future progression for an individual patient, after the values of the 
predictors have been filled out.  
 
Quality of care is another societal issue that is addressed in this thesis. In this thesis an 
“epidemiological autopsy” is described in Chapter 7. Deceased glaucoma patients were 
identified and their visual field loss and visual acuity before death registered from their 
medical records. These data provide the risk of glaucoma patients to become severely 
visually impaired. Moreover, the causes of visual impairment can be identified. These 
can be separated in three major elements: the presence and amount of visual field loss 
at the start of treatment, progression of visual field loss, and life expectancy. Disease 
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progression partly reflects the quality of care. It was shown, however, that a considera-
ble number of the impaired glaucoma patients had already substantial visual loss at the 
initial visit. This indicates a delayed presentation of glaucoma to the ophthalmologist 
with a subsequent delay in glaucoma treatment. If the intraocular pressure is not 
lowered enough, patients are more at risk of becoming blind.  
 
These findings have implications for those who have the opportunity to detect glauco-
ma at an early stage. Opticians and optometrist have the knowledge and equipment to 
do so. Another implication is in the assessment of the quality of care. An “epidemiologi-
cal autopsy” should be obligatory for an ophthalmologist for all his deceased patients. It 
will reveal process characteristics that need improvement: the successive process of 
screening for glaucoma, diagnosis, indication for treatment, quality of treatment, and 
compliance with the treatment. It will also demonstrate which diseases have most 
impact on end-of-life visual impairment. 
 
In summary, this thesis on monitoring of glaucoma patients contributes to the debate 
on personalized medicine and shows the need to improve on the criteria to decide on 
personalizing care. This needs to be known by ophthalmologists, patients, health care 
insurance companies and health policy makers. It has consequences for effectiveness 
and efficiency of healthcare.  
 
Monitoring should be seen from a new perspective. It is in fact a kind of screening and 
ophthalmologists and other clinicians should be aware of that. Every glaucoma control 
patient needs to be observed from this perspective in order to improve effectiveness, 
efficiency and alleviate the large burden on the work at the outpatients’ department.  
 
An “epidemiological autopsy” is a must for every ophthalmologist to show his excellent 
results or improve his practice.  
 
Finally, guidelines are guiding and, like other research from the University Eye Clinic 
Maastricht, this thesis will contribute to the new guidelines of the European Glaucoma 
Society.  
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Het onderwerp van dit proefschrift is gezichtsveldprogressie bij patiënten met openka-
merhoekglaucoom (hierna te noemen ‘glaucoom’). Glaucoom is een levenslange, 
chronische oogziekte waarbij de functie van de oogzenuw in meer of mindere mate 
wordt aangetast.  
 
Het gevolg hiervan is uitval van de randen van het zien, ofwel een beperking van het 
gezichtsveld (tunnelvisus). Hierdoor ziet iemand bijvoorbeeld een auto van opzij niet 
aankomen. Deze gezichtsvelduitval neemt -in de meeste gevallen langzaam- toe in de 
loop van het leven en is onherstelbaar. Dit wordt ook wel gezichtsveldprogressie ge-
noemd. In ernstige gevallen kan de gezichtsvelduitval leiden tot slechtziendheid of 
blindheid.  
 
Het belangrijkste doel van de behandeling van glaucoom is het voorkomen van blind-
heid en slechtziendheid en daarmee gerelateerd verlies van kwaliteit van leven. Tot op 
heden is de enige manier om glaucoom te behandelen het verlagen van de oogdruk, 
waardoor de gezichtsveldprogressie meestal kan worden afgeremd. Dit kan met behulp 
van medicatie (meestal in de vorm van oogdruppels), laserbehandelingen of operatieve 
ingrepen. In de praktijk krijgen vrijwel alle glaucoompatiënten een behandeling gericht 
op de verlaging van de oogdruk. 
 
Hoe intensief een glaucoompatiënt behandeld moet worden, hangt af van zijn progno-
se. Met andere woorden, hoe snel het gezichtsveld van een glaucoompatiënt in de 
komende jaren achteruit zal gaan en wat de kans op uiteindelijke blindheid zal zijn. De 
kans op gezichtsveldprogressie bij glaucoom kan worden voorspeld met behulp van 
prognostische factoren. Prognostische factoren zijn specifieke kenmerken van een 
patiënt van wie het gezichtsveld in de toekomst sneller achteruit zal gaan. In hoofdstuk 
2 wordt beschreven hoe in de literatuur 103 verschillende prognostische factoren 
werden onderzocht. Middels een systematisch literatuuronderzoek hebben we de 
belangrijkste factoren hieruit bepaald, te weten: hoge leeftijd, bloedinkjes op de rand 
van de oogzenuw, reeds veel gezichtsvelduitval als de diagnose gesteld wordt, hoge 
oogdruk, pseudo-exfoliatie (aanwezigheid van wit schilferig materiaal in het oog), 
centrale hoornvliesdikte, aanwezigheid van een gebied waarin het netvlies zich heeft 
teruggetrokken rondom de oogzenuw en veel gezichtsveldprogressie in het verleden. 
 
In hoofdstuk 3 hebben we vervolgens onderzocht hoe gezichtsveldprogressie accuraat 
kan worden voorspeld. Met behulp van gegevens van een groep van 613 glaucoompati-
enten hebben we een rekenkundige methode ontwikkeld waarmee met leeftijd, oog-
druk en mate van gezichtsvelduitval, de progressie voorspeld kan worden (een 
predictiemodel). Met deze methode kan voorspeld worden of een patiënt bij de snel 
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progressieve groep glaucoompatiënten behoort. De voorspelling van de individuele 
mate van progressie bleek echter niet nauwkeurig genoeg.  
 
Naast het voorspellen van gezichtsveldprogressie wordt er in de praktijk gemeten hoe 
snel die progressie daadwerkelijk is. Dit noemen we monitoren van gezichtsveldpro-
gressie. Wanneer dan een te snelle progressie wordt vastgesteld, kan de behandeling 
geïntensiveerd worden. Over de manier (de methode) waarop gezichtsveldprogressie 
gemeten moet worden bestaat echter geen overeenstemming. In hoofdstuk 4 is voor 
elk van dertig verschillende methoden onderzocht hoeveel glaucoompatiënten ge-
zichtsveldprogressie hadden. Hiervoor hebben we onderzoeken (studies) bestudeerd 
waarin meerdere methoden met elkaar worden vergeleken. Vervolgens zijn alle resulta-
ten van de verschillende studies middels een rekenkundige methode (een netwerk 
meta-analyse) samengevoegd en met elkaar vergeleken. Het gemiddeld optreden van 
progressie (de incidentie) was 21 procent in zes jaar, variërend van twee procent tot 62 
procent, afhankelijk van de gekozen methode. De gekozen methode voor het meten 
van gezichtsveldprogressie is bovendien de meest belangrijke factor die bepaalt hoeveel 
patiënten in een studie gezichtsveldprogressie hebben.  
 
In hoofdstuk 5 hebben we middels een systematisch literatuuronderzoek beschreven 
wat bekend is over de beste methode om gezichtsveldprogressie te meten. De validiteit 
van een methode is de mate van waarschijnlijkheid waarmee de uitkomst van een 
methode overeenkomt met de werkelijkheid. Met andere woorden, is de gemeten 
gezichtsveldprogressie ook werkelijke progressie van glaucoom? In de literatuur zijn 301 
verschillende methoden beschreven, waarvan slechts enkele zijn onderzocht op hun 
kwaliteit (gevalideerd). Sommige hiervan zijn meerdere keren onderzocht. Er bleek geen 
methode te bestaan voor het meten van progressie die duidelijk beter was dan alle 
andere methoden (geen gouden standaard). 
 
Om het probleem van het ontbreken van een gouden standaard te omzeilen hebben we 
in hoofdstuk 6 de constructvaliditeit gebruikt om tien methoden voor het meten van 
gezichtsveldprogressie bij glaucoom verder te valideren. Constructvaliditeit houdt in dat 
de validiteit van een methode wordt getest met behulp van andere verbanden waarvan 
bekend is dat ze bestaan (een achterliggend concept). Een voorbeeld van een bekend 
verband, is het verband tussen oogdruk en gezichtsveldprogressie. Een methode die 
gezichtsveldprogressie meet zou theoretisch een relatie moeten hebben met de oog-
druk, omdat we weten dat oogdruk een belangrijke prognostische factor is voor ge-
zichtsveldprogressie. Met het verband tussen vijf bekende prognostische factoren en 
gezichtsveldprogressie in onze eigen populatie glaucoompatiënten, hebben we de 
constructvaliditeit van tien methoden onderzocht. We hebben hierbij aangenomen dat 
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een methode meer valide is als er een sterker verband bestaat met de combinatie van 
deze vijf prognostische factoren. Hieruit is gebleken dat er verschillen zijn in construct-
validiteit. 
 
Ten slotte hebben we in hoofdstuk 7 bestudeerd in welke mate, onder de huidige 
omstandigheden van voorspellen, monitoren en behandelen van gezichtsveld-
progressie, blindheid en slechtziendheid worden voorkomen. Hiervoor hebben we een 
groep van 61 overleden glaucoompatiënten nader bestudeerd en bekeken hoeveel 
patiënten uiteindelijk gestorven zijn met een ernstige visuele beperking. Van de bestu-
deerde groep glaucoompatiënten, bleek 26 procent te zijn overleden met een visuele 
beperking, bij vijftien procent van de totale groep werd dit veroorzaakt door glaucoom. 
Over het algemeen lieten deze laatste patiënten zich pas voor het eerst door een 
oogarts onderzoeken als er al veel schade aan het gezichtsveld opgetreden was. De 
mate van uitval van het gezichtsveld aan het begin van het behandeltraject lijkt dus de 
belangrijkste verklaring te zijn voor een visuele beperking bij overlijden. Nader onder-
zoek in een grotere groep moet dit bevestigen. 
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